

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(10) International Publication Number  
**WO 2014/106593 A1**

(43) International Publication Date  
10 July 2014 (10.07.2014)

W I P O | P C T

(51) International Patent Classification:

CI2N 9/28 (2006.01)

(21) International Application Number:

PCT/EP20 13/077678

(22) International Filing Date:

20 December 2013 (20.12.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

13 150126.4 3 January 2013 (03.01.2013) EP

(71) Applicant: NOVOZYMES A/S [DK/DK]; Krogshoejvej  
36, DK-2880 Bagsvaerd (DK).

(72) Inventor: ANDERSEN, Carsten; Hoejeloft Vaenge 162,  
DK-3500 Vaerloese (DK).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,  
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,  
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,  
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,  
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,  
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))



WO 2014/106593 A1

(54) Title: ALPHA-AMYLASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAME

(57) Abstract: The present invention relates to alpha-amylase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.

## ALPHA-AMYLASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAME

### REFERENCE TO A SEQUENCE LISTING

This application contains a Sequence Listing in computer readable form, which is  
5 incorporated herein by reference.

### BACKGROUND OF THE INVENTION

#### Field of the Invention

The present invention relates to alpha-amylase variants, polynucleotides encoding the  
10 variants, methods of producing the variants, and methods of using the variants.

#### Description of the Related Art

Alpha-amylases (alpha-1,4-glucan-4-glucanohydrolases, E.C. 3.2.1.1) constitute a group of  
enzymes, which catalyses hydrolysis of starch and other linear and branched 1,4-gluosidic oligo-  
15 and polysaccharides.

There is a long history of industrial use of alpha-amylases in several known applications  
such as detergent, baking, brewing, starch liquefaction and saccharification e.g. in preparation of  
high fructose syrups or as part of ethanol production from starch. These and other applications of  
alpha-amylases are known and utilize alpha-amylases derived from microorganisms, in particular  
20 bacterial alpha-amylases.

WO 2000/060058 discloses the two alpha-amylases AAI-6 and AAI-10 (as SEQ ID NOs 2  
and 4 which in the present application are SEQ ID NOs 1 and 2) and discloses thermostable  
variants thereof.

For environmental reasons it has been increasingly important to lower the temperature in  
25 washing, dishwashing and/or cleaning processes. However, most enzymes including the amylases  
of AAI-6 and AAI-10 have a temperature optimum which is above the temperature usually used in  
low temperature washing. Alpha-amylase is a key enzyme for use in detergent compositions and its  
use has become increasingly important for removal of starchy stains during laundry washing or  
dishwashing. Therefore, it is important to find alpha-amylase variants, which retain their wash  
30 performance, stain removal effect and/or activity when the temperature is lowered. Thus, it is  
desirable to have amylolytic enzymes that can function under low temperature and at the same  
time preserve or increase other desirable properties such as specific activity (amylolytic activity),  
stability and/or wash performance.

Thus, it is an object of the present invention to provide alpha-amylases variants which have  
35 high performance, in particular high wash performance, at low temperatures and/or which have

high stability in detergent compositions and/or which have high amylase activity after storage in detergents.

The present invention provides alpha-amylase variants with improved properties compared to its parent.

5

**SUMMARY OF THE INVENTION**

The present invention relates to isolated alpha-amylase variants, comprising an alteration at two or more (several) positions corresponding to W140, W159, W167, Q169, W189, E194, N260, F262, F289, W284, G304, G305, W347, R439, W469, D476 and G477 of the mature polypeptide of SEQ ID NO: 1, wherein each alteration is independently a substitution, deletion or insertion, and wherein the variants have at least 85%, such as at least 90%, or at least 95%, but less than 100% sequence identity with the mature polypeptide of SEQ ID NO: 1 or 2, and wherein the variants have alpha-amylase activity.

The present invention also relates to detergent compositions comprising the variants, isolated polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of producing the variants.

The present invention also relates to the use of the variants in a cleaning process.

20 **DEFINITIONS**

**Alpha-amylase:** The term "alpha-amylase activity" means the activity of alpha-1,4-glucan-4-glucanohydrolases, E.C. 3.2.1.1, which constitute a group of enzymes, which catalyze hydrolysis of starch and other linear and branched 1,4-glucosidic oligo- and polysaccharides. For purposes of the present invention, alpha-amylase activity is determined according to the procedure described in the Examples. In one aspect, the variants of the present invention have at least 20%, e.g., at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100% of the alpha-amylase activity of the mature polypeptide of SEQ ID NO: 1 or 2.

**SEQ ID NO: 1:**

30 HHDTGNGTIM QYFEWNPND GQHWNRLLHNN AQNLKNAGIT AIWIPPAWKG  
 TSQNDVGYGA YDLYDLGEFN QKGTVRTKYG TKAELEAIR SLKANGIQVY  
 GDVVMNHKGG ADFTERVQAV EVNPQNRNQE VSGTYEIEAW TGFNFPGRGN  
 QHSSFKWRWY HFDGTDWDQS RQLSNRIYKF RGDGKAWE VDTENGNVDY  
 LMYADVDMNH PEVINELNRW GVWYANTLNL DGFRLDAVKH IQFSFMRNWL  
 35 GHVRGQTGKN LFAVAEYWKD DLGALENYLS KTNWTMSAFD VPLHYNLYQA  
 SNSGGNYDMR NLLNGTLVQR HPSHAVTFVD NHDTQPGEAL ESFVQGWFKP  
 LAYATILTRE QGYPQVFYGD YYGIPSDGVP SYRQQIDPLL KARQKYAYGP

QHDYLDHPDV IGWTREGDSS HPKSGLATLI TDGPGGSKRM YAGLKNAGET  
 WYDITGNRSD TVKIGSDGWG EFHVNDGSVS IYVQK

**SEQ ID NO: 2:**

5 HHDTGTNGTIM QYFEWNPND GQHWNRHLHNN AQNLNKAGIT AIWIPPAWKG  
 TSQNDVGYGA YDLYDLGFEFN QKGTVRTKYG TKAELEAIR SLKANGIQVY  
 GDVVMNHKGG ADFTERVQAV EVNPQNRNQE VSGTYQIEAW TGFNFPGRGN  
 QHSSFKWRWY HFDGTDWDQS RQLANRIYKF RGDGKAWDWE VDTENGNIDY  
 LMYADVMDH PEVINELNRW GVWYANTLNL DGFRLDAVKH IKFSFMRDWL  
 10 GHVVRGQTGKN LFAVAEYWKN DLGALENYLS KTNWTMSAFD VPLHYNLYQA  
 SNSSGNIDMR NLLNGTLVQR HPSHAVTFVD NHDTQPGEAL ESFVQGWFKP  
 LAYATILTRE QGYPPQVFYGD YYGIPSDGVP SYRQQIDPLL KARQQYAYGR  
 QHDYFDHWDV IGWTREGNAS HPNSGLATIM SDGPGGSKWM YVGRQKAGEV  
 15 WHDMTGNRSG TVTINQDGWG HFFVNGGSVS VWVKR

**Allelic variant:** The term "allelic variant" means any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequences. An allelic variant of a polypeptide is a polypeptide encoded by an allelic variant of a gene.

**Expression:** The term "expression" includes any step involved in the production of a variant including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion.

**Expression vector:** The term "expression vector" means a linear or circular DNA molecule that comprises a polynucleotide encoding a variant and is operably linked to control sequences that provide for its expression.

**Fragment:** The term "fragment" means a polypeptide having one or more (*e.g.*, several) amino acids absent from the amino and/or carboxyl terminus of a mature polypeptide; wherein the fragment has alpha-amylase activity. In one aspect, a fragment contains at least 470 amino acid residues, at least 475 amino acid residues, or at least 480 amino acid residues.

**Host cell:** The term "host cell" means any cell type that is susceptible to transformation, transfection, transduction, or the like with a nucleic acid construct or expression vector comprising a polynucleotide of the present invention. The term "host cell" encompasses any progeny of a parent cell that is not identical to the parent cell due to mutations that occur during replication.

**Improved property:** The term "improved property" means a characteristic associated with a variant of the present invention that is improved compared to the parent which parent only differs from the variant in the one or more claimed positions. Alternatively, it is compared to the mature polypeptide of SEQ ID NO: 1 or 2. Such improved properties include, but are not limited to, catalytic

efficiency, catalytic rate, chemical stability, oxidation stability, pH activity, pH stability, specific activity, stability under storage conditions, substrate binding, substrate cleavage, substrate specificity, substrate stability, surface properties, thermal activity, and thermo stability, and improved wash performance, particularly improved wash performance at low temperatures, such as 5 temperatures between 5°C and 35°C, such as below 35°C, or below 30°C, or even below 20°C, or at temperatures below 15°C, or even at temperatures below 10°C. Another property that may be improved in the variants is the stability during storage in detergent compositions.

**Wash performance:** In the present context the term "wash performance" is used as an enzyme's ability to remove starch or starch-containing stains present on the object to be cleaned during e.g. laundry or hard surface cleaning, such as dish wash. The wash performance may be quantified by calculating the so-called delta remission value (ARem) as described in the definition herein.

**Improved wash performance:** The term "improved wash performance" is defined herein as a variant enzyme displaying an alteration of the wash performance of an amylase variant relative to the wash performance of the parent amylase or relative to the alpha-amylase having the amino acid sequence shown in SEQ ID NO 1 or 2, e.g. by increased stain removal. The term "wash performance" includes cleaning in general e.g. hard surface cleaning as in dish wash, but also wash performance on textiles such as laundry, and also industrial and institutional cleaning. Improved wash performance may be measured by comparing of the so-called delta remission value (ARem) as described in the definition herein.

**Low temperature:** "Low temperature" is a temperature of 5-35°C, preferably 5-30°C, more preferably 5-25°C, more preferably 5-20°C, most preferably 5-15°C, and in particular 5-10°C. In a preferred embodiment, "Low temperature" is a temperature of 10-35°C, preferably 10-30°C, more preferably 10-25°C, most preferably 10-20°C, and in particular 10-15°C.

**Delta remission value (ARem):** The terms "Delta remission" or "Delta remission value" are defined herein as the result of a reflectance or remission measurement at 460 nm of a test material, e.g. a swatch CS-28 (Center For Testmaterials BV, P.O. Box 120, 3133 KT Vlaardingen, the Netherlands) or a hard surface. The swatch is measured with at least one other swatch, washed under identical conditions, as background. The delta remission is the remission value of the test material washed with amylase subtracted the remission value of the test material washed without amylase.

**Isolated:** The term "isolated" means a substance in a form or environment which does not occur in nature. Non-limiting examples of isolated substances include (1) any non-naturally occurring substance, (2) any substance including, but not limited to, any enzyme, variant, nucleic acid, protein, peptide or cofactor, that is at least partially removed from one or more or all of the

naturally occurring constituents with which it is associated in nature; (3) any substance modified by the hand of man relative to that substance found in nature; or (4) any substance modified by increasing the amount of the substance relative to other components with which it is naturally associated (e.g., multiple copies of a gene encoding the substance; use of a stronger promoter than the promoter naturally associated with the gene encoding the substance). An isolated substance may be present in a fermentation broth sample.

**Mature polypeptide:** The term "mature polypeptide" means a polypeptide in its final form following translation and any post-translational modifications, such as N-terminal processing, C-terminal truncation, glycosylation, phosphorylation, etc. In one aspect, the mature polypeptide is amino acids 1 to 485 of SEQ ID NO: 1 or 2.

It is known in the art that a host cell may produce a mixture of two or more different mature polypeptides (i.e., with a different C-terminal and/or N-terminal amino acid) expressed by the same polynucleotide.

**Mature polypeptide coding sequence:** The term "mature polypeptide coding sequence" means a polynucleotide that encodes a mature polypeptide having alpha-amylase activity.

**Mutant:** The term "mutant" means a polynucleotide encoding a variant.

**Nucleic acid construct:** The term "nucleic acid construct" means a nucleic acid molecule, either single- or double-stranded, which is isolated from a naturally occurring gene or is modified to contain segments of nucleic acids in a manner that would not otherwise exist in nature or which is synthetic, which comprises one or more control sequences.

**Operably linked:** The term "operably linked" means a configuration in which a control sequence is placed at an appropriate position relative to the coding sequence of a polynucleotide such that the control sequence directs expression of the coding sequence.

**Parent or parent alpha-amylase:** The term "parent" or "parent alpha-amylase" means an alpha-amylase to which an alteration is made to produce the enzyme variants of the present invention. The parent may be a naturally occurring (wild-type) polypeptide or a variant or fragment thereof.

**Sequence identity:** The relatedness between two amino acid sequences or between two nucleotide sequences is described by the parameter "sequence identity".

For purposes of the present invention, the sequence identity between two amino acid sequences is determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, *J. Mol. Biol.* 48: 443-453) as implemented in the Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice *et al.*, 2000, *Trends Genet.* 16: 276-277), preferably version 5.0.0 or later. The parameters used are gap open penalty of 10, gap extension penalty of 0.5, and the EBLOSUM62 (EMBOSS version of BLOSUM62) substitution

matrix. The output of Needle labeled "longest identity" (obtained using the -nobrief option) is used as the percent identity and is calculated as follows:

$$(\text{Identical Residues} \times 100) / (\text{Length of Alignment} - \text{Total Number of Gaps in Alignment})$$

For purposes of the present invention, the sequence identity between two deoxyribonucleotide sequences is determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, *supra*) as implemented in the Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice *et al.*, 2000, *supra*), preferably version 5.0.0 or later. The parameters used are gap open penalty of 10, gap extension penalty of 0.5, and the EDNAFULL (EMBOSS version of NCBI NUC4.4) substitution matrix. The output of Needle labeled "longest identity" (obtained using the -nobrief option) is used as the percent identity and is calculated as follows:

$$(\text{Identical Deoxyribonucleotides} \times 100) / (\text{Length of Alignment} - \text{Total Number of Gaps in Alignment})$$

**Variants:** The term "variant" means a polypeptide having alpha-amylase activity comprising an alteration, *i.e.*, a substitution, insertion, and/or deletion, at one or more (*e.g.*, several) positions. A substitution means replacement of the amino acid occupying a position with a different amino acid; a deletion means removal of the amino acid occupying a position; and an insertion means adding an amino acid adjacent to and immediately following the amino acid occupying a position. The variants of the present invention have at least 20%, *e.g.*, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 100% of the alpha-amylase activity of the mature polypeptide of SEQ ID NO: 1 or 2.

**Very high stringency conditions:** The term "very high stringency conditions" means for probes of at least 100 nucleotides in length, prehybridization and hybridization at 42°C in 5X SSPE, 0.3% SDS, 200 micrograms/ml sheared and denatured salmon sperm DNA, and 50% formamide, following standard Southern blotting procedures for 12 to 24 hours. The carrier material is finally washed three times each for 15 minutes using 2X SSC, 0.2% SDS at 70°C.

**Very low stringency conditions:** The term "very low stringency conditions" means for probes of at least 100 nucleotides in length, prehybridization and hybridization at 42°C in 5X SSPE, 0.3% SDS, 200 micrograms/ml sheared and denatured salmon sperm DNA, and 25% formamide, following standard Southern blotting procedures for 12 to 24 hours. The carrier material is finally washed three times each for 15 minutes using 2X SSC, 0.2% SDS at 45°C.

**Wild-type alpha-amylase:** The term "wild-type" alpha-amylase means an alpha-amylase expressed by a naturally occurring microorganism, such as a bacterium, archaea, yeast, or filamentous fungus found in nature.

### Conventions for Designation of Variants

For purposes of the present invention, the mature polypeptide disclosed in SEQ ID NO: 1 is used to determine the corresponding amino acid residue in another alpha-amylase. The amino acid sequence of another alpha-amylase is aligned with the mature polypeptide disclosed in SEQ ID NO: 1, and based on the alignment, the amino acid position number corresponding to any amino acid residue in the mature polypeptide disclosed in SEQ ID NO: 1 is determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, *J. Mol. Biol.* 48: 443-453) as implemented in the Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice *et al.*, 2000, *Trends Genet.* 16: 276-277), preferably version 5.0.0 or later. The parameters used are gap open penalty of 10, gap extension penalty of 0.5, and the EBLOSUM62 (EMBOSS version of BLOSUM62) substitution matrix.

Identification of the corresponding amino acid residue in another alpha-amylase can be determined by an alignment of multiple polypeptide sequences using several computer programs including, but not limited to, MUSCLE (multiple sequence comparison by log-expectation; version 3.5 or later; Edgar, 2004, *Nucleic Acids Research* 32: 1792-1797), MAFFT (version 6.857 or later; Katoh and Kuma, 2002, *Nucleic Acids Research* 30: 3059-3066; Katoh *et al.*, 2005, *Nucleic Acids Research* 33: 511-518; Katoh and Toh, 2007, *Bioinformatics* 23: 372-374; Katoh *et al.*, 2009, *Methods in Molecular Biology* 537: 39-64; Katoh and Toh, 2010, *Bioinformatics* 26: 1899-1900), and EMBOSS EMMA employing ClustalW (1.83 or later; Thompson *et al.*, 1994, *Nucleic Acids Research* 22: 4673-4680), using their respective default parameters.

When the other enzyme has diverged from the mature polypeptide of SEQ ID NO: 1 such that traditional sequence-based comparison fails to detect their relationship (Lindahl and Elofsson, 2000, *J. Mol. Biol.* 295: 613-615), other pairwise sequence comparison algorithms can be used. Greater sensitivity in sequence-based searching can be attained using search programs that utilize probabilistic representations of polypeptide families (profiles) to search databases. For example, the PSI-BLAST program generates profiles through an iterative database search process and is capable of detecting remote homologs (Atschul *et al.*, 1997, *Nucleic Acids Res.* 25: 3389-3402). Even greater sensitivity can be achieved if the family or superfamily for the polypeptide has one or more representatives in the protein structure databases. Programs such as GenTHREADER (Jones, 1999, *J. Mol. Biol.* 287: 797-815; McGuffin and Jones, 2003, *Bioinformatics* 19: 874-881) utilize information from a variety of sources (PSI-BLAST, secondary structure prediction, structural alignment profiles, and solvation potentials) as input to a neural network that predicts the structural fold for a query sequence. Similarly, the method of Gough *et al.*, 2000, *J. Mol. Biol.* 313: 903-919, can be used to align a sequence of unknown structure with the superfamily models present in the SCOP database. These alignments can in turn be used to generate homology models for the

polypeptide, and such models can be assessed for accuracy using a variety of tools developed for that purpose.

For proteins of known structure, several tools and resources are available for retrieving and generating structural alignments. For example the SCOP superfamilies of proteins have been structurally aligned, and those alignments are accessible and downloadable. Two or more protein structures can be aligned using a variety of algorithms such as the distance alignment matrix (Holm and Sander, 1998, *Proteins* 33: 88-96) or combinatorial extension (Shindyalov and Bourne, 1998, *Protein Engineering* 11: 739-747), and implementation of these algorithms can additionally be utilized to query structure databases with a structure of interest in order to discover possible structural homologs (e.g., Holm and Park, 2000, *Bioinformatics* 16: 566-567).

In describing the variants of the present invention, the nomenclature described below is adapted for ease of reference. The accepted IUPAC single letter or three letter amino acid abbreviation is employed.

Substitutions. For an amino acid substitution, the following nomenclature is used: Original amino acid, position, substituted amino acid. Accordingly, the substitution of threonine at position 226 with alanine is designated as "Thr226Ala" or "T226A". In situations where the amino acid at a given position may be substituted for any other amino acid it is designated T226ACDEFGHIKLMNPQRSWVY. Accordingly, this means that threonine at position 226 may be substituted with one amino acid selected from the group of A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, W, V or Y. Likewise, in situations where the amino acid at a given position may be substituted for one amino acid selected from a specific group of amino acids, e.g. where the threonine at position 226 may be substituted with any of tyrosine, phenylalanine or histidine it is designated T226YFH. The different alterations at a given position may also be separated by a comma, e.g., "Arg170Tyr,Glu" or "R170Y,E" represents a substitution of arginine at position 170 with tyrosine or glutamic acid. Thus, "Tyr167Gly,Ala + Arg170Gly,Ala" designates the following variants: "Tyr167Gly+Arg170Gly", "Tyr167Gly+Arg170Ala", "Tyr167Ala+Arg170Gly", and "Tyr167Ala+Arg170Ala".

Multiple mutations are separated by addition marks ("+"), e.g., "Gly205Arg + Ser41 1Phe" or "G205R + S41 1F", representing substitutions at positions 205 and 411 of glycine (G) with arginine (R) and serine (S) with phenylalanine (F), respectively.

Deletions. For an amino acid deletion, the following nomenclature is used: Original amino acid, position, \*. Accordingly, the deletion of glycine at position 195 is designated as "Gly195\*" or "G195\*". Multiple deletions are separated by addition marks ("+"), e.g., "Gly195\* + Ser41 1\*" or "G195\* + S41 1\*".

Insertions. For an amino acid insertion, the following nomenclature is used: Original amino acid, position, original amino acid, inserted amino acid. Accordingly the insertion of lysine after glycine at position 195 is designated "Gly195Gly\_ys" or "G195GK". An insertion of multiple amino acids is designated [Original amino acid, position, original amino acid, inserted amino acid #1, inserted amino acid #2; etc.]. For example, the insertion of lysine and alanine after glycine at position 195 is indicated as "Gly195Gly\_ysAla" or "G195GKA".

In such cases the inserted amino acid residue(s) are numbered by the addition of lower case letters to the position number of the amino acid residue preceding the inserted amino acid residue(s). In the above example, the sequence would thus be:

<u>Parent:</u>	<u>Variant:</u>
195	195 195a 195b
G	G - K - A

10

Multiple alterations. Variants comprising multiple alterations are separated by addition marks ("+"), e.g., "Arg170Tyr+Gly195Glu" or "R170Y+G195E" representing a substitution of arginine and glycine at positions 170 and 195 with tyrosine and glutamic acid, respectively.

15

**DETAILED DESCRIPTION OF THE INVENTION****Variants**

The present invention relates to isolated alpha-amylase variants, comprising an alteration at one, two or more (several) positions corresponding to positions W140; W159; W167, Q169, W189, E194, N260, F262, F289, W284, G304, G305, W347, R439, W469, D476 and G477 of the mature polypeptide of SEQ ID NO: 1, wherein each alteration is independently a substitution, deletion or insertion, and wherein the variant has at least 85%, such as at least 90%, or at least 95%, but less than 100% sequence identity with the mature polypeptide of SEQ ID NO: 1 and wherein the variant has alpha-amylase activity.

The present invention also relates to isolated alpha-amylase variants, comprising an alteration at one, two or more (several) positions corresponding to positions W140; W159; W167, Q169, W189, E194, N260, F262, F289, W284, S304, G305, W347, W439, W469, G476 and G477 of the mature polypeptide of SEQ ID NO: 2, wherein each alteration is independently a substitution, deletion or insertion, and wherein the variant has at least 85%, such as at least 90%, or at least 95%, but less than 100% sequence identity with the mature polypeptide of SEQ ID NO: 2 and wherein the variant has alpha-amylase activity.

Hereby, variants are provided which have improved washing performance at low temperature compared to the parent alpha-amylase or compared to the alpha-amylase of SEQ ID NO: 1 or 2.

In an embodiment, the alterations are substitutions.

In another embodiment of the invention the variants may comprise alterations at three or more of said positions mentioned above.

In yet another embodiment of the invention the variants may comprise alterations at four or more of said positions mentioned above.

In yet another embodiment of the invention the variants may comprise alterations at five or more of said positions mentioned above.

In yet another embodiment of the invention the variants may comprise alterations at six or more of said positions mentioned above.

In yet another embodiment of the invention the variants may comprise alterations at seven or more of said positions mentioned above.

In yet another embodiment of the invention the variants may comprise alterations at eight or more of said positions mentioned above.

In yet another embodiment of the invention the variants may comprise alterations at nine or more of said positions mentioned above.

In yet another embodiment of the invention the variants may comprise alterations at ten or more of said positions mentioned above.

In one aspect of the invention, one of the above mentioned one, two or more substitutions may be a substitution at position 140 when using SEQ ID NO: 1 for numbering. The substitution  
5 may be any of W140ACDEFGHIKLMNPQRSTVY, but preferably it is W140YFH and most preferred it is W140Y.

In another aspect of the invention, one of the above mentioned one, two or more substitutions may be a substitution at position 159 when using SEQ ID NO: 1 for numbering. The substitution may be any of W159ACDEFGHIKLMNPQRSTVY preferably W159YFH.

10 In one embodiment of the invention, one of the above mentioned one, two or more substitutions may be a substitution at position 167 when using SEQ ID NO: 1 for numbering. The substitution may be any of W167ACDEFGHIKLMNPQRSTVY, preferably W167YHF.

In one embodiment of the invention, one of the above mentioned one, two or more substitutions may be a substitution at position 169 when using SEQ ID NO: 1 for numbering. The  
15 substitution may be any of Q169ACDEFGHIKLMNPWRSTVY.

In one embodiment of the invention, one of the above mentioned one, two or more substitutions may be a substitution at position 189 when using SEQ ID NO: 1 for numbering. The substitution may be any of W189ACDEFGHIKLMNPQRSTVY. Alternatively E190P may be substituted.

20 In one embodiment of the invention, one of the above mentioned one, two or more substitutions may be a substitution at position 194 when using SEQ ID NO: 1 for numbering. The substitution may be any of E194ACDWFGHIKLMNPQRSTVY, preferably E194D.

In one embodiment of the invention, one of the above mentioned one, two or more substitutions may be a substitution at position 260 when using SEQ ID NO: 1 for numbering. The  
25 substitution may be any of N260ACFGHIKLMWPQ RSTVY, preferably N260G or N260P or N260A.

In one embodiment of the invention, one of the above mentioned one, two or more substitutions may be a substitution at position 262 when using SEQ ID NO: 1 for numbering. The substitution may be any of F262ACDEWGHKLMNPQRSTVY, preferably F262P or F262G.

30 In one embodiment of the invention, one of the above mentioned one, two or more substitutions may be a substitution at position 284 when using SEQ ID NO: 1 for numbering. The substitution may be any of W284ACDEFGHIKLMNPQRSTVY, preferably W284G or W284H.

In one embodiment of the invention, one of the above mentioned one, two or more substitutions may be a substitution at position F289 when using SEQ ID NO: 1 for numbering. The substitution may be any of F289ACDEWGHKLMNPQRSTVY, preferably F289H.

In one embodiment of the invention, one of the above mentioned one, two or more substitutions may be a substitution at position 304 when using SEQ ID NO: 1 for numbering. The substitution may be any of G304ACEFHKLMPQRWTVY, preferably it is G304K or G304R or G304Q or G304E, and most preferred it is G304K. In other amylases, e.g. the amylase of SEQ ID  
5 NO: 2, the natural occurring amino acid in this position is S. So, when using such other amylases as a starting point for the variants, the substitution may be any of S304ACEFHKLMPQRWTVY; preferably it is S304K or S304R or S304Q or S304E, and most preferred it is S304K.

In another embodiment of the invention, one of the above mentioned one, two or more substitutions may be a substitution at position 305 when using SEQ ID NO: 1 for numbering. The  
10 substitution may be any of G305ACEFVHKLMPQRWTVY, preferably it is G305K or G305R or G305Q or G305E, and most preferred it is G305K.

In one embodiment of the invention, one of the above mentioned one, two or more substitutions may be a substitution at position 347 when using SEQ ID NO: 1 for numbering. The substitution may be any of W347ACDEFGHIKLMNPQRSTVY, preferably W347Y or W347F or  
15 W347H.

In another embodiment of the invention, one of the above mentioned one, two or more substitutions may be a substitution at position 439 when using SEQ ID NO: 1 for numbering. The substitution may be any of R439ACDEFGHIKLMNPQRSTVY; preferably it is a substitution of R439N or R439Q. In other amylases, e.g. the amylase of SEQ ID NO: 2, the natural occurring amino acid  
20 in this position is W. So, when using such other amylases as a starting point for the variants, the substitution may be any of W439ACDEFGHIKLMNPQRSTVY, preferably it is a substitution of W439N or W439Q.

In another embodiment of the invention, one of the above mentioned one, two or more substitutions may be a substitution at position 469 when using SEQ ID NO: 1 for numbering. The  
25 substitution may be any W469ACDEFGHIKLMNPQRSTVY; preferably it is W469T or W469N.

In another embodiment of the invention, one of the above mentioned one, two or more substitutions may be a substitution at position 476 when using SEQ ID NO: 1 for numbering. The substitution may be any of D476ACEFHKLMPQRWTVY, preferably it is D476K or D476R or D476Q or D476E, and most preferred it is D476K. In other amylases, e.g. the amylase of SEQ ID  
30 NO: 2, the natural occurring amino acid in this position is G. So the substitution may be any of G476ACEFHKLMPQRWTVY, preferably it is G476K or G476R or G476Q or G476E, and most preferred it is G476K.

In another embodiment of the invention, one of the above mentioned one, two or more substitutions may be a substitution at position 477 when using SEQ ID NO: 1 for numbering. The  
35 substitution may be any of G477ACEFHKLMPQRWTVY, preferably it is G477K or G477R or

G477Q or G477E, and most preferred it is G477K.

The inventor of the present invention contemplates that variants having at least 85% sequence identity to SEQ ID NO: 1 or 2 and having one, two or more of the above mentioned substitutions have particularly high performance at low temperature washing. In particular, for variants of SEQ ID NO: 1 or 2 or variants having at least 85% sequence identity to SEQ ID NO: 1 or 2 it is an advantage to substitute tryptophans on the surface of the molecule, e.g. the tryptophans at positions 140, 159, 167, 189, 284, 347, 439, 469 e.g. with any amino acids, such as tyrosine, phenylalanine or histidine, and to substitute glycines or serines in the vicinity (on the surface) of these tryptophans with a larger amino acid, such as glutamic acid, glutamine, arginine or lysine. This is e.g. the substitutions of G304EQRK or G305EQRK or D476EQRK or G477EQRK. Such substitutions decrease the substrate binding of the alpha-amylase and improve the wash performance at low temperature washing.

The variants of the invention may further comprise a deletion of two positions selected from the group consisting of R181, G182, D183 and G184 when using SEQ ID NO: 1 for numbering, preferably a deletion of R181+G182, or of G182+D183 or of R181+G184 or of G182+G184, or more preferred of D183+G184. It has been found that such a double deletion stabilizes the molecule.

The variants of the invention may further comprise at least one of the substitutions selected from the group consisting of G109A, G149A, K179L, G186A, E190P, N195F, M202LIT, V206YF, Y243F, S244QAEDN and N209D and when using SEQ ID NO: 1 for numbering. These substitutions likewise provide improved stability to the alpha-amylases.

In another aspect, the invention relates to variants which comprise modifications in the positions, corresponding to the positions of the polypeptide of SEQ ID NO: 1, selected from the group consisting of:

- 25 W140Y+Y160S
- W140Y+E194D
- W140Y+N260P
- W140Y+G304K
- W140Y+G304R
- 30 W140Y+R439T
- W140Y+W469T
- W140Y+D476K
- W140Y+G477R
- Y160S+E194D
- 35 Y160S+E212D

Y160S+N260P  
Y160S+G304K  
Y160S+G304R  
Y160S+R439T  
5 Y160S+W469T  
Y160S+D476K  
Y160S+G477R  
N260P+G304K  
N260P+G305R  
10 N260P+R439K  
N260P+W469R  
N260P+D476K  
N260P+G477R  
W284G+G304K  
15 W284G+G305R  
W284G+R439N  
W284G+W469T  
W284G+D476K  
W284G+G477R  
20 L279T+W284G+H324N+G304K  
L279T+W284G+H324N+G305R  
L279T+W284G+H324N+R439N  
L279T+W284G+H324N+W469T  
L279T+W284G+H324N+D476K  
25 L279T+W284G+H324N+G477R  
G304K+R439K  
G304K+W469R  
G304K+D476K  
G304K+G477R  
30 G305K+R439K  
G305K+W469R  
G305K+D476K  
G305K+G477R  
R439N+W469R  
35 R439N+D476K

- R439N+G477R
- W469T+D476K
- W469T+G477R
- W140Y+G304R+G475K
- 5 W140Y+N260P+G304R+G475K
- W 140Y+E21 2D+G304R+G475K
- W 140Y+G304R+W438R+G475K
- W 140Y+G304R+W468T+G475K
- W140Y+G305K+G475K
- 10 W140Y+N260P+G305K+D476K
- W 140Y+E21 2D+G305K+D476K
- W 140Y+G305K+R439N+D476K
- W 140Y+G305K+W469T+D476K
- W140Y+G304R+D476K
- 15 W140Y+N260P+G304R+G477K
- W 140Y+E21 2D+G304R+G477K
- W 140Y+G304R+R439N+G477K
- W 140Y+G304R+W469T+G477K
- W140Y+G305K+G477K
- 20 W140Y+W284K+G305K+G477K
- W 140Y+N260P+G305K+G477K
- W 140Y+E21 2D+G305K+G477K
- W140Y+G305K+R439N+G477K and
- W 140Y+G305K+W469T+G477K

25 wherein the variants have at least 85% and less than 100% sequence identity to the alpha-amylase of SEQ ID NO: 1. These variants preferably further comprise a deletion of the amino acids occupying positions R181+G182, or of G182+D183, or most preferred of D183+G184.

In another aspect, the invention relates to variants which comprise modifications in the positions, corresponding to the positions of the polypeptide of SEQ ID NO: 1, selected from the

30 group consisting of:

- W140Y+Y160S
- W140Y+E194D
- W140Y+N260P
- W140Y+G304K
- 35 W140Y+G304R

W140Y+R439T  
W140Y+W469T  
W140Y+D476K  
W140Y+G477R  
5 Y160S+E194D  
Y160S+E212D  
Y160S+N260P  
Y160S+G304K  
Y160S+G304R  
10 Y160S+R439T  
Y160S+W469T  
Y160S+D476K  
Y160S+G477R  
N260P+G304K  
15 N260P+G305R  
N260P+R439K  
N260P+W469R  
N260P+D476K  
N260P+G477R  
20 W284G+G304K  
W284G+G305R  
W284G+R439N  
W284G+W469T  
W284G+D476K  
25 W284G+G477R  
L279T+W284G+H324N+G304K  
L279T+W284G+H324N+G305R  
L279T+W284G+H324N+R439N  
L279T+W284G+H324N+W469T  
30 L279T+W284G+H324N+D476K  
L279T+W284G+H324N+G477R  
G304K+R439K  
G304K+W469R  
G304K+D476K  
35 G304K+G477R

- G305K+R439K
- G305K+W469R
- G305K+D476K
- G305K+G477R
- 5 R439N+W469R
- R439N+D476K
- R439N+G477R
- W469T+D476K
- W469T+G477R
- 10 W140Y+G304R+G475K
- W 140Y+N260P+G304R+G475K
- W 140Y+E21 2D+G304R+G475K
- W 140Y+G304R+W438R+G475K
- W 140Y+G304R+W468T+G475K
- 15 W140Y+G305K+G475K
- W 140Y+N260P+G305K+D476K
- W 140Y+E21 2D+G305K+D476K
- W 140Y+G305K+R439N+D476K
- W 140Y+G305K+W469T+D476K
- 20 W140Y+G304R+D476K
- W 140Y+N260P+G304R+G477K
- W 140Y+E21 2D+G304R+G477K
- W 140Y+G304R+R439N+G477K
- W 140Y+G304R+W469T+G477K
- 25 W140Y+G305K+G477K
- W 140Y+W284K+G305K+G477K
- W 140Y+N260P+G305K+G477K
- W 140Y+E21 2D+G305K+G477K
- W140Y+G305K+R439N+G477K and
- 30 W140Y+G305K+W469T+G477K

wherein the variants have at least 90% and less than 100% sequence identity to the alpha-amylase of SEQ ID NO: 1.

In another aspect, the invention relates to variants which comprise modifications in the positions, corresponding to the positions of the polypeptide of SEQ ID NO: 1, selected from the group consisting of:

W140Y+Y160S  
W140Y+E194D  
W140Y+N260P  
W140Y+G304K  
5 W140Y+G304R  
W140Y+R439T  
W140Y+W469T  
W140Y+D476K  
W140Y+G477R  
10 Y160S+E194D  
Y160S+E212D  
Y160S+N260P  
Y160S+G304K  
Y160S+G304R  
15 Y160S+R439T  
Y160S+W469T  
Y160S+D476K  
Y160S+G477R  
N260P+G304K  
20 N260P+G305R  
N260P+R439K  
N260P+W469R  
N260P+D476K  
N260P+G477R  
25 W284G+G304K  
W284G+G305R  
W284G+R439N  
W284G+W469T  
W284G+D476K  
30 W284G+G477R  
L279T+W284G+H324N+G304K  
L279T+W284G+H324N+G305R  
L279T+W284G+H324N+R439N  
L279T+W284G+H324N+W469T  
35 L279T+W284G+H324N+D476K

- L279T+W284G+H324N+G477R
- G304K+R439K
- G304K+W469R
- G304K+D476K
- 5 G304K+G477R
- G305K+R439K
- G305K+W469R
- G305K+D476K
- G305K+G477R
- 10 R439N+W469R
- R439N+D476K
- R439N+G477R
- W469T+D476K
- W469T+G477R
- 15 W140Y+G304R+G475K
- W 140Y+N260P+G304R+G475K
- W 140Y+E21 2D+G304R+G475K
- W 140Y+G304R+W438R+G475K
- W 140Y+G304R+W468T+G475K
- 20 W140Y+G305K+G475K
- W 140Y+N260P+G305K+D476K
- W 140Y+E21 2D+G305K+D476K
- W 140Y+G305K+R439N+D476K
- W 140Y+G305K+W469T+D476K
- 25 W140Y+G304R+D476K
- W 140Y+N260P+G304R+G477K
- W 140Y+E21 2D+G304R+G477K
- W 140Y+G304R+R439N+G477K
- W 140Y+G304R+W469T+G477K
- 30 W140Y+G305K+G477K
- W 140Y+W284K+G305K+G477K
- W 140Y+N260P+G305K+G477K
- W 140Y+E21 2D+G305K+G477K
- W140Y+G305K+R439N+G477K and
- 35 W140Y+G305K+W469T+G477K

wherein the variants has at least 95% and less than 100% sequence identity to the alpha-amylase of SEQ ID NO: 1.

In another aspect, the invention relates to variants which comprise modifications in the positions, corresponding to the positions of the polypeptide of SEQ ID NO: 1, selected from the

5 group consisting of:

W140Y+Y160S

W140Y+E194D

W140Y+N260P

W140Y+G304K

10 W140Y+G304R

W140Y+R439T

W140Y+W469T

W140Y+D476K

W140Y+G477R

15 Y160S+E194D

Y160S+E212D

Y160S+N260P

Y160S+G304K

Y160S+G304R

20 Y160S+R439T

Y160S+W469T

Y160S+D476K

Y160S+G477R

N260P+G304K

25 N260P+G305R

N260P+R439K

N260P+W469R

N260P+D476K

N260P+G477R

30 W284G+G304K

W284G+G305R

W284G+R439N

W284G+W469T

W284G+D476K

35 W284G+G477R

L279T+W284G+H324N+G304K  
L279T+W284G+H324N+G305R  
L279T+W284G+H324N+R439N  
L279T+W284G+H324N+W469T  
5 L279T+W284G+H324N+D476K  
L279T+W284G+H324N+G477R  
G304K+R439K  
G304K+W469R  
G304K+D476K  
10 G304K+G477R  
G305K+R439K  
G305K+W469R  
G305K+D476K  
G305K+G477R  
15 R439N+W469R  
R439N+D476K  
R439N+G477R  
W469T+D476K  
W469T+G477R  
20 W140Y+G304R+G475K  
W 140Y+N260P+G304R+G475K  
W 140Y+E21 2D+G304R+G475K  
W 140Y+G304R+W438R+G475K  
W 140Y+G304R+W468T+G475K  
25 W140Y+G305K+G475K  
W 140Y+N260P+G305K+D476K  
W 140Y+E21 2D+G305K+D476K  
W 140Y+G305K+R439N+D476K  
W 140Y+G305K+W469T+D476K  
30 W140Y+G304R+D476K  
W 140Y+N260P+G304R+G477K  
W 140Y+E21 2D+G304R+G477K  
W 140Y+G304R+R439N+G477K  
W 140Y+G304R+W469T+G477K  
35 W140Y+G305K+G477K

W 140Y+W284K+G305K+G477K

W 140Y+N260P+G305K+G477K

W 140Y+E21 2D+G305K+G477K

W140Y+G305K+R439N+G477K and

5 W140Y+G305K+W469T+G477K

wherein the variants has at least 97% and less than 100% sequence identity to the alpha-amylase of SEQ ID NO: 1.

In another aspect, the invention relates to variants which comprise modifications in the positions, corresponding to the positions of the polypeptide of SEQ ID NO: 1, selected from the

10 group consisting of:

W140Y+Y160S

W140Y+E194D

W140Y+N260P

W140Y+G304K

15 W140Y+G304R

W140Y+R439T

W140Y+W469T

W140Y+D476K

W140Y+G477R

20 Y160S+E194D

Y160S+E212D

Y160S+N260P

Y160S+G304K

Y160S+G304R

25 Y160S+R439T

Y160S+W469T

Y160S+D476K

Y160S+G477R

N260P+G304K

30 N260P+G305R

N260P+R439K

N260P+W469R

N260P+D476K

N260P+G477R

35 W284G+G304K

W284G+G305R  
W284G+R439N  
W284G+W469T  
W284G+D476K  
5 W284G+G477R  
L279T+W284G+H324N+G304K  
L279T+W284G+H324N+G305R  
L279T+W284G+H324N+R439N  
L279T+W284G+H324N+W469T  
10 L279T+W284G+H324N+D476K  
L279T+W284G+H324N+G477R  
G304K+R439K  
G304K+W469R  
G304K+D476K  
15 G304K+G477R  
G305K+R439K  
G305K+W469R  
G305K+D476K  
G305K+G477R  
20 R439N+W469R  
R439N+D476K  
R439N+G477R  
W469T+D476K  
W469T+G477R  
25 W140Y+G304R+G475K  
W 140Y+N260P+G304R+G475K  
W 140Y+E21 2D+G304R+G475K  
W 140Y+G304R+W438R+G475K  
W 140Y+G304R+W468T+G475K  
30 W140Y+G305K+G475K  
W 140Y+N260P+G305K+D476K  
W 140Y+E21 2D+G305K+D476K  
W 140Y+G305K+R439N+D476K  
W 140Y+G305K+W469T+D476K  
35 W140Y+G304R+D476K

- W 140Y+N260P+G304R+G477K
- W 140Y+E21 2D+G304R+G477K
- W 140Y+G304R+R439N+G477K
- W 140Y+G304R+W469T+G477K
- 5 W140Y+G305K+G477K
- W 140Y+W284K+G305K+G477K
- W 140Y+N260P+G305K+G477K
- W 140Y+E21 2D+G305K+G477K
- W140Y+G305K+R439N+G477K and
- 10 W140Y+G305K+W469T+G477K

wherein the variants has at least 98% and less than 100% sequence identity to the alpha-amylase of SEQ ID NO: 1.

In yet another aspect, the invention relates to variants wherein the alterations consist of the following alterations in SEQ ID NO: 1:

- 15 W140Y+Y160S
- W140Y+E194D
- W140Y+N260P
- W140Y+G304K
- W140Y+G304R
- 20 W140Y+R439T
- W140Y+W469T
- W140Y+D476K
- W140Y+G477R
- Y160S+E194D
- 25 Y160S+E212D
- Y160S+N260P
- Y160S+G304K
- Y160S+G304R
- Y160S+R439T
- 30 Y160S+W469T
- Y160S+D476K
- Y160S+G477R
- N260P+G304K
- N260P+G305R
- 35 N260P+R439K

N260P+W469R  
N260P+D476K  
N260P+G477R  
W284G+G304K  
5 W284G+G305R  
W284G+R439N  
W284G+W469T  
W284G+D476K  
W284G+G477R  
10 L279T+W284G+H324N+G304K  
L279T+W284G+H324N+G305R  
L279T+W284G+H324N+R439N  
L279T+W284G+H324N+W469T  
L279T+W284G+H324N+D476K  
15 L279T+W284G+H324N+G477R  
G304K+R439K  
G304K+W469R  
G304K+D476K  
G304K+G477R  
20 G305K+R439K  
G305K+W469R  
G305K+D476K  
G305K+G477R  
R439N+W469R  
25 R439N+D476K  
R439N+G477R  
W469T+D476K  
W469T+G477R  
W140Y+G304R+G475K  
30 W140Y+N260P+G304R+G475K  
W 140Y+E21 2D+G304R+G475K  
W 140Y+G304R+W438R+G475K  
W 140Y+G304R+W468T+G475K  
W140Y+G305K+G475K  
35 W140Y+N260P+G305K+D476K

- W 140Y+E21 2D+G305K+D476K
- W 140Y+G305K+R439N+D476K
- W 140Y+G305K+W469T+D476K
- W140Y+G304R+D476K
- 5 W140Y+N260P+G304R+G477K
- W 140Y+E21 2D+G304R+G477K
- W 140Y+G304R+R439N+G477K
- W 140Y+G304R+W469T+G477K
- W140Y+G305K+G477K
- 10 W140Y+W284K+G305K+G477K
- W 140Y+N260P+G305K+G477K
- W 140Y+E21 2D+G305K+G477K
- W140Y+G305K+R439N+G477K and
- W 140Y+G305K+W469T+G477K
- 15 In yet another aspect, the invention relates to variants wherein the alterations consist of the alterations in SEQ ID NO: 2:
  - W140Y+Y160S
  - W140Y+E194D
  - W140Y+N260P
  - 20 W140Y+G304K
  - W140Y+G304R
  - W140Y+W439T
  - W140Y+W469T
  - W140Y+G476K
  - 25 W140Y+G477R
  - Y160S+E194D
  - Y160S+E212D
  - Y160S+N260P
  - Y160S+G304K
  - 30 Y160S+G304R
  - Y160S+W439T
  - Y160S+W469T
  - Y160S+G476K
  - Y160S+G477R
  - 35 N260P+G304K

N260P+G305R  
N260P+W439K  
N260P+W469R  
N260P+G476K  
5 N260P+G477R  
W284G+G304K  
W284G+G305R  
W284G+W439R  
W284G+W469T  
10 W284G+G476K  
W284G+G477R  
L279T+W284G+H324N+G304K  
L279T+W284G+H324N+G305R  
L279T+W284G+H324N+W439R  
15 L279T+W284G+H324N+W469T  
L279T+W284G+H324N+G476K  
L279T+W284G+H324N+G477R  
G304K+W439K  
G304K+W469R  
20 G304K+G476K  
G304K+G477R  
G305K+W439K  
G305K+W469R  
G305K+G476K  
25 G305K+G477R  
W439R+W469R  
W439R+G476K  
W439R+G477R  
W469T+G476K  
30 W469T+G477R  
W140Y+G304R+G475K  
W 140Y+N260P+G304R+G475K  
W 140Y+E21 2D+G304R+G475K  
W 140Y+G304R+W438R+G475K  
35 W140Y+G304R+W468T+G475K

- W140Y+G305K+G475K
- W 140Y+N260P+G305K+G476K
- W 140Y+E21 2D+G305K+G476K
- W 140Y+G305K+W439R+G476K
- 5 W140Y+G305K+W469T+G476K
- W140Y+G304R+G476K
- W 140Y+N260P+G304R+G477K
- W 140Y+E21 2D+G304R+G477K
- W 140Y+G304R+W439R+G477K
- 10 W140Y+G304R+W469T+G477K
- W140Y+G305K+G477K
- W 140Y+W284K+G305K+G477K
- W 140Y+N260P+G305K+G477K
- W 140Y+E21 2D+G305K+G477K
- 15 W 140Y+G305K+W439R+G477K and
- W 140Y+G305K+W469T+G477K

In yet another aspect, the invention relates to variants which comprise modifications in the positions, corresponding to the positions of the polypeptide of SEQ ID NO: 2, selected from the group consisting of:

- 20 W140Y+Y160S
- W140Y+E194D
- W140Y+N260P
- W140Y+G304K
- W140Y+G304R
- 25 W140Y+W439T
- W140Y+W469T
- W140Y+G476K
- W140Y+G477R
- Y160S+E194D
- 30 Y160S+E212D
- Y160S+N260P
- Y160S+G304K
- Y160S+G304R
- Y160S+W439T
- 35 Y160S+W469T

Y160S+G476K  
Y160S+G477R  
N260P+G304K  
N260P+G305R  
5 N260P+W439K  
N260P+W469R  
N260P+G476K  
N260P+G477R  
W284G+G304K  
10 W284G+G305R  
W284G+W439R  
W284G+W469T  
W284G+G476K  
W284G+G477R  
15 L279T+W284G+H324N+G304K  
L279T+W284G+H324N+G305R  
L279T+W284G+H324N+W439R  
L279T+W284G+H324N+W469T  
L279T+W284G+H324N+G476K  
20 L279T+W284G+H324N+G477R  
G304K+W439K  
G304K+W469R  
G304K+G476K  
G304K+G477R  
25 G305K+W439K  
G305K+W469R  
G305K+G476K  
G305K+G477R  
W439R+W469R  
30 W439R+G476K  
W439R+G477R  
W469T+G476K  
W469T+G477R  
W140Y+G304R+G475K  
35 W140Y+N260P+G304R+G475K

- W 140Y+E21 2D+G304R+G475K  
W 140Y+G304R+W438R+G475K  
W 140Y+G304R+W468T+G475K  
W140Y+G305K+G475K  
5 W140Y+N260P+G305K+G476K  
W 140Y+E21 2D+G305K+G476K  
W 140Y+G305K+W439R+G476K  
W 140Y+G305K+W469T+G476K  
W140Y+G304R+G476K  
10 W140Y+N260P+G304R+G477K  
W 140Y+E21 2D+G304R+G477K  
W 140Y+G304R+W439R+G477K  
W 140Y+G304R+W469T+G477K  
W140Y+G305K+G477K  
15 W140Y+W284K+G305K+G477K  
W 140Y+N260P+G305K+G477K  
W 140Y+E21 2D+G305K+G477K  
W140Y+G305K+W439R+G477K and  
W 140Y+G305K+W469T+G477K

20 wherein the variants has at least 85% and less than 100% sequence identity to the alpha-amylase of SEQ ID NO: 2.

In another aspect, the invention relates to variants which comprise modifications in the positions, corresponding to the positions of the polypeptide of SEQ ID NO: 2, selected from the group consisting of:

- 25 W140Y+Y160S  
W140Y+E194D  
W140Y+N260P  
W140Y+G304K  
W140Y+G304R  
30 W140Y+W439T  
W140Y+W469T  
W140Y+G476K  
W140Y+G477R  
Y160S+E194D  
35 Y160S+E212D

Y160S+N260P  
Y160S+G304K  
Y160S+G304R  
Y160S+W439T  
5 Y160S+W469T  
Y160S+G476K  
Y160S+G477R  
N260P+G304K  
N260P+G305R  
10 N260P+W439K  
N260P+W469R  
N260P+G476K  
N260P+G477R  
W284G+G304K  
15 W284G+G305R  
W284G+W439R  
W284G+W469T  
W284G+G476K  
W284G+G477R  
20 L279T+W284G+H324N+G304K  
L279T+W284G+H324N+G305R  
L279T+W284G+H324N+W439R  
L279T+W284G+H324N+W469T  
L279T+W284G+H324N+G476K  
25 L279T+W284G+H324N+G477R  
G304K+W439K  
G304K+W469R  
G304K+G476K  
G304K+G477R  
30 G305K+W439K  
G305K+W469R  
G305K+G476K  
G305K+G477R  
W439R+W469R  
35 W439R+G476K

- W439R+G477R
- W469T+G476K
- W469T+G477R
- W140Y+G304R+G475K
- 5 W140Y+N260P+G304R+G475K
- W 140Y+E21 2D+G304R+G475K
- W 140Y+G304R+W438R+G475K
- W 140Y+G304R+W468T+G475K
- W140Y+G305K+G475K
- 10 W140Y+N260P+G305K+G476K
- W 140Y+E21 2D+G305K+G476K
- W 140Y+G305K+W439R+G476K
- W 140Y+G305K+W469T+G476K
- W140Y+G304R+G476K
- 15 W140Y+N260P+G304R+G477K
- W 140Y+E21 2D+G304R+G477K
- W 140Y+G304R+W439R+G477K
- W 140Y+G304R+W469T+G477K
- W140Y+G305K+G477K
- 20 W140Y+W284K+G305K+G477K
- W 140Y+N260P+G305K+G477K
- W 140Y+E21 2D+G305K+G477K
- W140Y+G305K+W439R+G477K and
- W 140Y+G305K+W469T+G477K
- 25 wherein the variants has at least 90% and less than 100% sequence identity to the alpha-amylase of SEQ ID NO: 2.

In another aspect, the invention relates to variants which comprise modifications in the positions, corresponding to the positions of the polypeptide of SEQ ID NO: 2, selected from the group consisting of:

- 30 W140Y+Y160S
- W140Y+E194D
- W140Y+N260P
- W140Y+G304K
- W140Y+G304R
- 35 W140Y+W439T

W140Y+W469T  
W140Y+G476K  
W140Y+G477R  
Y160S+E194D  
5 Y160S+E212D  
Y160S+N260P  
Y160S+G304K  
Y160S+G304R  
Y160S+W439T  
10 Y160S+W469T  
Y160S+G476K  
Y160S+G477R  
N260P+G304K  
N260P+G305R  
15 N260P+W439K  
N260P+W469R  
N260P+G476K  
N260P+G477R  
W284G+G304K  
20 W284G+G305R  
W284G+W439R  
W284G+W469T  
W284G+G476K  
W284G+G477R  
25 L279T+W284G+H324N+G304K  
L279T+W284G+H324N+G305R  
L279T+W284G+H324N+W439R  
L279T+W284G+H324N+W469T  
L279T+W284G+H324N+G476K  
30 L279T+W284G+H324N+G477R  
G304K+W439K  
G304K+W469R  
G304K+G476K  
G304K+G477R  
35 G305K+W439K

- G305K+W469R
- G305K+G476K
- G305K+G477R
- W439R+W469R
- 5 W439R+G476K
- W439R+G477R
- W469T+G476K
- W469T+G477R
- W140Y+G304R+G475K
- 10 W140Y+N260P+G304R+G475K
- W 140Y+E21 2D+G304R+G475K
- W 140Y+G304R+W438R+G475K
- W 140Y+G304R+W468T+G475K
- W140Y+G305K+G475K
- 15 W140Y+N260P+G305K+G476K
- W 140Y+E21 2D+G305K+G476K
- W 140Y+G305K+W439R+G476K
- W 140Y+G305K+W469T+G476K
- W140Y+G304R+G476K
- 20 W140Y+N260P+G304R+G477K
- W 140Y+E21 2D+G304R+G477K
- W 140Y+G304R+W439R+G477K
- W 140Y+G304R+W469T+G477K
- W140Y+G305K+G477K
- 25 W140Y+W284K+G305K+G477K
- W 140Y+N260P+G305K+G477K
- W 140Y+E21 2D+G305K+G477K
- W140Y+G305K+W439R+G477K and
- W 140Y+G305K+W469T+G477K
- 30 wherein the variants has at least 95% and less than 100% sequence identity to the alpha-amylase of SEQ ID NO: 2.

In another aspect, the invention relates to variants which comprise modifications in the positions, corresponding to the positions of the polypeptide of SEQ ID NO: 2, selected from the group consisting of:

- 35 W140Y+Y160S

W140Y+E194D  
W140Y+N260P  
W140Y+G304K  
W140Y+G304R  
5 W140Y+W439T  
W140Y+W469T  
W140Y+G476K  
W140Y+G477R  
Y160S+E194D  
10 Y160S+E212D  
Y160S+N260P  
Y160S+G304K  
Y160S+G304R  
Y160S+W439T  
15 Y160S+W469T  
Y160S+G476K  
Y160S+G477R  
N260P+G304K  
N260P+G305R  
20 N260P+W439K  
N260P+W469R  
N260P+G476K  
N260P+G477R  
W284G+G304K  
25 W284G+G305R  
W284G+W439R  
W284G+W469T  
W284G+G476K  
W284G+G477R  
30 L279T+W284G+H324N+G304K  
L279T+W284G+H324N+G305R  
L279T+W284G+H324N+W439R  
L279T+W284G+H324N+W469T  
L279T+W284G+H324N+G476K  
35 L279T+W284G+H324N+G477R

- G304K+W439K
- G304K+W469R
- G304K+G476K
- G304K+G477R
- 5 G305K+W439K
- G305K+W469R
- G305K+G476K
- G305K+G477R
- 10 W439R+W469R
- W439R+G476K
- W439R+G477R
- W469T+G476K
- W469T+G477R
- W140Y+G304R+G475K
- 15 W140Y+N260P+G304R+G475K
- W 140Y+E21 2D+G304R+G475K
- W 140Y+G304R+W438R+G475K
- W 140Y+G304R+W468T+G475K
- W140Y+G305K+G475K
- 20 W140Y+N260P+G305K+G476K
- W 140Y+E21 2D+G305K+G476K
- W 140Y+G305K+W439R+G476K
- W 140Y+G305K+W469T+G476K
- W140Y+G304R+G476K
- 25 W140Y+N260P+G304R+G477K
- W 140Y+E21 2D+G304R+G477K
- W 140Y+G304R+W439R+G477K
- W 140Y+G304R+W469T+G477K
- W140Y+G305K+G477K
- 30 W140Y+W284K+G305K+G477K
- W 140Y+N260P+G305K+G477K
- W 140Y+E21 2D+G305K+G477K
- W140Y+G305K+W439R+G477K and
- W 140Y+G305K+W469T+G477K

wherein the variants has at least 96% and less than 100% sequence identity to the alpha-amylase of SEQ ID NO: 2.

In another aspect, the invention relates to variants which comprise modifications in the positions, corresponding to the positions of the polypeptide of SEQ ID NO: 2, selected from the

5 group consisting of:

W140Y+Y160S

W140Y+E194D

W140Y+N260P

W140Y+G304K

10 W140Y+G304R

W140Y+W439T

W140Y+W469T

W140Y+G476K

W140Y+G477R

15 Y160S+E194D

Y160S+E212D

Y160S+N260P

Y160S+G304K

Y160S+G304R

20 Y160S+W439T

Y160S+W469T

Y160S+G476K

Y160S+G477R

N260P+G304K

25 N260P+G305R

N260P+W439K

N260P+W469R

N260P+G476K

N260P+G477R

30 W284G+G304K

W284G+G305R

W284G+W439R

W284G+W469T

W284G+G476K

35 W284G+G477R

L279T+W284G+H324N+G304K  
L279T+W284G+H324N+G305R  
L279T+W284G+H324N+W439R  
L279T+W284G+H324N+W469T  
5 L279T+W284G+H324N+G476K  
L279T+W284G+H324N+G477R  
G304K+W439K  
G304K+W469R  
G304K+G476K  
10 G304K+G477R  
G305K+W439K  
G305K+W469R  
G305K+G476K  
G305K+G477R  
15 W439R+W469R  
W439R+G476K  
W439R+G477R  
W469T+G476K  
W469T+G477R  
20 W140Y+G304R+G475K  
W 140Y+N260P+G304R+G475K  
W 140Y+E21 2D+G304R+G475K  
W 140Y+G304R+W438R+G475K  
W 140Y+G304R+W468T+G475K  
25 W140Y+G305K+G475K  
W 140Y+N260P+G305K+G476K  
W 140Y+E21 2D+G305K+G476K  
W 140Y+G305K+W439R+G476K  
W 140Y+G305K+W469T+G476K  
30 W140Y+G304R+G476K  
W 140Y+N260P+G304R+G477K  
W 140Y+E21 2D+G304R+G477K  
W 140Y+G304R+W439R+G477K  
W 140Y+G304R+W469T+G477K  
35 W140Y+G305K+G477K

W 140Y+W284K+G305K+G477K

W 140Y+N260P+G305K+G477K

W 140Y+E21 2D+G305K+G477K

W140Y+G305K+W439R+G477K and

5 W140Y+G305K+W469T+G477K

wherein the variants has at least 97% and less than 100% sequence identity to the alpha-amylase of SEQ ID NO: 2.

In one embodiment, the variant of invention comprises between 2 and 20 alterations, e.g. between 2 and 10 or between 2 and 5, such as 2, 3, 4, 5, 6, 7, 8, 9 or 10 alterations. Preferably the alterations are substitutions and/or deletions.

In one embodiment, the invention provides variants that consists of 450 to 490, e.g., 460 to 485, 465 to 483, 480 to 483 amino acids, such as 481, 482, 483 or 484 amino acids, preferably 483.

In an embodiment, the variant has sequence identity of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, but less than 100%, to the amino acid sequence of the parent alpha-amylase.

In another embodiment, the variant has at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, but less than 100%, sequence identity to the mature polypeptide of SEQ ID NO: 1.

In another embodiment, the variant has at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, but less than 100%, sequence identity to the mature polypeptide of SEQ ID NO: 2.

The variants may further comprise one or more additional alterations at one or more (e.g., several) other positions.

The amino acid changes may be of a minor nature, that is conservative amino acid substitutions or insertions that do not significantly affect the folding and/or activity of the protein; small deletions, typically of 1-30 amino acids; small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue; a small linker peptide of up to 20-25 residues; or a small extension that facilitates purification by changing net charge or another function, such as a poly-histidine tract, an antigenic epitope or a binding domain.

Examples of conservative substitutions are within the groups of basic amino acids (arginine, lysine and histidine), acidic amino acids (glutamic acid and aspartic acid), polar amino acids (glutamine and asparagine), hydrophobic amino acids (leucine, isoleucine and valine), aromatic amino acids (phenylalanine, tryptophan and tyrosine), and small amino acids (glycine, alanine, serine, threonine and methionine). Amino acid substitutions that do not generally alter specific activity are known in the art and are described, for example, by H. Neurath and R.L. Hill, 1979, *In, The Proteins*, Academic Press, New York. Common substitutions are Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, AlaA/al, Ser/Gly, Tyr/Phe, Ala/Pro, Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu, and Asp/Gly.

Alternatively, the amino acid changes are of such a nature that the physico-chemical properties of the polypeptides are altered. For example, amino acid changes may improve the thermal stability of the polypeptide, alter the substrate specificity, change the pH optimum, improve wash performance and the like.

Essential amino acids in a polypeptide can be identified according to procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, 1989, *Science* 244: 1081-1085). In the latter technique, single alanine mutations are introduced at every residue in the molecule, and the resultant mutant molecules are tested for alpha-amylase activity to identify amino acid residues that are critical to the activity of the molecule. See also, Hilton *et al.*, 1996, *J. Biol. Chem.* 271 : 4699-4708. The active site of the enzyme or other biological interaction can also be determined by physical analysis of structure, as determined by such techniques as nuclear magnetic resonance, crystallography, electron diffraction, or photoaffinity labeling, in conjunction with mutation of putative contact site amino acids. See, for example, de Vos *et al.*, 1992, *Science* 255: 306-312; Smith *et al.*, 1992, *J. Mol. Biol.* 224: 899-904; Wlodaver *et al.*, 1992, *FEBS Lett.* 309: 59-64. The identity of essential amino acids can also be inferred from an alignment with a related polypeptide.

In an embodiment, the variant has improved catalytic efficiency compared to the parent enzyme.

In an embodiment, the variant has improved catalytic rate compared to the parent enzyme.

In an embodiment, the variant has improved chemical stability compared to the parent enzyme.

In an embodiment, the variant has improved oxidation stability compared to the parent enzyme.

In an embodiment, the variant has improved pH activity compared to the parent enzyme.

In an embodiment, the variant has improved pH stability compared to the parent enzyme.

In an embodiment, the variant has improved specific activity compared to the parent enzyme.

In an embodiment, the variant has improved stability under storage conditions compared to the parent enzyme.

5 In an embodiment, the variant has decreased substrate binding compared to the parent enzyme.

In an embodiment, the variant has improved substrate specificity compared to the parent enzyme.

10 In an embodiment, the variant has improved substrate stability compared to the parent enzyme.

In an embodiment, the variant has improved surface properties compared to the parent enzyme.

In an embodiment, the variant has improved thermal activity compared to the parent enzyme.

15 In an embodiment, the variant has improved thermostability compared to the parent enzyme.

In another embodiment the variant has improved wash performance, in particular improved wash performance at low temperature compared to the parent enzyme.

## 20 **Parent alpha-amylases**

The parent alpha-amylase may be (a) a polypeptide having at least 85% sequence identity to the mature polypeptide of SEQ ID NO: 1; (b) a fragment of the mature polypeptide of SEQ ID NO: 1, which has alpha-amylase activity or (c) a polypeptide having immunological cross reactivity with an antibody raised against the mature polypeptide of SEQ ID NO: 1.

25 In another aspect, the parent alpha-amylase may be (a) a polypeptide having at least 85% sequence identity to the mature polypeptide of SEQ ID NO: 2; (b) a fragment of the mature polypeptide of SEQ ID NO: 2, which has alpha-amylase activity or (c) a polypeptide having immunological cross reactivity with an antibody raised against the mature polypeptide of SEQ ID NO: 2.

30 In an aspect, the parent has a sequence identity to the mature polypeptide of SEQ ID NO: 1 of at least 87%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%. In one aspect, the amino acid sequence of the parent differs by no more than 10 amino acids, e.g., 1, 2, 3, 4, 5, 6, 7, 8, or 9, from the mature polypeptide of SEQ ID NO: 1.

In an aspect, the parent has a sequence identity to the mature polypeptide of SEQ ID NO: 2 of at least 87%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%. In one aspect, the amino acid sequence of the parent differs by no more than 10 amino acids, e.g., 1, 2, 3, 4, 5, 6, 7, 8, or 9, from the mature polypeptide of SEQ ID NO: 2.

In another aspect, the parent comprises or consists of the amino acid sequence of SEQ ID NO: 1. In another aspect, the parent comprises or consists of the amino acid sequence of SEQ ID NO: 2.

In yet another embodiment, the parent is an allelic variant of the mature polypeptide of SEQ ID NO: 1 or 2.

The parent may be a fusion polypeptide or cleavable fusion polypeptide in which another polypeptide is fused at the N-terminus or the C-terminus of the polypeptide of the present invention. A fusion polypeptide is produced by fusing a polynucleotide encoding another polypeptide to a polynucleotide of the present invention. Techniques for producing fusion polypeptides are known in the art, and include ligating the coding sequences encoding the polypeptides so that they are in frame and that expression of the fusion polypeptide is under control of the same promoter(s) and terminator. Fusion polypeptides may also be constructed using intein technology in which fusion polypeptides are created post-translationally (Cooper *et al.*, 1993, *EMBO J.* 12: 2575-2583; Dawson *et al.*, 1994, *Science* 266: 776-779).

A fusion polypeptide can further comprise a cleavage site between the two polypeptides. Upon secretion of the fusion protein, the site is cleaved releasing the two polypeptides. Examples of cleavage sites include, but are not limited to, the sites disclosed in Martin *et al.*, 2003, *J. Ind. Microbiol. Biotechnol.* 3: 568-576; Svetina *et al.*, 2000, *J. Biotechnol.* 76: 245-251; Rasmussen-Wilson *et al.*, 1997, *Appl. Environ. Microbiol.* 63: 3488-3493; Ward *et al.*, 1995, *Biotechnology* 13: 498-503; and Contreras *et al.*, 1991, *Biotechnology* 9: 378-381; Eaton *et al.*, 1986, *Biochemistry* 25: 505-512; Collins-Racie *et al.*, 1995, *Biotechnology* 13: 982-987; Carter *et al.*, 1989, *Proteins: Structure, Function, and Genetics* 6: 240-248; and Stevens, 2003, *Drug Discovery World* 4: 35-48.

The parent may be obtained from microorganisms of any genus. For purposes of the present invention, the term "obtained from" as used herein in connection with a given source shall mean that the parent encoded by a polynucleotide is produced by the source or by a strain in which the polynucleotide from the source has been inserted. In one aspect, the parent is secreted extracellularly.

The parent may be a bacterial alpha-amylase. For example, the parent may be a Gram-positive bacterial polypeptide such as a *Bacillus* alpha-amylase. Preferred strains are of *Bacillus sp.* DSM 12650 (the AAI-6 a-amylase) or DSM 12651 (the AAI-10 a-amylase). These strains were

deposited on 25<sup>th</sup> January 1999 under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure at Deutsche Sammlung von Microorganismen und Zellkulturen GmbH (DSMZ), Mascheroder Weg 1b, D-38124 Braunschweig DE. Thus, in one aspect the parent is a *Bacillus AAI-6* alpha-amylase or a  
5 *Bacillus AAI-10* alpha-amylase e.g., the alpha-amylase of SEQ ID NO: 1 or 2. The alpha-amylases of SEQ ID NOs 1 and 2 as well as the variants hereof may also be artificially manufactured by methods known in the art.

### Preparation of Variants

10 The present invention also relates to methods for obtaining a variant having alpha-amylase activity, comprising: (a) introducing into a parent alpha-amylase an alteration at two or more positions corresponding to positions W140; W159; W167, Q169, W189, E194, N260, F262, F289, W284, G304, G305, W347, R439, W469, D476 and G477 of the mature polypeptide of SEQ ID NO: 1, wherein each alteration is independently a substitution, deletion or insertion and the variant has  
15 alpha-amylase activity; and (b) recovering the variant.

The variants can be prepared using any mutagenesis procedure known in the art, such as site-directed mutagenesis, synthetic gene construction, semi-synthetic gene construction, random mutagenesis, shuffling, etc.

20 Site-directed mutagenesis is a technique in which one or more (e.g., several) mutations are introduced at one or more defined sites in a polynucleotide encoding the parent.

Site-directed mutagenesis can be accomplished *in vitro* by PCR involving the use of oligonucleotide primers containing the desired mutation. Site-directed mutagenesis can also be performed *in vitro* by cassette mutagenesis involving the cleavage by a restriction enzyme at a site in the plasmid comprising a polynucleotide encoding the parent and subsequent ligation of an  
25 oligonucleotide containing the mutation in the polynucleotide. Usually the restriction enzyme that digests the plasmid and the oligonucleotide is the same, permitting sticky ends of the plasmid and the insert to ligate to one another. See, e.g., Scherer and Davis, 1979, *Proc. Natl. Acad. Sci. USA* 76: 4949-4955; and Barton *et ai*, 1990, *Nucleic Acids Res.* 18: 7349-4966.

Site-directed mutagenesis can also be accomplished *in vivo* by methods known in the art.  
30 See, e.g., U.S. Patent Application Publication No. 2004/0171 154; Storici *et ai*, 2001, *Nature Biotechnol.* 19: 773-776; Kren *et ai*, 1998, *Nat. Med.* 4: 285-290; and Calissano and Macino, 1996, *Fungal Genet. Newslett.* 43: 15-16.

Any site-directed mutagenesis procedure can be used in the present invention. There are many commercial kits available that can be used to prepare variants.

Synthetic gene construction entails *in vitro* synthesis of a designed polynucleotide molecule to encode a polypeptide of interest. Gene synthesis can be performed utilizing a number of techniques, such as the multiplex microchip-based technology described by Tian *et al.* (2004, *Nature* 432: 1050-1054) and similar technologies wherein oligonucleotides are synthesized and assembled upon photo-programmable microfluidic chips.

Single or multiple amino acid substitutions, deletions, and/or insertions can be made and tested using known methods of mutagenesis, recombination, and/or shuffling, followed by a relevant screening procedure, such as those disclosed by Reidhaar-Olson and Sauer, 1988, *Science* 241: 53-57; Bowie and Sauer, 1989, *Proc. Natl. Acad. Sci. USA* 86: 2152-2156; WO 95/17413; or WO 95/22625. Other methods that can be used include error-prone PCR, phage display (e.g., Lowman *et al.*, 1991, *Biochemistry* 30: 10832-10837; U.S. Patent No. 5,223,409; WO 92/06204) and region-directed mutagenesis (Derbyshire *et al.*, 1986, *Gene* 46: 145; Ner *et al.*, 1988, *DNA* 7: 127).

Mutagenesis/shuffling methods can be combined with high-throughput, automated screening methods to detect activity of cloned, mutagenized polypeptides expressed by host cells (Ness *et al.*, 1999, *Nature Biotechnology* 17: 893-896). Mutagenized DNA molecules that encode active polypeptides can be recovered from the host cells and rapidly sequenced using standard methods in the art. These methods allow the rapid determination of the importance of individual amino acid residues in a polypeptide.

Semi-synthetic gene construction is accomplished by combining aspects of synthetic gene construction, and/or site-directed mutagenesis, and/or random mutagenesis, and/or shuffling. Semi-synthetic construction is typified by a process utilizing polynucleotide fragments that are synthesized, in combination with PCR techniques. Defined regions of genes may thus be synthesized *de novo*, while other regions may be amplified using site-specific mutagenic primers, while yet other regions may be subjected to error-prone PCR or non-error prone PCR amplification. Polynucleotide subsequences may then be shuffled.

### **Polynucleotides**

The present invention also relates to isolated polynucleotides encoding a variant of the present invention.

### **Nucleic Acid Constructs**

The present invention also relates to nucleic acid constructs comprising a polynucleotide encoding a variant of the present invention operably linked to one or more control sequences that

direct the expression of the coding sequence in a suitable host cell under conditions compatible with the control sequences.

The polynucleotide may be manipulated in a variety of ways to provide for expression of a variant. Manipulation of the polynucleotide prior to its insertion into a vector may be desirable or  
5 necessary depending on the expression vector. The techniques for modifying polynucleotides utilizing recombinant DNA methods are well known in the art.

The control sequence may be a promoter, a polynucleotide which is recognized by a host cell for expression of the polynucleotide. The promoter contains transcriptional control sequences that mediate the expression of the variant. The promoter may be any polynucleotide that shows  
10 transcriptional activity in the host cell including mutant, truncated, and hybrid promoters, and may be obtained from genes encoding extracellular or intracellular polypeptides either homologous or heterologous to the host cell.

Examples of suitable promoters for directing transcription of the nucleic acid constructs of the present invention in a bacterial host cell are the promoters obtained from the *Bacillus amyloliquefaciens* alpha-alpha-amylase gene (*amyQ*), *Bacillus licheniformis* alpha-alpha-amylase  
15 gene (*amyL*), *Bacillus licheniformis* penicillinase gene (*penP*), *Bacillus stearothermophilus* maltogenic alpha-amylase gene (*amyM*), *Bacillus subtilis* levansucrase gene (*sacB*), *Bacillus subtilis* *xylA* and *xylB* genes, *Bacillus thuringiensis cryIIIA* gene (Agaisse and Lereclus, 1994, *Molecular Microbiology* 13: 97-107), *E. coli lac* operon, *E. coli trc* promoter (Egon *et al.*, 1988, *Gene*  
20 69: 301-315), *Streptomyces coelicolor* agarase gene (*dagA*), and prokaryotic beta-lactamase gene (Villa-Kamaroff *et al.*, 1978, *Proc. Natl. Acad. Sci. USA* 75: 3727-3731), as well as the *tac* promoter (DeBoer *et al.*, 1983, *Proc. Natl. Acad. Sci. USA* 80: 21-25). Further promoters are described in "Useful proteins from recombinant bacteria" in Gilbert *et al.*, 1980, *Scientific American* 242: 74-94; and in Sambrook *et al.*, 1989, *supra*. Examples of tandem promoters are disclosed in WO  
25 99/43835.

Examples of suitable promoters for directing transcription of the nucleic acid constructs of the present invention in a filamentous fungal host cell are promoters obtained from the genes for *Aspergillus nidulans* acetamidase, *Aspergillus niger* neutral alpha-alpha-amylase, *Aspergillus niger* acid stable alpha-alpha-amylase, *Aspergillus niger* or *Aspergillus awamori* glucoalpha-amylase  
30 (*glaA*), *Aspergillus oryzae* TAKA alpha-amylase, *Aspergillus oryzae* alkaline protease, *Aspergillus oryzae* triose phosphate isomerase, *Fusarium oxysporum* trypsin-like protease (WO 96/00787), *Fusarium venenatum* amyloglucosidase (WO 00/56900), *Fusarium venenatum* Daria (WO 00/56900), *Fusarium venenatum* Quinn (WO 00/56900), *Rhizomucor miehei* lipase, *Rhizomucor miehei* aspartic proteinase, *Trichoderma reesei* beta-glucosidase, *Trichoderma reesei*  
35 cellobiohydrolase I, *Trichoderma reesei* cellobiohydrolase II, *Trichoderma reesei* endoglucanase I,

*Trichoderma reesei* endoglucanase II, *Trichoderma reesei* endoglucanase III, *Trichoderma reesei* endoglucanase IV, *Trichoderma reesei* endoglucanase V, *Trichoderma reesei* xylanase I, *Trichoderma reesei* xylanase II, *Trichoderma reesei* beta-xylosidase, as well as the NA2-tpi promoter (a modified promoter from an *Aspergillus* neutral alpha-alpha-amylase gene in which the untranslated leader has been replaced by an untranslated leader from an *Aspergillus* triose phosphate isomerase gene; non-limiting examples include modified promoters from an *Aspergillus niger* neutral alpha-alpha-amylase gene in which the untranslated leader has been replaced by an untranslated leader from an *Aspergillus nidulans* or *Aspergillus oryzae* triose phosphate isomerase gene); and mutant, truncated, and hybrid promoters thereof.

10 In a yeast host, useful promoters are obtained from the genes for *Saccharomyces cerevisiae* enolase (ENO-1), *Saccharomyces cerevisiae* galactokinase (GAL1), *Saccharomyces cerevisiae* alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase (ADH1, ADH2/GAP), *Saccharomyces cerevisiae* triose phosphate isomerase (TPI), *Saccharomyces cerevisiae* metallothionein (CUP1), and *Saccharomyces cerevisiae* 3-phosphoglycerate kinase.  
15 Other useful promoters for yeast host cells are described by Romanos *et al.*, 1992, *Yeast* 8: 423-488.

The control sequence may also be a transcription terminator, which is recognized by a host cell to terminate transcription. The terminator sequence is operably linked to the 3'-terminus of the polynucleotide encoding the variant. Any terminator that is functional in the host cell may be used.

20 Preferred terminators for bacterial host cells are obtained from the genes for *Bacillus clausii* alkaline protease (*aprH*), *Bacillus licheniformis* alpha-alpha-amylase (*amyL*), and *Escherichia coli* ribosomal RNA (*rrnB*).

Preferred terminators for filamentous fungal host cells are obtained from the genes for *Aspergillus nidulans* anthranilate synthase, *Aspergillus niger* glucoalpha-amylase, *Aspergillus niger* alpha-glucosidase, *Aspergillus oryzae* TAKA alpha-amylase, and *Fusarium oxysporum* trypsin-like protease.

Preferred terminators for yeast host cells are obtained from the genes for *Saccharomyces cerevisiae* enolase, *Saccharomyces cerevisiae* cytochrome C (CYC1), and *Saccharomyces cerevisiae* glyceraldehyde-3-phosphate dehydrogenase. Other useful terminators for yeast host  
30 cells are described by Romanos *et al.*, 1992, *supra*.

The control sequence may also be an mRNA stabilizer region downstream of a promoter and upstream of the coding sequence of a gene which increases expression of the gene.

Examples of suitable mRNA stabilizer regions are obtained from a *Bacillus thuringiensis cryIIIA* gene (WO 94/25612) and a *Bacillus subtilis* SP82 gene (Hue *et al.*, 1995, *Journal of Bacteriology* 177: 3465-3471 ).  
35

The control sequence may also be a leader, a nontranslated region of an mRNA that is important for translation by the host cell. The leader sequence is operably linked to the 5'-terminus of the polynucleotide encoding the variant. Any leader that is functional in the host cell may be used.

5 Preferred leaders for filamentous fungal host cells are obtained from the genes for *Aspergillus oryzae* TAKA alpha-amylase and *Aspergillus nidulans* triose phosphate isomerase.

Suitable leaders for yeast host cells are obtained from the genes for *Saccharomyces cerevisiae* enolase (ENO-1), *Saccharomyces cerevisiae* 3-phosphoglycerate kinase, *Saccharomyces cerevisiae* alpha-factor, and *Saccharomyces cerevisiae* alcohol  
10 dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase (ADH2/GAP).

The control sequence may also be a polyadenylation sequence, a sequence operably linked to the 3'-terminus of the variant-encoding sequence and, when transcribed, is recognized by the host cell as a signal to add polyadenosine residues to transcribed mRNA. Any polyadenylation sequence that is functional in the host cell may be used.

15 Preferred polyadenylation sequences for filamentous fungal host cells are obtained from the genes for *Aspergillus nidulans* anthranilate synthase, *Aspergillus niger* glucoalpha-amylase, *Aspergillus niger* alpha-glucosidase, *Aspergillus oryzae* TAKA alpha-amylase, and *Fusarium oxysporum* trypsin-like protease.

Useful polyadenylation sequences for yeast host cells are described by Guo and Sherman,  
20 1995, *Mol. Cellular Biol.* 15: 5983-5990.

The control sequence may also be a signal peptide coding region that encodes a signal peptide linked to the N-terminus of a variant and directs the variant into the cell's secretory pathway. The 5'-end of the coding sequence of the polynucleotide may inherently contain a signal peptide coding sequence naturally linked in translation reading frame with the segment of the  
25 coding sequence that encodes the variant. Alternatively, the 5'-end of the coding sequence may contain a signal peptide coding sequence that is foreign to the coding sequence. A foreign signal peptide coding sequence may be required where the coding sequence does not naturally contain a signal peptide coding sequence. Alternatively, a foreign signal peptide coding sequence may simply replace the natural signal peptide coding sequence in order to enhance secretion of the variant.  
30 However, any signal peptide coding sequence that directs the expressed variant into the secretory pathway of a host cell may be used.

Effective signal peptide coding sequences for bacterial host cells are the signal peptide coding sequences obtained from the genes for *Bacillus* NCIB 11837 maltogenic alpha-amylase, *Bacillus licheniformis* subtilisin, *Bacillus licheniformis* beta-lactamase, *Bacillus stearothermophilus*  
35 alpha-alpha-amylase, *Bacillus stearothermophilus* neutral proteases (*nprT*, *nprS*, *nprM*), and

*Bacillus subtilis prsA*. Further signal peptides are described by Simonen and Palva, 1993, *Microbiological Reviews* 57: 109-137.

Effective signal peptide coding sequences for filamentous fungal host cells are the signal peptide coding sequences obtained from the genes for *Aspergillus niger* neutral alpha-amylase, *Aspergillus niger* glucoalpha-amylase, *Aspergillus oryzae* TAKA alpha-amylase, *Humicola insolens* cellulase, *Humicola insolens* endoglucanase V, *Humicola lanuginosa* lipase, and *Rhizomucor miehei* aspartic proteinase.

Useful signal peptides for yeast host cells are obtained from the genes for *Saccharomyces cerevisiae* alpha-factor and *Saccharomyces cerevisiae* invertase. Other useful signal peptide coding sequences are described by Romanos *et al.*, 1992, *supra*.

The control sequence may also be a propeptide coding sequence that encodes a propeptide positioned at the N-terminus of a variant. The resultant polypeptide is known as a proenzyme or propolypeptide (or a zymogen in some cases). A propolypeptide is generally inactive and can be converted to an active polypeptide by catalytic or autocatalytic cleavage of the propeptide from the propolypeptide. The propeptide coding sequence may be obtained from the genes for *Bacillus subtilis* alkaline protease (*aprE*), *Bacillus subtilis* neutral protease (*nprT*), *Myceliophthora thermophila* laccase (WO 95/33836), *Rhizomucor miehei* aspartic proteinase, and *Saccharomyces cerevisiae* alpha-factor.

Where both signal peptide and propeptide sequences are present, the propeptide sequence is positioned next to the N-terminus of the variant and the signal peptide sequence is positioned next to the N-terminus of the propeptide sequence.

It may also be desirable to add regulatory sequences that regulate expression of the variant relative to the growth of the host cell. Examples of regulatory systems are those that cause expression of the gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound. Regulatory systems in prokaryotic systems include the *lac*, *tac*, and *trp* operator systems. In yeast, the ADH2 system or GAL1 system may be used. In filamentous fungi, the *Aspergillus niger* glucoalpha-amylase promoter, *Aspergillus oryzae* TAKA alpha-alpha-amylase promoter, and *Aspergillus oryzae* glucoalpha-amylase promoter may be used. Other examples of regulatory sequences are those that allow for gene amplification. In eukaryotic systems, these regulatory sequences include the dihydrofolate reductase gene that is amplified in the presence of methotrexate, and the metallothionein genes that are amplified with heavy metals. In these cases, the polynucleotide encoding the variant would be operably linked with the regulatory sequence.

## Expression Vectors

The present invention also relates to recombinant expression vectors comprising a polynucleotide encoding a variant of the present invention, a promoter, and transcriptional and translational stop signals. The various nucleotide and control sequences may be joined together to produce a recombinant expression vector that may include one or more convenient restriction sites to allow for insertion or substitution of the polynucleotide encoding the variant at such sites. Alternatively, the polynucleotide may be expressed by inserting the polynucleotide or a nucleic acid construct comprising the polynucleotide into an appropriate vector for expression. In creating the expression vector, the coding sequence is located in the vector so that the coding sequence is operably linked with the appropriate control sequences for expression.

The recombinant expression vector may be any vector (e.g., a plasmid or virus) that can be conveniently subjected to recombinant DNA procedures and can bring about expression of the polynucleotide. The choice of the vector will typically depend on the compatibility of the vector with the host cell into which the vector is to be introduced. The vector may be a linear or closed circular plasmid.

The vector may be an autonomously replicating vector, i.e., a vector that exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g., a plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome. The vector may contain any means for assuring self-replication. Alternatively, the vector may be one that, when introduced into the host cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated. Furthermore, a single vector or plasmid or two or more vectors or plasmids that together contain the total DNA to be introduced into the genome of the host cell, or a transposon, may be used.

The vector preferably contains one or more selectable markers that permit easy selection of transformed, transfected, transduced, or the like cells. A selectable marker is a gene the product of which provides for biocide or viral resistance, resistance to heavy metals, prototrophy to auxotrophs, and the like.

Examples of bacterial selectable markers are *Bacillus licheniformis* or *Bacillus subtilis* *dal* genes, or markers that confer antibiotic resistance such as ampicillin, chloramphenicol, kanamycin, neomycin, spectinomycin or tetracycline resistance. Suitable markers for yeast host cells include, but are not limited to, ADE2, HIS3, LEU2, LYS2, MET3, TRP1, and URA3. Selectable markers for use in a filamentous fungal host cell include, but are not limited to, *amdS* (acetamidase), *argB* (ornithine carbamoyltransferase), *bar* (phosphinothricin acetyltransferase), *hph* (hygromycin phosphotransferase), *niaD* (nitrate reductase), *pyrG* (orotidine-5'-phosphate decarboxylase), *sC* (sulfate adenylyltransferase), and *trpC* (anthranilate synthase), as well as equivalents thereof.

Preferred for use in an *Aspergillus* cell are *Aspergillus nidulans* or *Aspergillus oryzae amdS* and *pyrG* genes and a *Streptomyces hygroscopicus bar* gene.

The vector preferably contains an element(s) that permits integration of the vector into the host cell's genome or autonomous replication of the vector in the cell independent of the genome.

5 For integration into the host cell genome, the vector may rely on the polynucleotide's sequence encoding the variant or any other element of the vector for integration into the genome by homologous or non-homologous recombination. Alternatively, the vector may contain additional polynucleotides for directing integration by homologous recombination into the genome of the host cell at a precise location(s) in the chromosome(s). To increase the likelihood of integration at a  
10 precise location, the integrational elements should contain a sufficient number of nucleic acids, such as 100 to 10,000 base pairs, 400 to 10,000 base pairs, and 800 to 10,000 base pairs, which have a high degree of sequence identity to the corresponding target sequence to enhance the probability of homologous recombination. The integrational elements may be any sequence that is homologous with the target sequence in the genome of the host cell. Furthermore, the integrational  
15 elements may be non-encoding or encoding polynucleotides. On the other hand, the vector may be integrated into the genome of the host cell by non-homologous recombination.

For autonomous replication, the vector may further comprise an origin of replication enabling the vector to replicate autonomously in the host cell in question. The origin of replication may be any plasmid replicator mediating autonomous replication that functions in a cell. The term  
20 "origin of replication" or "plasmid replicator" means a polynucleotide that enables a plasmid or vector to replicate *in vivo*.

Examples of bacterial origins of replication are the origins of replication of plasmids pBR322, pUC19, pACYC177, and pACYC184 permitting replication in *E. coli*, and pUB1 10, pE194, pTA1060, and pAM $\beta$ I permitting replication in *Bacillus*.

25 Examples of origins of replication for use in a yeast host cell are the 2 micron origin of replication, ARS1, ARS4, the combination of ARS1 and CEN3, and the combination of ARS4 and CEN6.

Examples of origins of replication useful in a filamentous fungal cell are AMA1 and ANSI (Gems *et al.*, 1991, *Gene* 98: 61-67; Cullen *et al.*, 1987, *Nucleic Acids Res.* 15: 9163-9175;  
30 WO 00/24883). Isolation of the AMA1 gene and construction of plasmids or vectors comprising the gene can be accomplished according to the methods disclosed in WO 00/24883.

More than one copy of a polynucleotide of the present invention may be inserted into a host cell to increase production of a variant. An increase in the copy number of the polynucleotide can be obtained by integrating at least one additional copy of the sequence into the host cell genome or  
35 by including an amplifiable selectable marker gene with the polynucleotide where cells containing

amplified copies of the selectable marker gene, and thereby additional copies of the polynucleotide, can be selected for by cultivating the cells in the presence of the appropriate selectable agent.

The procedures used to ligate the elements described above to construct the recombinant expression vectors of the present invention are well known to one skilled in the art (see, e.g.,  
5 Sambrook *et al.*, 1989, *supra*).

### Host Cells

The present invention also relates to recombinant host cells, comprising a polynucleotide encoding a variant of the present invention operably linked to one or more control sequences that  
10 direct the production of a variant of the present invention. A construct or vector comprising a polynucleotide is introduced into a host cell so that the construct or vector is maintained as a chromosomal integrant or as a self-replicating extra-chromosomal vector as described earlier. The term "host cell" encompasses any progeny of a parent cell that is not identical to the parent cell due to mutations that occur during replication. The choice of a host cell will to a large extent depend  
15 upon the gene encoding the variant and its source.

The host cell may be any cell useful in the recombinant production of a variant, e.g., a prokaryote or a eukaryote.

The prokaryotic host cell may be any Gram-positive or Gram-negative bacterium. Gram-positive bacteria include, but are not limited to, *Bacillus*, *Clostridium*, *Enterococcus*, *Geobacillus*,  
20 *Lactobacillus*, *Lactococcus*, *Oceanobacillus*, *Staphylococcus*, *Streptococcus*, and *Streptomyces*. Gram-negative bacteria include, but are not limited to, *Campylobacter*, *E. coli*, *Flavobacterium*, *Fusobacterium*, *Helicobacter*, *Ilyobacter*, *Neisseria*, *Pseudomonas*, *Salmonella*, and *Ureaplasma*.

The bacterial host cell may be any *Bacillus* cell including, but not limited to, *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus brevis*, *Bacillus circulans*, *Bacillus clausii*, *Bacillus*  
25 *coagulans*, *Bacillus firmus*, *Bacillus lautus*, *Bacillus lentus*, *Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus pumilus*, *Bacillus stearothermophilus*, *Bacillus subtilis*, and *Bacillus thuringiensis* cells.

The bacterial host cell may also be any *Streptococcus* cell including, but not limited to, *Streptococcus equisimilis*, *Streptococcus pyogenes*, *Streptococcus uberis*, and *Streptococcus equi*  
30 subsp. *Zooepidemicus* cells.

The bacterial host cell may also be any *Streptomyces* cell, including, but not limited to, *Streptomyces achromogenes*, *Streptomyces avermitilis*, *Streptomyces coelicolor*, *Streptomyces griseus*, and *Streptomyces lividans* cells.

The introduction of DNA into a *Bacillus* cell may be effected by protoplast transformation  
35 (see, e.g., Chang and Cohen, 1979, *Mol. Gen. Genet.* 168: 111-115), competent cell transformation

(see, e.g., Young and Spizizen, 1961, *J. Bacteriol.* 81: 823-829, or Dubnau and Davidoff-Abelson, 1971, *J. Mol. Biol.* 56: 209-221), electroporation (see, e.g., Shigekawa and Dower, 1988, *Biotechniques* 6: 742-751), or conjugation (see, e.g., Koehler and Thorne, 1987, *J. Bacteriol.* 169: 5271-5278). The introduction of DNA into an *E. coli* cell may be effected by protoplast transformation (see, e.g., Hanahan, 1983, *J. Mol. Biol.* 166: 557-580) or electroporation (see, e.g., Dower *et al.*, 1988, *Nucleic Acids Res.* 16: 6127-6145). The introduction of DNA into a *Streptomyces* cell may be effected by protoplast transformation, electroporation (see, e.g., Gong *et al.*, 2004, *Folia Microbiol. (Praha)* 49: 399-405), conjugation (see, e.g., Mazodier *et al.*, 1989, *J. Bacteriol.* 171: 3583-3585), or transduction (see, e.g., Burke *et al.*, 2001, *Proc. Natl. Acad. Sci. USA* 98: 6289-6294). The introduction of DNA into a *Pseudomonas* cell may be effected by electroporation (see, e.g., Choi *et al.*, 2006, *J. Microbiol. Methods* 64: 391-397), or conjugation (see, e.g., Pinedo and Smets, 2005, *Appl. Environ. Microbiol.* 71: 51-57). The introduction of DNA into a *Streptococcus* cell may be effected by natural competence (see, e.g., Perry and Kuramitsu, 1981, *Infect. Immun.* 32: 1295-1297), protoplast transformation (see, e.g., Catt and Jollick, 1991, *Microbios* 68: 189-207), electroporation (see, e.g., Buckley *et al.*, 1999, *Appl. Environ. Microbiol.* 65: 3800-3804) or conjugation (see, e.g., Clewell, 1981, *Microbiol. Rev.* 45: 409-436). However, any method known in the art for introducing DNA into a host cell can be used.

The host cell may also be a eukaryote, such as a mammalian, insect, plant, or fungal cell.

The host cell may be a fungal cell. "Fungi" as used herein includes the phyla Ascomycota, Basidiomycota, Chytridiomycota, and Zygomycota as well as the Oomycota and all mitosporic fungi (as defined by Hawksworth *et al.*, *In, Ainsworth and Bisby's Dictionary of The Fungi*, 8th edition, 1995, CAB International, University Press, Cambridge, UK).

The fungal host cell may be a yeast cell. "Yeast" as used herein includes ascosporeogenous yeast (Endomycetales), basidiosporeogenous yeast, and yeast belonging to the Fungi Imperfecti (Blastomycetes). Since the classification of yeast may change in the future, for the purposes of this invention, yeast shall be defined as described in *Biology and Activities of Yeast* (Skinner, Passmore, and Davenport, editors, *Soc. App. Bacteriol. Symposium Series No. 9*, 1980).

The yeast host cell may be a *Candida*, *Hansenula*, *Kluyveromyces*, *Pichia*, *Saccharomyces*, *Schizosaccharomyces*, or *Yarrowia* cell such as a *Kluyveromyces lactis*, *Saccharomyces carlsbergensis*, *Saccharomyces cerevisiae*, *Saccharomyces diastaticus*, *Saccharomyces douglasii*, *Saccharomyces kluyveri*, *Saccharomyces norbensis*, *Saccharomyces oviformis*, or *Yarrowia lipolytica* cell.

The fungal host cell may be a filamentous fungal cell. "Filamentous fungi" include all filamentous forms of the subdivision Eumycota and Oomycota (as defined by Hawksworth *et al.*, 1995, *supra*). The filamentous fungi are generally characterized by a mycelial wall composed of

chitin, cellulose, glucan, chitosan, mannan, and other complex polysaccharides. Vegetative growth is by hyphal elongation and carbon catabolism is obligately aerobic. In contrast, vegetative growth by yeasts such as *Saccharomyces cerevisiae* is by budding of a unicellular thallus and carbon catabolism may be fermentative.

5 The filamentous fungal host cell may be an *Acremonium*, *Aspergillus*, *Aureobasidium*, *Bjerkandera*, *Ceriporiopsis*, *Chrysosporium*, *Coprinus*, *Coriolus*, *Cryptococcus*, *Filibasidium*, *Fusarium*, *Humicola*, *Magnaporthe*, *Mucor*, *Myceliophthora*, *Neocallimastix*, *Neurospora*, *Paecilomyces*, *Penicillium*, *Phanerochaete*, *Phlebia*, *Piromyces*, *Pleurotus*, *Schizophyllum*, *Talaromyces*, *Thermoascus*, *Thielavia*, *Tolypocladium*, *Trametes*, or *Trichoderma* cell.

10 For example, the filamentous fungal host cell may be an *Aspergillus awamori*, *Aspergillus foetidus*, *Aspergillus fumigatus*, *Aspergillus japonicus*, *Aspergillus nidulans*, *Aspergillus niger*, *Aspergillus oryzae*, *Bjerkandera adusta*, *Ceriporiopsis aneirina*, *Ceriporiopsis caregiea*, *Ceriporiopsis gilvescens*, *Ceriporiopsis pannocinta*, *Ceriporiopsis rivulosa*, *Ceriporiopsis subrufa*, *Ceriporiopsis subvermispora*, *Chrysosporium inops*, *Chrysosporium keratinophilum*, *Chrysosporium*  
15 *lucknowense*, *Chrysosporium merdarium*, *Chrysosporium pannicola*, *Chrysosporium queenslandicum*, *Chrysosporium tropicum*, *Chrysosporium zonatum*, *Coprinus cinereus*, *Coriolus hirsutus*, *Fusarium bactridioides*, *Fusarium cerealis*, *Fusarium crookwellense*, *Fusarium culmorum*, *Fusarium graminearum*, *Fusarium graminum*, *Fusarium heterosporum*, *Fusarium negundi*, *Fusarium oxysporum*, *Fusarium reticulatum*, *Fusarium roseum*, *Fusarium sambucinum*, *Fusarium*  
20 *sarcochromum*, *Fusarium sporotrichioides*, *Fusarium sulphureum*, *Fusarium torulosum*, *Fusarium trichothecioides*, *Fusarium venenatum*, *Humicola insolens*, *Humicola lanuginosa*, *Mucor miehei*, *Myceliophthora thermophila*, *Neurospora crassa*, *Penicillium purpurogenum*, *Phanerochaete chrysosporium*, *Phlebia radiata*, *Pleurotus eryngii*, *Thielavia terrestris*, *Trametes villosa*, *Trametes versicolor*, *Trichoderma harzianum*, *Trichoderma koningii*, *Trichoderma longibrachiatum*,  
25 *Trichoderma reesei*, or *Trichoderma viride* cell.

Fungal cells may be transformed by a process involving protoplast formation, transformation of the protoplasts, and regeneration of the cell wall in a manner known *per se*. Suitable procedures for transformation of *Aspergillus* and *Trichoderma* host cells are described in EP 238023, Yelton *et al.*, 1984, *Proc. Natl. Acad. Sci. USA* 81: 1470-1474, and Christensen *et al.*, 1988, *Bio/Technology*  
30 6: 1419-1422. Suitable methods for transforming *Fusarium* species are described by Malardier *et al.*, 1989, *Gene* 78: 147-156, and WO 96/00787. Yeast may be transformed using the procedures described by Becker and Guarente, *In* Abelson, J.N. and Simon, M.I., editors, *Guide to Yeast Genetics and Molecular Biology, Methods in Enzymology*, Volume 194, pp 182-187, Academic Press, Inc., New York; Ito *et al.*, 1983, *J. Bacteriol.* 153: 163; and Hinnen *et al.*, 1978, *Proc. Natl.*  
35 *Acad. Sci. USA* 75: 1920.

## Methods of Production

The present invention also relates to methods of producing a variant, comprising: (a) cultivating a host cell of the present invention under conditions suitable for expression of the variant; and (b) recovering the variant.

5           The host cells are cultivated in a nutrient medium suitable for production of the variant using methods known in the art. For example, the cell may be cultivated by shake flask cultivation, or small-scale or large-scale fermentation (including continuous, batch, fed-batch, or solid state fermentations) in laboratory or industrial fermentors performed in a suitable medium and under conditions allowing the variant to be expressed and/or isolated. The cultivation takes place in a  
10           suitable nutrient medium comprising carbon and nitrogen sources and inorganic salts, using procedures known in the art. Suitable media are available from commercial suppliers or may be prepared according to published compositions (*e.g.*, in catalogues of the American Type Culture Collection). If the variant is secreted into the nutrient medium, the variant can be recovered directly from the medium. If the variant is not secreted, it can be recovered from cell lysates.

15           The variant may be detected using methods known in the art that are specific for the variants. These detection methods include, but are not limited to, use of specific antibodies, formation of an enzyme product, or disappearance of an enzyme substrate. For example, an enzyme assay may be used to determine the activity of the variant.

          The variant may be recovered using methods known in the art. For example, the variant  
20           may be recovered from the nutrient medium by conventional procedures including, but not limited to, collection, centrifugation, filtration, extraction, spray-drying, evaporation, or precipitation.

          The variant may be purified by a variety of procedures known in the art including, but not limited to, chromatography (*e.g.*, ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (*e.g.*, preparative isoelectric focusing), differential solubility  
25           (*e.g.*, ammonium sulfate precipitation), SDS-PAGE, or extraction (see, *e.g.*, *Protein Purification*, Janson and Ryden, editors, VCH Publishers, New York, 1989) to obtain substantially pure variants.

          In an alternative aspect, the variant is not recovered, but rather a host cell of the present invention expressing the variant is used as a source of the variant.

## 30           Compositions

          The present invention also relates to compositions comprising a variant of the present invention. Preferably, the compositions are enriched in such a variant. The term "enriched" means that the alpha-amylase activity of the composition has been increased, *e.g.*, with an enrichment factor of 1.1.

The composition may comprise a variant as the major enzymatic component, e.g., a mono-component composition. Alternatively, the composition may comprise multiple enzymatic activities, such as an aminopeptidase, amylase, carbohydrase, carboxypeptidase, catalase, cellulase, chitinase, cutinase, cyclodextrin glycosyltransferase, deoxyribonuclease, esterase, alpha-galactosidase, beta-galactosidase, glucoamylase, alpha-glucosidase, beta-glucosidase, haloperoxidase, invertase, laccase, lipase, mannosidase, oxidase, pectinolytic enzyme, peptidoglucaminase, peroxidase, phytase, polyphenoloxidase, proteolytic enzyme, ribonuclease, transglutaminase, or xylanase. The additional enzyme(s) may be produced, for example, by a microorganism belonging to the genus *Aspergillus*, e.g., *Aspergillus aculeatus*, *Aspergillus awamori*, *Aspergillus foetidus*, *Aspergillus fumigatus*, *Aspergillus japonicus*, *Aspergillus nidulans*, *Aspergillus niger*, or *Aspergillus oryzae*; *Fusarium*, e.g., *Fusarium bactridioides*, *Fusarium cerealis*, *Fusarium crookwellense*, *Fusarium culmorum*, *Fusarium graminearum*, *Fusarium graminum*, *Fusarium heterosporum*, *Fusarium negundi*, *Fusarium oxysporum*, *Fusarium reticulatum*, *Fusarium roseum*, *Fusarium sambucinum*, *Fusarium sarcochroum*, *Fusarium sulphureum*, *Fusarium toruloseum*, *Fusarium trichothecioides*, or *Fusarium venenatum*; *Humicola*, e.g., *Humicola insolens* or *Humicola lanuginosa*; or *Trichoderma*, e.g., *Trichoderma harzianum*, *Trichoderma koningii*, *Trichoderma longibrachiatum*, *Trichoderma reesei*, or *Trichoderma viride*.

The compositions may be prepared in accordance with methods known in the art and may be in the form of a liquid or a dry composition. For instance, the composition may be in the form of a granulate or a microgranulate. The variant may be stabilized in accordance with methods known in the art.

### **Detergent compositions**

In one embodiment, the invention is directed to detergent compositions comprising an alpha-amylase variant of the present invention in combination with one or more additional cleaning composition components.

The choice of additional components is within the skill of the artisan and includes conventional ingredients, including the exemplary non-limiting components set forth below. The choice of components may include, for fabric care, the consideration of the type of fabric to be cleaned, the type and/or degree of soiling, the temperature at which cleaning is to take place, and the formulation of the detergent product. Although components mentioned below are categorized by general header according to a particular functionality, this is not to be construed as a limitation, as a component may comprise additional functionalities as will be appreciated by the skilled artisan.

### Enzyme of the present invention

In one embodiment of the present invention, the a polypeptide of the present invention may be added to a detergent composition in an amount corresponding to 0.001-100 mg of protein, such as 0.01-100 mg of protein, preferably 0.005-50 mg of protein, more preferably 0.01-25 mg of protein, even more preferably 0.05-10 mg of protein, most preferably 0.05-5 mg of protein, and even most preferably 0.01-1 mg of protein per liter of wash liquor.

The enzyme(s) of the detergent composition of the invention may be stabilized using conventional stabilizing agents, e.g., a polyol such as propylene glycol or glycerol, a sugar or sugar alcohol, lactic acid, boric acid, or a boric acid derivative, e.g., an aromatic borate ester, or a phenyl boronic acid derivative such as 4-formylphenyl boronic acid, and the composition may be formulated as described in, for example, WO92/19709 and WO92/19708.

A polypeptide of the present invention may also be incorporated in the detergent formulations disclosed in WO97/07202, which is hereby incorporated by reference.

### 15 Surfactants

The detergent composition may comprise one or more surfactants, which may be anionic and/or cationic and/or non-ionic and/or semi-polar and/or zwitterionic, or a mixture thereof. In a particular embodiment, the detergent composition includes a mixture of one or more nonionic surfactants and one or more anionic surfactants. The surfactant(s) is typically present at a level of from about 0.1% to 60% by weight, such as about 1% to about 40%, or about 3% to about 20%, or about 3% to about 10%. The surfactant(s) is chosen based on the desired cleaning application, and includes any conventional surfactant(s) known in the art. Any surfactant known in the art for use in detergents may be utilized.

When included therein the detergent will usually contain from about 1% to about 40% by weight, such as from about 5% to about 30%, including from about 5% to about 15%, or from about 20% to about 25% of an anionic surfactant. Non-limiting examples of anionic surfactants include sulfates and sulfonates, in particular, linear alkylbenzenesulfonates (LAS), isomers of LAS, branched alkylbenzenesulfonates (BABS), phenylalkanesulfonates, alpha-olefinsulfonates (AOS), olefin sulfonates, alkene sulfonates, alkane-2,3-diylbis(sulfates), hydroxyalkanesulfonates and disulfonates, alkyl sulfates (AS) such as sodium dodecyl sulfate (SDS), fatty alcohol sulfates (FAS), primary alcohol sulfates (PAS), alcohol ethersulfates (AES or AEOS or FES, also known as alcohol ethoxysulfates or fatty alcohol ether sulfates), secondary alkanesulfonates (SAS), paraffin sulfonates (PS), ester sulfonates, sulfonated fatty acid glycerol esters, alpha-sulfo fatty acid methyl esters (alpha-SFMe or SES) including methyl ester sulfonate (MES), alkyl- or alkenylsuccinic acid, dodecenylyl/tetradecenylyl succinic acid (DTSA), fatty acid derivatives of amino acids, diesters and monoesters of sulfo-succinic

acid or soap, and combinations thereof.

When included therein the detergent will usually contain from about 0 % to about 40% by weight of a cationic surfactant. Non-limiting examples of cationic surfactants include alkyldimethylethanolamine quat (ADMEAQ), cetyltrimethylammonium bromide (CTAB),  
5 dimethyldistearylammonium chloride (DSDMAC), and alkylbenzyltrimethylammonium, alkyl quaternary ammonium compounds, alkoxyated quaternary ammonium (AQA) compounds, and combinations thereof.

When included therein the detergent will usually contain from about 0.2% to about 40% by weight of a non-ionic surfactant, for example from about 0.5% to about 30%, in particular from about  
10 1% to about 20%, from about 3% to about 10%, such as from about 3% to about 5%, or from about 8% to about 12%. Non-limiting examples of non-ionic surfactants include alcohol ethoxylates (AE or AEO), alcohol propoxylates, propoxylated fatty alcohols (PFA), alkoxyated fatty acid alkyl esters, such as ethoxylated and/or propoxylated fatty acid alkyl esters, alkylphenol ethoxylates (APE), nonylphenol ethoxylates (NPE), alkylpolyglycosides (APG), alkoxyated amines, fatty acid  
15 monoethanolamides (FAM), fatty acid diethanolamides (FADA), ethoxylated fatty acid monoethanolamides (EFAM), propoxylated fatty acid monoethanolamides (PFAM), polyhydroxy alkyl fatty acid amides, or *N*-acyl *N*-alkyl derivatives of glucosamine (glucamides, GA, or fatty acid glucamide, FAGA), as well as products available under the trade names SPAN and TWEEN, and combinations thereof.

When included therein the detergent will usually contain from about 0 % to about 40% by weight of a semipolar surfactant. Non-limiting examples of semipolar surfactants include amine oxides (AO) such as alkyldimethylamineoxide, *N*-(coco alkyl)-*N,N*-dimethylamine oxide and *N*-(tallow-alkyl)-*N,N*-bis(2-hydroxyethyl)amine oxide, fatty acid alkanolamides and ethoxylated fatty acid  
20 alkanolamides, and combinations thereof.

When included therein the detergent will usually contain from about 0% to about 40% by weight of a zwitterionic surfactant. Non-limiting examples of zwitterionic surfactants include betaine, alkyldimethylbetaine, sulfobetaine, and combinations thereof.

### Hydrotropes

A hydrotrope is a compound that solubilises hydrophobic compounds in aqueous solutions (or  
30 oppositely, polar substances in a non-polar environment). Typically, hydrotropes have both hydrophilic and a hydrophobic character (so-called amphiphilic properties as known from surfactants); however the molecular structure of hydrotropes generally do not favor spontaneous self-aggregation, see e.g. review by Hodgdon and Kaler (2007), Current Opinion in Colloid & Interface Science 12: 121-128.  
35 Hydrotropes do not display a critical concentration above which self-aggregation occurs as found for

surfactants and lipids forming micellar, lamellar or other well defined meso-phases. Instead, many hydrotropes show a continuous-type aggregation process where the sizes of aggregates grow as concentration increases. However, many hydrotropes alter the phase behavior, stability, and colloidal properties of systems containing substances of polar and non-polar character, including mixtures of water, oil, surfactants, and polymers. Hydrotropes are classically used across industries from pharma, personal care, food, to technical applications. Use of hydrotropes in detergent compositions allow for example more concentrated formulations of surfactants (as in the process of compacting liquid detergents by removing water) without inducing undesired phenomena such as phase separation or high viscosity.

5 The detergent may contain 0-5% by weight, such as about 0.5 to about 5%, or about 3% to about 5%, of a hydrotrope. Any hydrotrope known in the art for use in detergents may be utilized. Non-limiting examples of hydrotropes include sodium benzene sulfonate, sodium p-toluene sulfonate (STS), sodium xylene sulfonate (SXS), sodium cumene sulfonate (SCS), sodium cymene sulfonate, amine oxides, alcohols and polyglycoethers, sodium hydroxynaphthoate, sodium hydroxynaphthalene sulfonate, sodium ethylhexyl sulfate, and combinations thereof.

#### **Builders and Co-Builders**

The detergent composition may contain about 0-65% by weight, such as about 10% to about 40% of a detergent builder or co-builder, or a mixture thereof. In a dish wash detergent, the level of builder is typically 40-65%, particularly 50-65%. The builder and/or co-builder may particularly be a chelating agent that forms water-soluble complexes with Ca and Mg. Any builder and/or co-builder known in the art for use in laundry detergents may be utilized. Non-limiting examples of builders include zeolites, diphosphates (pyrophosphates), triphosphates such as sodium triphosphate (STP or STPP), carbonates such as sodium carbonate, soluble silicates such as sodium metasilicate, layered silicates (*e.g.*, SKS-6 from Hoechst), ethanolamines such as 2-aminoethan-1-ol (MEA), diethanolamine (DEA, also known as iminodiethanol), triethanolamine (TEA, also known as 2,2',2"-nitrilotriethanol), and carboxymethyl inulin (CMI), and combinations thereof.


The detergent composition may also contain 0-50% by weight, such as about 10% to about 40%, of a detergent co-builder, or a mixture thereof. The detergent composition may include include a co-builder alone, or in combination with a builder, for example a zeolite builder. Non-limiting examples of co-builders include homopolymers of polyacrylates or copolymers thereof, such as poly(acrylic acid) (PAA) or copoly(acrylic acid/maleic acid) (PAA/PMA). Further non-limiting examples include citrate, chelators such as aminocarboxylates, aminopolycarboxylates and phosphonates, and alkyl- or alkenylsuccinic acid. Additional specific examples include 2,2',2"-nitrilotriacetic acid (NTA), ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), iminodisuccinic

acid (IDS), ethylenediamine-*A,A'*-disuccinic acid (EDDS), methylglycinediacetic acid (MGDA), glutamic acid-*N,N*-diacetic acid (GLDA), 1-hydroxyethane-1,1-diphosphonic acid (HEDP), ethylenediaminetetra(methylenephosphonic acid) (EDTMPA), diethylenetriaminepenta(methylenephosphonic acid) (DTMPA or DTPMPA), *A*-(2-hydroxyethyl)iminodiacetic acid (EDG), aspartic acid-*A*-monoacetic acid (ASMA), aspartic acid-*A,A'*-diacetic acid (ASDA), aspartic acid-*A*-monopropionic acid (ASMP), iminodisuccinic acid (IDA), *A*-(2-sulfomethyl)-aspartic acid (SMAS), *A*-(2-sulfoethyl)-aspartic acid (SEAS), *A*-(2-sulfomethyl)-glutamic acid (SMGL), *A*-(2-sulfoethyl)-glutamic acid (SEGL), *A*-methyliminodiacetic acid (MIDA),  $\alpha$ -alanine-*A,A'*-diacetic acid ( $\alpha$ -ALDA), serine-*A,A'*-diacetic acid (SEDA), isoserine-*A,A'*-diacetic acid (ISDA), phenylalanine- $\alpha$ , *A*-diacetic acid (PHDA), anthranilic acid-*A,A'*-diacetic acid (ANDA), sulfanilic acid-*A,A'*-diacetic acid (SLDA), taurine-*A,A'*-diacetic acid (TUDA) and sulfomethyl-*A,A'*-diacetic acid (SMDA), *A*-(2-hydroxyethyl)-ethylidenediamine-*A,A'*-triacetate (HEDTA), diethanolglycine (DEG), diethylenetriamine penta(methylenephosphonic acid) (DTPMP), aminotris(methylenephosphonic acid) (ATMP), and combinations and salts thereof. Further exemplary builders and/or co-builders are described in, e.g., WO 09/102854, US 5977053.

### Bleaching Systems

The detergent may contain 0-20% by weight, such as about 0 % to about 10%, of a bleaching system. Any bleaching system known in the art for use in laundry + dish wash + I&I detergents may be utilized. Suitable bleaching system components include bleaching catalysts, photobleaches, bleach activators, sources of hydrogen peroxide such as sodium percarbonate and sodium perborates, preformed peracids and mixtures thereof. Suitable preformed peracids include, but are not limited to, peroxy-carboxylic acids and salts, percarbonic acids and salts, perimidic acids and salts, peroxy-monosulfuric acids and salts, for example, Oxone (R), and mixtures thereof. Non-limiting examples of bleaching systems include peroxide-based bleaching systems, which may comprise, for example, an inorganic salt, including alkali metal salts such as sodium salts of perborate (usually mono- or tetra-hydrate), percarbonate, persulfate, perphosphate, persilicate salts, in combination with a peracid-forming bleach activator. The term bleach activator is meant herein as a compound which reacts with peroxygen bleach like hydrogen peroxide to form a peracid. The peracid thus formed constitutes the activated bleach. Suitable bleach activators to be used herein include those belonging to the class of esters amides, imides or anhydrides. Suitable examples are tetracetylene diamine (TAED), sodium 4-[(3,5,5-trimethylhexanoyl)oxy]benzene sulfonate (ISONOBS), diperoxy dodecanoic acid, 4-(dodecanoyloxy)benzenesulfonate (LOBS), 4-(decanoyloxy)benzenesulfonate, 4-(decanoyloxy)benzoate (DOBS), 4-(nonanoyloxy)-benzenesulfonate (NOBS), and/or those disclosed in W098/17767. A particular family of bleach activators of interest was disclosed in

EP624154 and particularly preferred in that family is acetyl triethyl citrate (ATC). ATC or a short chain triglyceride like triacetin has the advantage that it is environmental friendly as it eventually degrades into citric acid and alcohol. Furthermore acetyl triethyl citrate and triacetin has a good hydrolytical stability in the product upon storage and it is an efficient bleach activator. Finally ATC provides a good building capacity to the laundry additive. Alternatively, the bleaching system may comprise peroxyacids of, for example, the amide, imide, or sulfone type. The bleaching system may also comprise peracids such as 6-(phthalimido)peroxyhexanoic acid (PAP). The bleaching system may also include a bleach catalyst. In some embodiments the bleach component may be an organic catalyst selected from the group consisting of organic catalysts having the following formulae:



15 (iii) and mixtures thereof; wherein each  $R^1$  is independently a branched alkyl group containing from 9 to 24 carbons or linear alkyl group containing from 11 to 24 carbons, preferably each  $R^1$  is independently a branched alkyl group containing from 9 to 18 carbons or linear alkyl group containing from 11 to 18 carbons, more preferably each  $R^1$  is independently selected from the group consisting of 2-propylheptyl, 2-butyloctyl, 2-pentylnonyl, 2-hexyldecyl, n-dodecyl, n-tetradecyl, n-hexadecyl, n-octadecyl, iso-nonyl, iso-decyl, iso-tridecyl and iso-pentadecyl. Other exemplary bleaching systems are described, e.g. in WO2007/087258, WO2007/087244, WO2007/087259 and WO2007/087242. Suitable photobleaches may for example be sulfonated zinc phthalocyanine.

## 25 Polymers

The detergent may contain 0-10% by weight, such as 0.5-5%, 2-5%, 0.5-2% or 0.2-1% of a polymer. Any polymer known in the art for use in detergents may be utilized. The polymer may function as a co-builder as mentioned above, or may provide antiredeposition, fiber protection, soil release, dye transfer inhibition, grease cleaning and/or anti-foaming properties. Some polymers may have more than one of the above-mentioned properties and/or more than one of the below-mentioned motifs. Exemplary polymers include (carboxymethyl)cellulose (CMC), polyvinyl alcohol (PVA), poly(vinylpyrrolidone) (PVP), poly(ethyleneglycol) or poly(ethylene oxide) (PEG), ethoxylated poly(ethyleneimine), carboxymethyl inulin (CMI), and polycarboxylates such as PAA, PAA/PMA, poly-aspartic acid, and lauryl methacrylate/acrylic acid copolymers, hydrophobically modified CMC (HM-CMC) and silicones, copolymers of terephthalic acid and oligomeric glycols, copolymers of

poly(ethylene terephthalate) and poly(oxyethene terephthalate) (PET-POET), PVP, poly(vinylimidazole) (PVI), poly(vinylpyridine-A/-oxide) (PVPO or PVPNO) and polyvinylpyrrolidone-vinylimidazole (PVPVI). Further exemplary polymers include sulfonated polycarboxylates, polyethylene oxide and polypropylene oxide (PEO-PPO) and diquatonium ethoxy sulfate. Other exemplary  
5 polymers are disclosed in, e.g., WO 2006/130575. Salts of the above-mentioned polymers are also contemplated.

### Fabric hueing agents

The detergent compositions of the present invention may also include fabric hueing agents  
10 such as dyes or pigments, which when formulated in detergent compositions can deposit onto a fabric when said fabric is contacted with a wash liquor comprising said detergent compositions and thus altering the tint of said fabric through absorption/reflection of visible light. Fluorescent whitening agents emit at least some visible light. In contrast, fabric hueing agents alter the tint of a surface as they absorb at least a portion of the visible light spectrum. Suitable fabric hueing agents  
15 include dyes and dye-clay conjugates, and may also include pigments. Suitable dyes include small molecule dyes and polymeric dyes. Suitable small molecule dyes include small molecule dyes selected from the group consisting of dyes falling into the Colour Index (C.I.) classifications of Direct Blue, Direct Red, Direct Violet, Acid Blue, Acid Red, Acid Violet, Basic Blue, Basic Violet and Basic Red, or mixtures thereof, for example as described in WO2005/03274, WO2005/03275,  
20 WO2005/03276 and EP1 876226 (hereby incorporated by reference). The detergent composition preferably comprises from about 0.00003 wt% to about 0.2 wt%, from about 0.00008 wt% to about 0.05 wt%, or even from about 0.0001 wt% to about 0.04 wt% fabric hueing agent. The composition may comprise from 0.0001 wt% to 0.2 wt% fabric hueing agent, this may be especially preferred when the composition is in the form of a unit dose pouch. Suitable hueing agents are also disclosed  
25 in, e.g. WO 2007/087257 and WO2007/087243.

### Additional Enzymes

The detergent additive as well as the detergent composition may comprise one or more  
30 additional enzymes such as a protease, lipase, cutinase, an amylase, carbohydrase, cellulase, pectinase, mannanase, arabinase, galactanase, xylanase, oxidase, e.g., a laccase, and/or peroxidase.

In general the properties of the selected enzyme(s) should be compatible with the selected detergent, (*i.e.*, pH-optimum, compatibility with other enzymatic and non-enzymatic ingredients, etc.), and the enzyme(s) should be present in effective amounts.

35

## Cellulases

Suitable cellulases include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Suitable cellulases include cellulases from the genera *Bacillus*, *Pseudomonas*, *Humicola*, *Fusarium*, *Thielavia*, *Acremonium*, e.g., the fungal cellulases produced from *Humicola insolens*, *Myceliophthora thermophila* and *Fusarium oxysporum* disclosed in US 4,435,307, US 5,648,263, US 5,691,178, US 5,776,757 and WO 89/09259.

Especially suitable cellulases are the alkaline or neutral cellulases having colour care benefits. Examples of such cellulases are cellulases described in EP 0 495 257, EP 0 531 372, WO 96/1 1262, WO 96/29397, WO 98/08940. Other examples are cellulase variants such as those described in WO 94/07998, EP 0 531 315, US 5,457,046, US 5,686,593, US 5,763,254, WO 95/24471, WO 98/12307 and WO99/001544.

Other cellulases are endo-beta-1,4-glucanase enzyme having a sequence of at least 97% identity to the amino acid sequence of position 1 to position 773 of SEQ ID NO:2 of WO 2002/099091 or a family 44 xyloglucanase, which a xyloglucanase enzyme having a sequence of at least 60% identity to positions 40-559 of SEQ ID NO: 2 of WO 2001/062903.

Commercially available cellulases include Celluzyme™, and Carezyme™ (Novozymes A/S) Carezyme Premium™ (Novozymes A/S), Celluclean™ (Novozymes A/S), Celluclean Classic™ (Novozymes A/S), Cellusoft™ (Novozymes A/S), Whitezyme™ (Novozymes A/S), Clazinase™, and Puradax HA™ (Genencor International Inc.), and KAC-500(B)™ (Kao Corporation).

## Proteases

Suitable proteases include those of bacterial, fungal, plant, viral or animal origin e.g. vegetable or microbial origin. Microbial origin is preferred. Chemically modified or protein engineered mutants are included. It may be an alkaline protease, such as a serine protease or a metalloprotease. A serine protease may for example be of the S1 family, such as trypsin, or the S8 family such as subtilisin. A metalloproteases protease may for example be a thermolysin from e.g. family M4 or other metalloprotease such as those from M5, M7 or M8 families.

The term "subtilases" refers to a sub-group of serine protease according to Siezen et al., Protein Engng. 4 (1991) 719-737 and Siezen et al. Protein Science 6 (1997) 501-523. Serine proteases are a subgroup of proteases characterized by having a serine in the active site, which forms a covalent adduct with the substrate. The subtilases may be divided into 6 sub-divisions, i.e. the Subtilisin family, the Thermitase family, the Proteinase K family, the Lantibiotic peptidase family, the Kexin family and the Pyrolysin family.

Examples of subtilases are those derived from *Bacillus* such as *Bacillus lentus*, *B. alkalophilus*, *B. subtilis*, *B. amyloliquefaciens*, *Bacillus pumilus* and *Bacillus gibsonii* described in; US7262042 and WO09/021867, and *subtilisin lentus*, *subtilisin Novo*, *subtilisin Carlsberg*, *Bacillus*

*licheniformis*, *subtilisin BPN'*, *subtilisin 309*, *subtilisin 147* and *subtilisin 168* described in WO89/06279 and protease PD138 described in (WO93/18140). Other useful proteases may be those described in W092/175177, WO01/016285, WO02/026024 and WO02/016547. Examples of trypsin-like proteases are trypsin (e.g. of porcine or bovine origin) and the *Fusarium* protease described in WO89/06270, W094/25583 and WO05/040372, and the chymotrypsin proteases derived from *Cellomonas* described in WO05/052161 and WO05/052146.

A further preferred protease is the alkaline protease from *Bacillus lentus* DSM 5483, as described for example in W095/23221, and variants thereof which are described in WO92/21760, W095/23221, EP1921 147 and EP1921 148.

Examples of metalloproteases are the neutral metalloprotease as described in WO07/044993 (Genencor Int.) such as those derived from *Bacillus amyloliquefaciens*.

Examples of useful proteases are the variants described in: W092/19729, WO96/034946, WO98/201 15, WO98/201 16, WO99/01 1768, WO01/44452, WO03/006602, WO04/03186, WO04/041979, WO07/006305, W01 1/036263, W01 1/036264, especially the variants with substitutions in one or more of the following positions: 3, 4, 9, 15, 27, 36, 57, 68, 76, 87, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 106, 118, 120, 123, 128, 129, 130, 160, 167, 170, 194, 195, 199, 205, 206, 217, 218, 222, 224, 232, 235, 236, 245, 248, 252 and 274 using the BPN' numbering. More preferred the subtilase variants may comprise the mutations: S3T, V4I, S9R, A15T, K27R, \*36D, V68A, N76D, N87S,R, \*97E, A98S, S99G,D,A, S99AD, S101G.M.R S103A, V104I.Y.N, S106A, G118V.R, H120D.N, N123S, S128L, P129Q, S130A, G160D, Y167A, R170S, A194P, G195E, V199M, V205I, L217D, N218D, M222S, A232V, K235L, Q236H, Q245R, N252K, T274A (using BPN' numbering).

Suitable commercially available protease enzymes include those sold under the trade names Alcalase®, Duralase™, Durazym™, Release®, Release® Ultra, Savinase®, Savinase® Ultra, Primase®, Polarzyme®, Kannase®, Liquanase®, Liquanase® Ultra, Ovozyme®, Coronase®, Coronase® Ultra, Neutrase®, Everlase® and Esperase® (Novozymes A/S), those sold under the tradename Maxatase®, Maxacal®, Maxapem®, Purafect®, Purafect Prime®, Preferenz™, Purafect MA®, Purafect Ox®, Purafect OxP®, Puramax®, Properase®, Effectenz™, FN2®, FN3®, FN4®, Excellase®, , Opticlean® and Optimase® (Danisco/DuPont), Axapem™ (Gist-Brocades N.V.), BLAP (sequence shown in Figure 29 of US5352604) and variants hereof (Henkel AG) and KAP (*Bacillus alkalophilus subtilisin*) from Kao.

#### **Lipases and Cutinases:**

Suitable lipases and cutinases include those of bacterial or fungal origin. Chemically modified or protein engineered mutant enzymes are included. Examples include lipase from *Thermomyces*, e.g. from *T. lanuginosus* (previously named *Humicola lanuginosa*) as described in

EP258068 and EP305216, cutinase from *Humicola*, e.g. *H. insolens* (WO96/13580), lipase from strains of *Pseudomonas* (some of these now renamed to *Burkholderia*), e.g. *P. alcaligenes* or *P. pseudoalcaligenes* (EP218272), *P. cepacia* (EP331376), *P. sp.* strain SD705 (WO95/06720 & WO96/27002), *P. wisconsinensis* (WO96/12012), GDSL-type *Streptomyces* lipases  
 5 (W01 0/065455), cutinase from *Magnaporthe grisea* (W01 0/1 07560), cutinase from *Pseudomonas mendocina* (US5,389,536), lipase from *Thermobifida fusca* (W0 11/084412), *Geobacillus stearothermophilus* lipase (W01 1/084417), lipase from *Bacillus subtilis* (W01 1/084599), and lipase from *Streptomyces griseus* (W01 1/150157) and *S. pristinaespiralis* (W012/137147).

Other examples are lipase variants such as those described in EP407225, WO92/05249,  
 10 WO94/01541 , W094/25578, W095/14783, W095/30744, W095/35381 , W095/22615, WO96/00292, WO97/04079, WO97/07202, WO00/34450, WO00/60063, WO01/92502, WO07/87508 and WO09/1 09500.

Preferred commercial lipase products include include Lipolase™, Lipex™; Lipolex™ and Lipoclean™ (Novozymes A/S), Lumafast (originally from Genencor) and Lipomax (originally from  
 15 Gist-Brocades).

Still other examples are lipases sometimes referred to as acyltransferases or perhydrolases, e.g. acyltransferases with homology to *Candida antarctica* lipase A (WO10/1 11143), acyltransferase from *Mycobacterium smegmatis* (WO05/56782), perhydrolases from the CE 7 family (WO09/67279), and variants of the *M. smegmatis* perhydrolase in particular the S54V variant  
 20 used in the commercial product Gentle Power Bleach from Huntsman Textile Effects Pte Ltd (W01 0/1 00028).

#### **Amylases:**

Suitable amylases which can be used together with the variant of the invention may be an alpha-amylase or a glucoamylase and may be of bacterial or fungal origin. Chemically modified or  
 25 protein engineered mutants are included. Amylases include, for example, alpha-amylases obtained from *Bacillus*, e.g., a special strain of *Bacillus licheniformis*, described in more detail in GB 1,296,839.

Suitable amylases include amylases having SEQ ID NO: 2 in WO 95/10603 or variants having 90% sequence identity to SEQ ID NO: 3 thereof. Preferred variants are described in WO  
 30 94/02597, WO 94/18314, WO 97/43424 and SEQ ID NO: 4 of WO 99/019467, such as variants with substitutions in one or more of the following positions: 15, 23, 105, 106, 124, 128, 133, 154, 156, 178, 179, 181 , 188, 190, 197, 201 , 202, 207, 208, 209, 211, 243, 264, 304, 305, 391 , 408, and 444.

Different suitable amylases include amylases having SEQ ID NO: 6 in WO 02/010355 or  
 35 variants thereof having 90% sequence identity to SEQ ID NO: 6. Preferred variants of SEQ ID NO: 6 are those having a deletion in positions 181 and 182 and a substitution in position 193.

Other amylases which are suitable are hybrid alpha-amylase comprising residues 1-33 of the alpha-amylase derived from *B. amyloliquefaciens* shown in SEQ ID NO: 6 of WO 2006/066594 and residues 36-483 of the *B. licheniformis* alpha-amylase shown in SEQ ID NO: 4 of WO 2006/066594 or variants having 90% sequence identity thereof.

5 Further amylases which are suitable are amylases having SEQ ID NO: 6 in WO 99/019467 or variants thereof having 90% sequence identity to SEQ ID NO: 6. Preferred variants of SEQ ID NO: 6 are those having a substitution, a deletion or an insertion in one or more of the following positions: R181, G182, H183, G184, N195, I206, E212, E216 and K269. Particularly preferred amylases are those having deletion in positions R181 and G182, or positions H183 and G184.

10 Additional amylases which can be used are those having SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 2 or SEQ ID NO: 7 of WO 96/023873 or variants thereof having 90% sequence identity to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 7. Preferred variants of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 7 are those having a substitution, a deletion or an insertion in one or more of the following positions: 140, 181, 182, 183, 184, 195, 206, 212, 243, 15 260, 269, 304 and 476, using SEQ ID 2 of WO 96/023873 for numbering. More preferred variants are those having a deletion in two positions selected from 181, 182, 183 and 184, such as 181 and 182, 182 and 183, or positions 183 and 184. Most preferred amylase variants of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 7 are those having a deletion in positions 183 and 184 and a substitution in one or more of positions 140, 195, 206, 243, 260, 304 and 476.

20 Other amylases which can be used are amylases having SEQ ID NO: 2 of WO 08/153815, SEQ ID NO: 10 in WO 01/66712 or variants thereof having 90% sequence identity to SEQ ID NO: 2 of WO 08/153815 or 90% sequence identity to SEQ ID NO: 10 in WO 01/66712. Preferred variants of SEQ ID NO: 10 in WO 01/66712 are those having a substitution, a deletion or an insertion in one of more of the following positions: 176, 177, 178, 179, 190, 201, 207, 211 and 264.

25 Further suitable amylases are amylases having SEQ ID NO: 2 of WO 09/061380 or variants having 90% sequence identity to SEQ ID NO: 2 thereof. Preferred variants of SEQ ID NO: 2 are those having a truncation of the C-terminus and/or a substitution, a deletion or an insertion in one of more of the following positions: Q87, Q98, S125, N128, T131, T165, K178, R180, S181, T182, G183, M201, F202, N225, S243, N272, N282, Y305, R309, D319, Q320, Q359, K444 and 30 G475. More preferred variants of SEQ ID NO: 2 are those having the substitution in one of more of the following positions: Q87E,R, Q98R, S125A, N128C, T131I, T165I, K178L, T182G, M201L, F202Y, N225E,R, N272E,R, S243Q,A,E,D, Y305R, R309A, Q320R, Q359E, K444E and G475K and/or deletion in position R180 and/or S181 or of T182 and/or G183. Most preferred amylase variants of SEQ ID NO: 2 are those having the substitutions:

35 N128C+K178L+T182G+Y305R+G475K;  
N128C+K178L+T182G+F202Y+Y305R+D319T+G475K;

S125A+N128C+K178L+T182G+Y305R+G475K; or

S125A+N128C+T131 I+T165I+K178L+T182G+Y305R+G475K wherein the variants are C-terminally truncated and optionally further comprises a substitution at position 243 and/or a deletion at position 180 and/or position 181 .

5 Other suitable amylases are the alpha-amylase having SEQ ID NO: 12 in WO01/66712 or a variant having at least 90% sequence identity to SEQ ID NO: 12. Preferred amylase variants are those having a substitution, a deletion or an insertion in one of more of the following positions of SEQ ID NO: 12 in WO01/66712: R28, R118, N174; R181, G182, D183, G184, G186, W189, N195, M202, Y298, N299, K302, S303, N306, R310, N314; R320, H324, E345, Y396, R400, W439, R444, 10 N445, K446, Q449, R458, N471, N484. Particular preferred amylases include variants having a deletion of D183 and G184 and having the substitutions R118K, N195F, R320K and R458K, and a variant additionally having substitutions in one or more position selected from the group: M9, G149, G182, G186, M202, T257, Y295, N299, M323, E345 and A339, most preferred a variant that additionally has substitutions in all these positions.

15 Other examples are amylase variants such as those described in WO2011/098531, WO2013/001078 and WO2013/001087.

Commercially available amylases are Duramyl™, Termamyl™, Fungamyl™, Stainzyme™, Stainzyme Plus™, Natalase™, (from Novozymes A/S), and Rapidase™, Purastar™/Effectenz™, Powerase and Preferenz S100, Preferenz S110 (from Genencor International Inc./DuPont).

## 20 Peroxidases/Oxidases

A peroxidase according to the invention is a peroxidase enzyme comprised by the enzyme classification EC 1.11.1.7, as set out by the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (IUBMB), or any fragment derived therefrom, exhibiting peroxidase activity.

25 Suitable peroxidases include those of plant, bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Examples of useful peroxidases include peroxidases from *Coprinopsis*, e.g., from *C. cinerea* (EP 179,486), and variants thereof as those described in WO 93/24618, WO 95/10602, and WO 98/15257.

30 A peroxidase according to the invention also include a haloperoxidase enzyme, such as chloroperoxidase, bromoperoxidase and compounds exhibiting chloroperoxidase or bromoperoxidase activity. Haloperoxidases are classified according to their specificity for halide ions. Chloroperoxidases (E.C. 1.11.1.10) catalyze formation of hypochlorite from chloride ions.

In an embodiment, the haloperoxidase of the invention is a chloroperoxidase. Preferably, the haloperoxidase is a vanadium haloperoxidase, i.e., a vanadate-containing haloperoxidase. In a 35 preferred method of the present invention the vanadate-containing haloperoxidase is combined with a source of chloride ion.

Haloperoxidases have been isolated from many different fungi, in particular from the fungus group dematiaceous hyphomycetes, such as *Caldariomyces*, e.g., *C. fumago*, *Alternaria*, *Curvularia*, e.g., *C. verruculosa* and *C. inaequalis*, *Drechslera*, *Ulocladium* and *Botrytis*.

Haloperoxidases have also been isolated from bacteria such as *Pseudomonas*, e.g., *P. pyrocinia* and *Streptomyces*, e.g., *S. aureofaciens*.

In an preferred embodiment, the haloperoxidase is derivable from *Curvularia* sp., in particular *Curvularia verruculosa* or *Curvularia inaequalis*, such as *C. inaequalis* CBS 102.42 as described in WO 95/27046; or *C. verruculosa* CBS 147.63 or *C. verruculosa* CBS 444.70 as described in WO 97/04102; or from *Drechslera hartlebii* as described in WO 01/79459, *Dendryphiella salina* as described in WO 01/79458, *Phaeotrichoconis crotalarie* as described in WO 01/79461, or *Geniculosporium* sp. as described in WO 01/79460.

An oxidase according to the invention include, in particular, any laccase enzyme comprised by the enzyme classification EC 1.10.3.2, or any fragment derived therefrom exhibiting laccase activity, or a compound exhibiting a similar activity, such as a catechol oxidase (EC 1.10.3.1), an o-aminophenol oxidase (EC 1.10.3.4), or a bilirubin oxidase (EC 1.3.3.5).

Preferred laccase enzymes are enzymes of microbial origin. The enzymes may be derived from plants, bacteria or fungi (including filamentous fungi and yeasts).

Suitable examples from fungi include a laccase derivable from a strain of *Aspergillus*, *Neurospora*, e.g., *N. crassa*, *Podospora*, *Botrytis*, *Collybia*, *Fomes*, *Lentinus*, *Pleurotus*, *Trametes*, e.g., *T. villosa* and *T. versicolor*, *Rhizoctonia*, e.g., *R. solani*, *Coprinopsis*, e.g., *C. cinerea*, *C. comatus*, *C. friesii*, and *C. plicatilis*, *Psathyrella*, e.g., *P. condelleana*, *Panaeolus*, e.g., *P. papilionaceus*, *Myceliophthora*, e.g., *M. thermophila*, *Schytalidium*, e.g., *S. thermophilum*, *Polyporus*, e.g., *P. pinsitus*, *Phlebia*, e.g., *P. radiata* (WO 92/01046), or *Coriolus*, e.g., *C. hirsutus* (JP 2238885).

Suitable examples from bacteria include a laccase derivable from a strain of *Bacillus*.

A laccase derived from *Coprinopsis* or *Myceliophthora* is preferred; in particular a laccase derived from *Coprinopsis cinerea*, as disclosed in WO 97/08325; or from *Myceliophthora thermophila*, as disclosed in WO 95/33836.

The detergent enzyme(s) may be included in a detergent composition by adding separate additives containing one or more enzymes, or by adding a combined additive comprising all of these enzymes. A detergent additive of the invention, i.e., a separate additive or a combined additive, can be formulated, for example, as a granulate, liquid, slurry, etc. Preferred detergent additive formulations are granulates, in particular non-dusting granulates, liquids, in particular stabilized liquids, or slurries.

Non-dusting granulates may be produced, e.g. as disclosed in US 4,106,991 and 4,661,452 and may optionally be coated by methods known in the art. Examples of waxy coating materials are poly(ethylene oxide) products (polyethyleneglycol, PEG) with mean molar weights of 1000 to 20000; ethoxylated nonylphenols having from 16 to 50 ethylene oxide units; ethoxylated fatty alcohols in which the alcohol contains from 12 to 20 carbon atoms and in which there are 15 to 80 ethylene oxide units; fatty alcohols; fatty acids; and mono- and di- and triglycerides of fatty acids. Examples of film-forming coating materials suitable for application by fluid bed techniques are given in GB 1483591. Liquid enzyme preparations may, for instance, be stabilized by adding a polyol such as propylene glycol, a sugar or sugar alcohol, lactic acid or boric acid according to established methods. Protected enzymes may be prepared according to the method disclosed in EP 238,216.

### Adjunct materials

Any detergent components known in the art for use in laundry detergents may also be utilized. Other optional detergent components include anti-corrosion agents, anti-shrink agents, anti-soil redeposition agents, anti-wrinkling agents, bactericides, binders, corrosion inhibitors, disintegrants/disintegration agents, dyes, enzyme stabilizers (including boric acid, borates, CMC, and/or polyols such as propylene glycol), fabric conditioners including clays, fillers/processing aids, fluorescent whitening agents/optical brighteners, foam boosters, foam (suds) regulators, perfumes, soil-suspending agents, softeners, suds suppressors, tarnish inhibitors, and wicking agents, either alone or in combination. Any ingredient known in the art for use in laundry detergents may be utilized. The choice of such ingredients is well within the skill of the artisan.

Dispersants - The detergent compositions of the present invention can also contain dispersants. In particular powdered detergents may comprise dispersants. Suitable water-soluble organic materials include the homo- or co-polymeric acids or their salts, in which the polycarboxylic acid comprises at least two carboxyl radicals separated from each other by not more than two carbon atoms. Suitable dispersants are for example described in Powdered Detergents, Surfactant science series volume 71, Marcel Dekker, Inc.

Dye Transfer Inhibiting Agents - The detergent compositions of the present invention may also include one or more dye transfer inhibiting agents. Suitable polymeric dye transfer inhibiting agents include, but are not limited to, polyvinylpyrrolidone polymers, polyamine *N*-oxide polymers, copolymers of *N*-vinylpyrrolidone and *N*-vinylimidazole, polyvinylloxazolidones and polyvinylimidazoles or mixtures thereof. When present in a subject composition, the dye transfer inhibiting agents may be present at levels from about 0.0001 % to about 10%, from about 0.01% to

about 5% or even from about 0.1% to about 3% by weight of the composition.

Fluorescent whitening agent - The detergent compositions of the present invention will preferably also contain additional components that may tint articles being cleaned, such as fluorescent whitening agent or optical brighteners. Where present the brightener is preferably at a level of about 0.01% to about 0.5%. Any fluorescent whitening agent suitable for use in a laundry detergent composition may be used in the composition of the present invention. The most commonly used fluorescent whitening agents are those belonging to the classes of diaminostilbene-sulfonic acid derivatives, diarylpyrazoline derivatives and bisphenyl-distyryl derivatives. Examples of the diaminostilbene-sulfonic acid derivative type of fluorescent whitening agents include the sodium salts of: 4,4'-bis-(2-diethanolamino-4-anilino-s-triazin-6-ylamino) stilbene-2,2'-disulfonate, 4,4'-bis-(2,4-dianilino-s-triazin-6-ylamino) stilbene-2,2'-disulfonate, 4,4'-bis-(2-anilino-4-(A-methyl-A/2-hydroxy-ethylamino)-s-triazin-6-ylamino) stilbene-2,2'-disulfonate, 4,4'-bis-(4-phenyl-1,2,3-triazol-2-yl)stilbene-2,2'-disulfonate and sodium 5-(2H-naphtho[1,2-cf][1,2,3]triazol-2-yl)-2-[(E)-2-phenylvinyl]benzenesulfonate. Preferred fluorescent whitening agents are Tinopal DMS and Tinopal CBS available from Ciba-Geigy AG, Basel, Switzerland. Tinopal DMS is the disodium salt of 4,4'-bis-(2-morpholino-4-anilino-s-triazin-6-ylamino) stilbene-2,2'-disulfonate. Tinopal CBS is the disodium salt of 2,2'-bis-(phenyl-styryl)-disulfonate. Also preferred are fluorescent whitening agents is the commercially available Parawhite KX, supplied by Paramount Minerals and Chemicals, Mumbai, India. Other fluorescers suitable for use in the invention include the 1-3-diaryl pyrazolines and the 7-alkylaminocoumarins.

Suitable fluorescent brightener levels include lower levels of from about 0.01, from 0.05, from about 0.1 or even from about 0.2 wt % to upper levels of 0.5 or even 0.75 wt%.

Soil release polymers - The detergent compositions of the present invention may also include one or more soil release polymers which aid the removal of soils from fabrics such as cotton and polyester based fabrics, in particular the removal of hydrophobic soils from polyester based fabrics. The soil release polymers may for example be nonionic or anionic terephthalate based polymers, polyvinyl caprolactam and related copolymers, vinyl graft copolymers, polyester polyamides see for example Chapter 7 in Powdered Detergents, Surfactant science series volume 71, Marcel Dekker, Inc. Another type of soil release polymers are amphiphilic alkoxyated grease cleaning polymers comprising a core structure and a plurality of alkoxyate groups attached to that core structure. The core structure may comprise a polyalkylenimine structure or a polyalkanolamine structure as described in detail in WO 2009/087523 (hereby incorporated by reference). Furthermore random graft co-polymers are suitable soil release polymers. Suitable graft co-polymers are described in

more detail in WO 2007/138054, WO 2006/108856 and WO 2006/1 13314 (hereby incorporated by reference). Other soil release polymers are substituted polysaccharide structures especially substituted cellulosic structures such as modified cellulose derivatives such as those described in EP 1867808 or WO 2003/040279 (both are hereby incorporated by reference). Suitable cellulosic polymers include cellulose, cellulose ethers, cellulose esters, cellulose amides and mixtures thereof. Suitable cellulosic polymers include anionically modified cellulose, nonionically modified cellulose, cationically modified cellulose, zwitterionically modified cellulose, and mixtures thereof. Suitable cellulosic polymers include methyl cellulose, carboxy methyl cellulose, ethyl cellulose, hydroxyl ethyl cellulose, hydroxyl propyl methyl cellulose, ester carboxy methyl cellulose, and mixtures thereof.

Anti-redeposition agents - The detergent compositions of the present invention may also include one or more anti-redeposition agents such as carboxymethylcellulose (CMC), polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), polyoxyethylene and/or polyethyleneglycol (PEG), homopolymers of acrylic acid, copolymers of acrylic acid and maleic acid, and ethoxylated polyethyleneimines. The cellulose based polymers described under soil release polymers above may also function as anti-redeposition agents.

Other suitable adjunct materials include, but are not limited to, anti-shrink agents, anti-wrinkling agents, bactericides, binders, carriers, dyes, enzyme stabilizers, fabric softeners, fillers, foam regulators, hydrotropes, perfumes, pigments, sod suppressors, solvents, and structurants for liquid detergents and/or structure elasticizing agents.

### **Formulation of detergent products**

The detergent composition of the invention may be in any convenient form, e.g., a bar, a homogenous tablet, a tablet having two or more layers, a pouch having one or more compartments, a regular or compact powder, a granule, a paste, a gel, or a regular, compact or concentrated liquid.

Pouches can be configured as single or multicompartments. It can be of any form, shape and material which is suitable for hold the composition, e.g. without allowing the release of the composition to release of the composition from the pouch prior to water contact. The pouch is made from water soluble film which encloses an inner volume. Said inner volume can be divided into compartments of the pouch. Preferred films are polymeric materials preferably polymers which are formed into a film or sheet. Preferred polymers, copolymers or derivatives thereof are selected polyacrylates, and water soluble acrylate copolymers, methyl cellulose, carboxy methyl cellulose, sodium dextrin, ethyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, malto dextrin, poly methacrylates,

most preferably polyvinyl alcohol copolymers and, hydroxypropyl methyl cellulose (HPMC). Preferably the level of polymer in the film for example PVA is at least about 60%. Preferred average molecular weight will typically be about 20,000 to about 150,000. Films can also be of blended compositions comprising hydrolytically degradable and water soluble polymer blends such as polylactide and polyvinyl alcohol (known under the Trade reference M8630 as sold by MonoSol LLC, Indiana, USA) plus plasticisers like glycerol, ethylene glycerol, propylene glycol, sorbitol and mixtures thereof. The pouches can comprise a solid laundry cleaning composition or part components and/or a liquid cleaning composition or part components separated by the water soluble film. The compartment for liquid components can be different in composition than compartments containing solids. Ref: (US2009/001 1970 A1).

Detergent ingredients can be separated physically from each other by compartments in water dissolvable pouches or in different layers of tablets. Thereby negative storage interaction between components can be avoided. Different dissolution profiles of each of the compartments can also give rise to delayed dissolution of selected components in the wash solution.

15

Definition/characteristics of the forms:

A liquid or gel detergent, which is not unit dosed, may be aqueous, typically containing at least 20% by weight and up to 95% water, such as up to about 70% water, up to about 65% water, up to about 55% water, up to about 45% water, up to about 35% water. Other types of liquids, including without limitation, alkanols, amines, diols, ethers and polyols may be included in an aqueous liquid or gel. An aqueous liquid or gel detergent may contain from 0-30% organic solvent.

A liquid or gel detergent may also be non-aqueous.

### **Laundry soap bars**

The alpha-amylases of the invention may be added to laundry soap bars and used for hand washing laundry, fabrics and/or textiles. The term laundry soap bar includes laundry bars, soap bars, combo bars, syndet bars and detergent bars. The types of bar usually differ in the type of surfactant they contain, and the term laundry soap bar includes those containing soaps from fatty acids and/or synthetic soaps. The laundry soap bar has a physical form which is solid and not a liquid, gel or a powder at room temperature. The term solid is defined as a physical form which does not significantly change over time, i.e. if a solid object (e.g. laundry soap bar) is placed inside a container, the solid object does not change to fill the container it is placed in. The bar is a solid typically in bar form but can be in other solid shapes such as round or oval.

The laundry soap bar may contain one or more additional enzymes, protease inhibitors such as peptide aldehydes (or hydrosulfite adduct or hemiacetal adduct), boric acid, borate, borax and/or

35

phenylboronic acid derivatives such as 4-formylphenylboronic acid, one or more soaps or synthetic surfactants, polyols such as glycerine, pH controlling compounds such as fatty acids, citric acid, acetic acid and/or formic acid, and/or a salt of a monovalent cation and an organic anion wherein the monovalent cation may be for example Na<sup>+</sup>, K<sup>+</sup> or NH<sub>4</sub><sup>+</sup> and the organic anion may be for example formate, acetate, citrate or lactate such that the salt of a monovalent cation and an organic anion may be, for example, sodium formate.

The laundry soap bar may also contain complexing agents like EDTA and HEDP, perfumes and/or different type of fillers, surfactants e.g. anionic synthetic surfactants, builders, polymeric soil release agents, detergent chelators, stabilizing agents, fillers, dyes, colorants, dye transfer inhibitors, alkoxyated polycarbonates, suds suppressers, structurants, binders, leaching agents, bleaching activators, clay soil removal agents, anti-redeposition agents, polymeric dispersing agents, brighteners, fabric softeners, perfumes and/or other compounds known in the art.

The laundry soap bar may be processed in conventional laundry soap bar making equipment such as but not limited to: mixers, plodders, e.g a two stage vacuum plodder, extruders, cutters, logo-stampers, cooling tunnels and wrappers. The invention is not limited to preparing the laundry soap bars by any single method. The premix of the invention may be added to the soap at different stages of the process. For example, the premix containing a soap, an alpha-amylase, optionally one or more additional enzymes, a protease inhibitor, and a salt of a monovalent cation and an organic anion may be prepared and the mixture is then plodded. The alpha-amylase and optional additional enzymes may be added at the same time as the protease inhibitor for example in liquid form. Besides the mixing step and the plodding step, the process may further comprise the steps of milling, extruding, cutting, stamping, cooling and/or wrapping.

### Granular detergent formulations

A granular detergent may be formulated as described in WO09/092699, EP1 705241, EP1382668, WO07/001262, US6472364, WO04/074419 or WO09/1 02854. Other useful detergent formulations are described in WO09/124162, WO09/124163, WO09/1 17340, WO09/1 17341, WO09/1 17342, WO09/072069, WO09/063355, WO09/1 32870, WO09/121757, WO09/1 12296, WO09/1 12298, WO09/103822, WO09/087033, WO09/050026, WO09/047125, WO09/047126, WO09/047127, WO09/047128, WO09/021784, WO09/010375, WO09/000605, WO09/122125, WO09/095645, WO09/040544, WO09/040545, WO09/024780, WO09/004295, WO09/004294, WO09/121725, WO09/1 15391, WO09/1 15392, WO09/074398, WO09/074403, WO09/068501, WO09/065770, WO09/021813, WO09/030632, and WO09/015951 .

WO201 102561 5, WO201 1016958, WO201 1005803, WO201 1005623, WO201 1005730, WO201 1005844, WO201 1005904, WO201 1005630, WO201 1005830, WO201 1005912,

WO201 1005905, WO201 1005910, WO201 1005813, WO201 0135238, WO201 0120863,  
 WO201 0108002, WO20101 11365, WO201 0108000, WO201 0107635, WO201 009091 5,  
 WO201 0033976, WO201 0033746, WO201 0033747, WO201 0033897, WO201 0033979,  
 WO201 0030540, WO201 0030541, WO201 0030539, WO201 0024467, WO201 0024469,  
 5 WO201 0024470, WO201 00251 6 1, WO201 001 4395, WO201 0044905,  
 WO201 0145887, WO201 0142503, WO201 0122051, WO201 0102861, WO201 0099997,  
 WO201 0084039, WO201 0076292, WO201 0069742, WO201 006971 8, WO201 0069957,  
 WO201 0057784, WO201 0054986, WO201 001 8043, WO201 0003783, WO201 0003792,  
 WO201 1023716, WO201 0142539, WO201 0118959, WO201 0115813, WO201 0105942,  
 10 WO201 0105961, WO201 0105962, WO201 0094356, WO201 0084203, WO201 0078979,  
 WO201 0072456, WO201 0069905, WO201 00761 65, WO201 0072603, WO201 0066486,  
 WO201 0066631, WO201 0066632, WO201 0063689, WO201 0060821, WO201 00491 87,  
 WO201 0031 607, WO201 0000636.

## 15 **Uses**

The present invention is also directed to methods for using the alpha-amylase variants.

The alpha-amylase variants of the invention are useful in detergent compositions, laundry washing, dishwashing and/or cleaning processes at low temperature as well as hard surface cleaning (ADW, car wash, Industrial surface).

20 Use in detergents. The polypeptides of the present invention may be added to and thus become a component of a detergent composition.

The detergent composition of the present invention may be formulated, for example, as a hand or machine laundry detergent composition including a laundry additive composition suitable for pre-treatment of stained fabrics and a rinse added fabric softener composition, or be formulated as a  
 25 detergent composition for use in general household hard surface cleaning operations, or be formulated for hand or machine dishwashing operations.

The detergent composition may further be formulated in unit dosage form or in form a soap bar or a laundry bar,

30 In a specific aspect, the present invention provides a detergent additive comprising a polypeptide of the present invention as described herein. In another aspect, the present invention provides a detergent suited to cleaning at temperatures at or below 35 °C.

## **METHODS**

### 35 pNP-G7 assay for determination of alpha-amylase activity

The alpha-amylase activity may be determined by a method employing the G7-pNP substrate.

G7-pNP which is an abbreviation for 4,6-ethylidene(G<sub>7</sub>)-p-nitrophenyl(Gi)-α-D-maltoheptaoside, a blocked oligosaccharide which can be cleaved by an endo-amylase, such as an alpha-amylase. Following the cleavage, the alpha-Glucosidase included in the kit digest the hydrolysed substrate further to liberate a free PNP molecule which has a yellow color and thus can be measured by visible spectrophotometry at  $\lambda=405\text{nm}$  (400-420 nm.). Kits containing G7-pNP substrate and alpha-Glucosidase is manufactured by Roche/Hitachi (cat. No. 11876473).

#### REAGENTS:

The G7-pNP substrate from this kit contains 22 mM 4,6-ethylidene- G7-pNP and 52.4 mM HEPES (2-[4-(2-hydroxyethyl)-1-piperazinyl]-ethanesulfonic acid), pH 7.0).

The alpha-Glucosidase reagent contains 52.4 mM HEPES, 87 mM NaCl, 12.6 mM MgCl<sub>2</sub>, 0.075 mM CaCl<sub>2</sub>,  $\geq 4$  kU/L alpha-glucosidase).

The substrate working solution is made by mixing 1 mL of the alpha-Glucosidase reagent with 0.2 mL of the G7-pNP substrate. This substrate working solution is made immediately before use.

Dilution buffer: 50 mM MOPS, 0.05% (w/v) Triton X100 (polyethylene glycol p-(1,1,3,3-tetramethylbutyl)-phenyl ether (C<sub>14</sub>H<sub>22</sub>O(C<sub>2</sub>W)<sub>n</sub> (n = 9-10))), 1mM CaCl<sub>2</sub>, pH8.0.

#### PROCEDURE:

The amylase sample to be analyzed was diluted in dilution buffer to ensure the pH in the diluted sample is 7. The assay was performed by transferring 20 $\mu$ L diluted enzyme samples to 96 well microtiter plate and adding 80 $\mu$ L substrate working solution. The solution was mixed and pre-incubated 1 minute at room temperature and absorption is measured every 20 sec. over 5 minutes at OD 405 nm.

The slope (absorbance per minute) of the time dependent absorption-curve is directly proportional to the specific activity (activity per mg enzyme) of the alpha-amylase in question under the given set of conditions. The amylase sample should be diluted to a level where the slope is below 0.4 absorbance units per minute.

#### Determination of binding to starch

#### 30 Assay principle:

Amylase variants are incubated in the presence or absence of insoluble raw rice starch at a selected pH value, in the range of pH 4.0 to 11.0 depending on the intended pH value for the application of the alpha-amylases to be selected; e.g. for detergent applications the pH is suitably selected in the alkaline area such as pH 8.0 or pH10.0; at a selected time, in general between 5

minutes and one hour, preferably in the range of 10 to 30 min such as 10 min or 30 minutes; and at a selected temperature, in general in the range of 0°C to 30°C, preferably at 4°C. After centrifugation, amylase activity is determined in the supernatants. Difference in activity in the samples incubated in the presence and absence of rice starch is a measure of binding of amylase to insoluble starch.

#### Materials and methods:

Rice starch (Sigma Inc, Cat No. S7260), HEPES, Calcium chloride, Triton X-100, Glycine, EnzChek Ultra Amylase Assay Kit (Life Technologies, Cat No. E33651), 96 microwell plates for incubation and dilution (Nunc, Cat No. 269620) and 96 well half-area black plates for fluorescence measurements (Corning, Cat No. 3694).

Assay buffer containing 50 mM HEPES (pH 8.0), 0.1 mM CaCl<sub>2</sub> and 0.01% Triton X-100. Enzyme protein solutions are diluted to 0.15 mg/ml with the assay buffer. High pH binding buffer contains 50 mM Glycine-NaOH (pH 10.0) and 0.01% Triton X-100. Rice starch solution (2.5%) is to be prepared in the assay buffer and/or in high pH binding buffer for the variants of SEQ ID NO: 1 and 2. EnzCheck Ultra Amylase substrate solution is prepared according to the manufacturer's instructions and diluted to 50 µg/ml in the assay buffer.

- a) Buffer with or without rice starch (2.5%), 100 µl is added to 96 microwell plate and preincubated at 4°C for 30 min
- b) Enzyme solutions, 20 µl are added to the above wells and the plate is placed on a mixer and mixed at 900 rpm for 30 min at 4°C.
- c) The plate is centrifuged at 2000 rpm for 5 min at 4°C for the starch to settle down and the supernatant is carefully removed and diluted to about 1250 times in the assay buffer so that the enzyme protein concentration is about 20 ng/ml.
- d) Diluted enzyme samples, 25 µl are added to 96 well half-area black plates containing 25 µl of EnzCheck Ultra Amylase substrate solution and the plate is immediately placed in a plate reader for fluorescence measurements.
- e) Change in fluorescence intensity ( $\Delta$  F.I.) is measured at 25°C for 30 min at an excitation wavelength of 485 nm and emission wavelength of 512 nm. Fluorescence readings between the time intervals of 0.5 to 5 min are taken for the calculation of activity (i.e.) change in fluorescence intensity per min ( $\Delta$  F.I./min).

$$Binding (\%) = \frac{Activity\ for\ without\ starch - Activity\ for\ with\ starch}{Activity\ for\ without\ starch} \times 100$$

$$Binding\ relative\ to\ parent = \frac{Binding\ for\ variants}{Binding\ for\ parent}$$

**Automatic Mechanical Stress Assay (AMSA) for laundry**

5 In order to assess the wash performance in laundry, washing experiments are performed using the Automatic Mechanical Stress Assay (AMSA). With the AMSA, the wash performance of many small volume enzyme-detergent solutions can be examined. The AMSA plate has a number of slots for test solutions and a lid that firmly squeezes the textile to be washed against the slot openings. During the wash, the plate, test solutions, textile and lid are vigorously shaken to bring the test solution in contact with the textile and apply mechanical stress in a regular, periodic, oscillating manner. For further description see WO02/42740 especially the paragraph "Special method embodiments" at page 23-24.

The laundry experiments may be conducted under the experimental conditions specified below:

Detergent dosage	5 g/L (liquid detergent) 2.5 g/L (powder detergent)
Test solution volume	160 micro L
pH	Adjusted to pH 7 or pH 6 (liquid detergent) As is (powder detergent)
Wash time	20 minutes
Temperature	60°C, 40°C and 20°C or 15°C
Water hardness	15°dH

15 Model detergents and test materials may be as follows:

Laundry liquid model detergent	Sodium alkylethoxy sulfate (C-9-15, 2EO) 6.0% Sodium dodecyl benzene sulfonate 3.0% Sodium toluene sulfonate 3.0% Olic acid 2.0% Primary alcohol ethoxylate (C12-15, 7EO) 3.0% Primary alcohol ethoxylate (C12-15, 3EO) 2.5% Ethanol 0.5% Monopropylene glycol 2.0% Tri-sodium citrate dihydrate 4.0%
--------------------------------	---

	Triethanolamine 0.4% De-ionized water ad 100% pH adjusted to 8.5 with NaOH
Laundry powder model detergent	Sodium citrate dihydrate 32.3% Sodium-LAS 24.2% Sodium lauryl sulfate 32.2% Neodol 25-7 (alcohol ethoxylate) 6.4% Sodium sulfate 4.9%
Test material	CS-28 (Rice starch on cotton)

Test materials are obtained from EMPA Testmaterials AG, Movenstrasse 12, CH-9015 St. Gallen, Switzerland, from Center For Testmaterials BV, P.O. Box 120, 3133 KT Vlaardingen, the Netherlands, and WFK Testgewebe GmbH, Christenfeld 10, D-41379 Bruggen, Germany.

5 Water hardness is adjusted to 15°dH by addition of  $\text{CaCl}_2$ ,  $\text{MgCl}_2$ , and  $\text{NaHCO}_3$  ( $\text{Ca}^{2+}:\text{Mg}^{2+} = 4:1:7.5$ ) to the test system. After washing the textiles are flushed in tap water and dried.

The wash performance is measured as the brightness of the colour of the textile washed. Brightness can also be expressed as the intensity of the light reflected from the sample when illuminated with white light. When the sample is stained the intensity of the reflected light is lower,  
10 than that of a clean sample. Therefore the intensity of the reflected light can be used to measure wash performance.

Colour measurements are made with a professional flatbed scanner (Kodak iQsmart, Kodak, Midtager 29, DK-2605 Brøndby, Denmark or Expression 10000XL, Epson Danmark, Transformervej 6, 2730 Herlev, Denmark), which is used to capture an image of the washed textile.  
15 To extract a value for the light intensity from the scanned images, 24-bit pixel values from the image are converted into values for red, green and blue (RGB). The intensity value (Int) is calculated by adding the RGB values together as vectors and then taking the length of the resulting vector:

$$Int = \sqrt{r^2 + g^2 + b^2}$$

20

#### **Automatic Mechanical Stress Assay (AMSA) for Automatic Dish Wash**

Washing experiments are performed in order to assess the wash performance of selected alpha-amylase variants in dishwasher detergent compositions. The alpha-amylase variants of the present application may be tested using the Automatic Mechanical Stress Assay (AMSA).

With the AMSA, the wash performance of many small volume enzyme-detergent solutions can be examined. The AMSA plate has a number of slots for test solutions and a lid that firmly squeezes the melamine tile to be washed against the slot openings. During the wash, the plate, test solutions, melamine tile and lid are vigorously shaken to bring the test solution in contact with the soiled melamine tile and apply mechanical stress in a regular, periodic oscillating manner. For further description see WO 02/42740 especially the paragraph "Special method embodiments" at page 23-24.

The experiment may be conducted under the experimental conditions as specified in the table(s) below:

ADW model detergent with MGDA	MGDA (40 %) 30 % Sodium carbonate 20 % Sodium percarbonate 10 % Sodium disilicate 5 % TAED 5% Sokalan CP5 (39.5 %) 10 % Surfac 23-6.5 (100 %) 5 % Sodium Sulfate 15 %
Detergent dosage	3.33 g/L
Test solution volume	160 micro L
pH	As is
Wash time	20 minutes
Temperature	50 °C
Water hardness	17 °dH
Enzyme concentration in test solution	0.925, 1.85, 5.55, 11 mg enzyme protein/liter
Test material	melamine tiles with starch such as DM-77 and DM-78

ADW model detergent with STPP	STPP 50 % Sodium carbonate 20% Sodium percarbonate 10% Sodium disilicate 5% TAED 2% Sokalan CP5 (39.5%) 5%
-------------------------------	---

	Surfac 23-6.5 (100%) 2% Phosphonate 6%
Detergent dosage	3.33 g/L
Test solution volume	160 micro L
PH	As is
Wash time	20 minutes
Temperature	50°C
Water hardness	17°dH
Enzyme concentration in test solution	0.925, 1.85, 5.55, 11 mg enzyme protein/liter
Test material	melamine tiles with starch such as DM-77 and DM-78

Water hardness is adjusted to 17°dH by addition of CaCl<sub>2</sub>, MgCl<sub>2</sub>, and NaHCO<sub>3</sub> (Ca<sup>2+</sup>:Mg<sup>2+</sup> = 4:1 :10) to the test system. After washing the melamine tiles were flushed in tap water and dried.

5 The performance of the enzyme variant is measured as the brightness of the colour of the melamine tile washed with that specific alpha-amylase. Brightness can also be expressed as the intensity of the light reflected from the sample when illuminated with white light. When the sample is stained the intensity of the reflected light is lower, than that of a clean sample. Therefore the intensity of the reflected light can be used to measure wash performance of a protease.

10 Colour measurements are made with a professional flatbed scanner (Kodak iQsmart, Kodak, Midtager 29, DK-2605 Brondby, Denmark), which is used to capture an image of the washed melamine tiles.

To extract a value for the light intensity from the scanned images, a special designed software application is used (*Novozymes Colour Vector Analyzer*). The program retrieves the 24 bit pixel values from the image and converts them into values for red, green and blue (RGB). The intensity value (Int) is calculated by adding the RGB values together as vectors and then taking the length of the resulting vector:

$$Int = \sqrt{r^2 + g^2 + b^2}$$

20 Textiles:

Standard melamine tiles with starch such as DM-77 and DM-78 may be obtained from Center For Testmaterials BV, P.O. Box 120, 3133 KT Vlaardingen, the Netherlands.

**AMSA wash performance**

The wash performance of the variants and corresponding parent alpha-amylases is tested by the AMSA-test method as described in the Methods section. The results are given as (performance of variant minus performance of blank) divided by (performance of parent minus performance of blank) multiplied by 100, where the blank is the performance obtained by washing at the same conditions, but in the absence of alpha-amylase.

**Terg-O-tometer (TOM) wash assay**

The Tergo-To-Meter (TOM) is a medium scale model wash system that can be applied to test 12 different wash conditions simultaneously. A TOM is basically a large temperature controlled water bath with up to 12 open metal beakers submerged into it. Each beaker constitutes one small top loader style washing machine and during an experiment, each of them will contain a solution of a specific detergent/enzyme system and the soiled and unsoiled fabrics its performance is tested on. Mechanical stress is achieved by a rotating stirring arm, which stirs the liquid within each beaker. Because the TOM beakers have no lid, it is possible to withdraw samples during a TOM experiment and assay for information on-line during wash.

The TOM model wash system is mainly used in medium scale testing of detergents and enzymes at US or LA/AP wash conditions. In a TOM experiment, factors such as the ballast to soil ratio and the fabric to wash liquor ratio can be varied. Therefore, the TOM provides the link between small scale experiments, such as AMSA and mini-wash, and the more time consuming full scale experiments in top loader washing machines.

Equipment: The water bath with 12 steel beakers and 1 rotating arm per beaker with capacity of 500 or 1200 mL of detergent solution. Temperature ranges from 5 to 80°C. The water bath has to be filled up with deionised water. Rotational speed can be set up to 70 to 120 rpm/min.

**TOM wash performance**

Water hardness is adjusted to the strength described below by addition of  $\text{CaCl}_2$ ,  $\text{MgCl}_2$  and  $\text{NaHCO}_3$ . Wash solutions are prepared with desired amount of detergent, temperature and water hardness in a bucket as described below. Detergent is dissolved during magnet stirring for 10 min.

Temperature and rotation (rpm) in the water bath in the Terg-O-Tometer is set according to the settings below. When temperature is adjusted according to settings (tolerance is +/- 0.5°C) wash solution is added to TOM beaker according to the amount described below.

Agitation in the beaker is at 120 rpm. 2 rice starch swatches (CS-28) and soil ballast are added to each of the beakers and wash carried out according to time stated below. Swatches are rinsed in cold tap water for 5 min. The swatches are left to dry in the dark overnight.

Textile: Textile sample CS-28 (rice starch on cotton) is obtained from Center for Testmaterials BV, P.O. Box 120, 3133 KT Vlaardingen, the Netherlands.

Soil ballast: Soil ballast Rice starch on cotton/polyester (EMPA 162) is obtained from Center for Testmaterials BV, P.O. Box 120, 3133 KT Vlaardingen, the Netherlands. Bistro gravy (063KC), Frij Chocolate milkshake, Heinz spaghetti (113KC), Herseys double chocolate is obtained from Warwick Equest Ltd, Unit 55, Consett Business Park, Consett, County Durham, DH8 6BN UK

10

Table 1: Experimental conditions

	European (EU) conditions	Northern America (US) conditions
Detergent dosage	5.77 g/L (liquid detergent)	0.78 g/L (liquid detergent)
Water hardness	15°dH (Ca <sup>2+</sup> :Mg <sup>2+</sup> :HCO <sub>3</sub> <sup>-</sup> = 4:1:7.5)	6°dH (Ca <sup>2+</sup> :Mg <sup>2+</sup> :HCO <sub>3</sub> <sup>-</sup> = 2:1:4.5)
Enzyme concentration in wash solution	0.25 mg enzyme protein/L	0.08 mg enzyme protein/L
Test solution volume	500 ml	800 ml
Wash time	30 minutes	18 minutes
Rotation	120 rpm	
pH	as is	
Temperature	15°C	

Detergents and test materials were as follows:

Laundry liquid detergent	May be as described below
Test material	CS-28 (Rice starch on cotton)
Soil ballast	Rice starch on polyester/cotton (EMPA 162), Bistro gravy (063KC), Frij Chocolate milkshake, Heinz spaghetti (113KC), Herseys double chocolate (2 swatches of each)

15

The wash performance is measured as the brightness of the color of the textile washed, expressed in remission values. Remission measurements are made using a Macbeth 7000 Color Eye spectrophotometer. Each of the dry swatches is to be measured. As there is a risk of

interference from the back-ground, the swatches are placed on top of 4 layers of fabric during the measurement of the remission. The remission is measured at 460 nm. The UV filter is not included. An average result for remission for the swatches is calculated.

## 5 Media and Solutions

Cleaning compositions:

### Model detergents 1 and 2

	<b>Model 1</b>	<b>Model 2</b>
Component	% w/w	% w/w
LAS	12	12
AEOS	4,9	4,9
Soap (cocoa)	2,75	2,75
Soap (soya)	2,75	2,75
AEO N25-7	11	11
NaOH	1,75	1,75
Ethanol	3	3
MPG	6	6
Glycerol	1,7	1,7
TEA	3,3	3,3
Sodium formate	1	1
Sodium citrate	2	2
HEDP	0	0,5
PCA (Sokalan CP-5)	0,18	0,18
Ion exchanged water	34,2	34,2
DTMPA	0,2	0

## 10 Model detergent A

<b>Compound</b>	<b>Amount g/100g</b>	<b>% active ingre- dient</b>
	<i>Surfactants</i>	
Na-LAS (92%) (Nacconol 90G) (anionic)	21.74	20
STEOL CS-370E (70%) (anionic)	14.28	10

Bio-soft N25-7 (99.5%) (non-ionic)	10	10
Oleic acid (fatty acid)	4	4
	<i>Solvents</i>	
H <sub>2</sub> O	25	-33
Ethanol	0.5	0.5
STS (sodium p-toluene sulfonate (40%))	3.75	1.5
Mono propylene glycol	7	7
	<i>Builder</i>	
Tri-sodium-citrate	8	8
Triethanolamine (TEA)	0.5	0.5
	<i>Inhibitor</i>	
Boric acid	1.5	1.5
	<i>Minors</i>	
10N NaOH (for adjustment to pH 8.5)	2	

Model detergent X

<b>Compound</b>	<b>wt%</b>
<b>Surfactant system</b>	
LAS	15
AEO	2*
soap	0
<b>Builder system</b>	
sodium carbonate	20
sodium disilicate	12
zeolite A	15
PCA	1
sodium sulfate	37

\*Model X is mixed without AEO. AEO is added to the wash separately.

The invention described and claimed herein is not to be limited in scope by the specific aspects herein disclosed, since these aspects are intended as illustrations of several aspects of the invention. Any equivalent aspects are intended to be within the scope of this invention. Indeed, 5 various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. In the case of conflict, the present disclosure including definitions will control.

**CLAIMS**

1. An alpha-amylase variant comprising an alteration at two or more (several) positions corresponding to positions W140, W159, W167, Q169, W189, E194, N260, F262, F289, W284,  
5 G304, G305, W347, R439, W469, D476 and G477 of the mature polypeptide of SEQ ID NO: 1, wherein each alteration is independently a substitution, deletion or insertion, and wherein the variant has at least 85%, such as at least 90%, but less than 100% sequence identity with the mature polypeptide of SEQ ID NO: 1 or 2 and wherein the variant has alpha-amylase activity.
- 10 2. The variant of claim 1, comprising an alteration at three or more of said positions.
3. The variant of claims 1 or 2, comprising an alteration at four or more of said positions.
4. The variant of any of the above claims comprising an alteration at five or more of said  
15 positions.
5. The variant of any of the above claims comprising an alteration at six or more of said positions.
- 20 6. The variant of any of the above claims comprising an alteration at seven or more of said positions.
7. The variant of any of the above claims comprising an alteration at eight or more of said  
25 positions.
8. The variant of any of the above claims comprising an alteration at nine or more of said positions.
9. The variant of any of the above claims wherein the alterations are substitutions.
- 30 10. The variant of any of the above claims wherein the two or more alterations comprise a substitution of W140ACDEFGHIKLMNPQRSTVY, preferably W140YFH, most preferred W140Y.
11. The variant of any of the above claims wherein the two or more alterations comprise a  
35 substitution of W159ACDEFGHIKLMNPQRSTVY, preferably W159YFH.

12. The variant of any of the above claims wherein the two or more alterations comprise a substitution of W167ACDEFGHIKLMNPQRSTVY, preferably W167YFH.
13. The variant of any of the above claims wherein the two or more alterations comprise a substitution of Q169ACDEFGHIKLMNPWRSTVY.
14. The variant of any of the above claims wherein the two or more alterations comprise a substitution of W189ACDEFGHIKLMNPQRSTVY, preferably W189YFHEDQN.
15. The variant of any of the above claims wherein the two or more alterations comprise a substitution of E194ACDWFGHIKLMNPQRSTVY, preferably E194DNS, most preferred E194D.
16. The variant of any of the above claims wherein the two or more alterations comprise a substitution of N260ACFGHIKLMWPQRSTVY preferably N260G or N260P or N260A.
17. The variant of any of the above claims wherein the two or more alterations comprise a substitution of F262ACDEWGHKLMNPQRSTVY, preferably F262P or F262G.
18. The variant of any of the above claims wherein the two or more alterations comprise a substitution of W284ACDEFGHIKLMNPQRSTVY, preferably W284G or W284H.
19. The variant of any of the above claims wherein the two or more alterations comprise a substitution of F289ACDEWGHKLMNPQRSTVY, preferably F289H.
20. The variant of any of the above claims wherein the two or more alterations comprise a substitution of G304ACEFHKLMNPQRWTVY, preferably G304KRQE, most preferred G304K.
21. The variant of any of the above claims wherein the two or more alterations comprise a substitution of G305ACEFWHIKLMNPQRTVY, preferably G305KRQE, most preferred G305K.
22. The variant of any of the above claims wherein the two or more alterations comprise a substitution of W347ACDEFGHIKLMNPQRSTVY, preferably W347YFH.
23. The variant of any of the above claims wherein the two or more alterations comprise a substitution of R439ACDEFGHIKLMNPQSTVY, preferably R439NQT.
24. The variant of any of the above claims wherein the two or more alterations comprise a substitution of W469ACDEFGHIKLMNPQRSTVY preferably W469T or W469N.

25. The variant of any of the above claims wherein the two or more alterations comprise a substitution of D476ACEFHILMNPQRTVWY, preferably it is D476K or D476R or D476Q or D476E, and most preferred it is D476K.

5 26. The variant of any of the above claims wherein the two or more alterations comprise a substitution of G477ACEFHILMNPQRTVWY, preferably G477K or G477R or G477Q or G477E, and most preferred it is G477K.

10 27. The variant of any of the above claims, further comprising a deletion in two positions selected from the group consisting of R181, G182, D183 and G184 when using SEQ ID NO: 1 for numbering, preferably a deletion of R181+D183, or of R181+184, or of R181+G182, or of G182+D183, or of G182+G184, or more preferred of D183 +G184.

15 28. The variant of any of the above claims, further comprising at least one of the substitutions selected from the group consisting of: G109A, G149A, K179L, G186A, E190P, N195F, M202LIT, V206YF, N209D, Y243F, S244QAEDN when using SEQ ID NO: 1 for numbering.

29. The variant according to any of the above claims, comprising alterations in positions corresponding to the following positions in SEQ ID NO: 1:

- 20 W140Y+Y160S
- W140Y+E194D
- W140Y+N260P
- W140Y+G304K
- 25 W140Y+G304R
- W140Y+R439T
- W140Y+W469T
- W140Y+D476K
- W140Y+G477R
- 30 Y160S+E194D
- Y160S+E212D
- Y160S+N260P
- Y160S+G304K
- Y160S+G304R
- 35 Y160S+R439T

Y160S+W469T  
Y160S+D476K  
Y160S+G477R  
N260P+G304K  
5 N260P+G305R  
N260P+R439K  
N260P+W469R  
N260P+D476K  
N260P+G477R  
10 W284G+G304K  
W284G+G305R  
W284G+R439N  
W284G+W469T  
W284G+D476K  
15 W284G+G477R  
L279T+W284G+ H324N+G304K  
L279T+W284G+ H324N+G305R  
L279T+W284G+ H324N+R439N  
L279T+W284G+ H324N+W469T  
20 L279T+W284G+ H324N+D476K  
L279T+W284G+ H324N+G477R  
G304K+R439K  
G304K+W469R  
G304K+D476K  
25 G304K+G477R  
G305K+R439K  
G305K+W469R  
G305K+D476K  
G305K+G477R  
30 R439N+W469R  
R439N+D476K  
R439N+G477R  
W469T+D476K  
W469T+G477R  
35 W140Y+G304R+G475K

- W 140Y+N260P+G304R+G475K
- W 140Y+E21 2D+G304R+G475K
- W 140Y+G304R+W438R+G475K
- W 140Y+G304R+W468T+G475K
- 5 W140Y+G305K+G475K
- W 140Y+N260P+G305K+D476K
- W 140Y+E21 2D+G305K+D476K
- W 140Y+G305K+R439N+D476K
- W 140Y+G305K+W469T+D476K
- 10 W140Y+G304R+D476K
- W 140Y+N260P+G304R+G477K
- W 140Y+E21 2D+G304R+G477K
- W 140Y+G304R+R439N+G477K
- W 140Y+G304R+W469T+G477K
- 15 W140Y+G305K+G477K
- W 140Y+W284K+G305K+G477K
- W 140Y+N260P+G305K+G477K
- W 140Y+E21 2D+G305K+G477K
- W140Y+G305K+R439N+G477K and
- 20 W140Y+G305K+W469T+G477K

30. The variant according to any of the above claims, wherein the alterations consist of the alterations in positions corresponding to the following positions in SEQ ID NO: 1:

- 25 W140Y+Y160S
- W140Y+E194D
- W140Y+N260P
- W140Y+G304K
- W140Y+G304R
- 30 W140Y+R439T
- W140Y+W469T
- W140Y+D476K
- W140Y+G477R
- Y160S+E194D
- 35 Y160S+E212D

Y160S+N260P  
Y160S+G304K  
Y160S+G304R  
Y160S+R439T  
5 Y160S+W469T  
Y160S+D476K  
Y160S+G477R  
N260P+G304K  
N260P+G305R  
10 N260P+R439K  
N260P+W469R  
N260P+D476K  
N260P+G477R  
W284G+G304K  
15 W284G+G305R  
W284G+R439N  
W284G+W469T  
W284G+D476K  
W284G+G477R  
20 L279T+W284G+H324N+G304K  
L279T+W284G+H324N+G305R  
L279T+W284G+H324N+R439N  
L279T+W284G+H324N+W469T  
L279T+W284G+H324N+D476K  
25 L279T+W284G+H324N+G477R  
G304K+R439K  
G304K+W469R  
G304K+D476K  
G304K+G477R  
30 G305K+R439K  
G305K+W469R  
G305K+D476K  
G305K+G477R  
R439N+W469R  
35 R439N+D476K

R439N+G477R

W469T+D476K

W469T+G477R

W140Y+G304R+G475K

5 W 140Y+N260P+G304R+G475K

W 140Y+E21 2D+G304R+G475K

W 140Y+G304R+W438R+G475K

W 140Y+G304R+W468T+G475K

W140Y+G305K+G475K

10 W 140Y+N260P+G305K+D476K

W 140Y+E21 2D+G305K+D476K

W 140Y+G305K+R439N+D476K

W 140Y+G305K+W469T+D476K

W140Y+G304R+D476K

15 W 140Y+N260P+G304R+G477K

W 140Y+E21 2D+G304R+G477K

W 140Y+G304R+R439N+G477K

W 140Y+G304R+W469T+G477K

W140Y+G305K+G477K

20 W 140Y+W284K+G305K+G477K

W 140Y+N260P+G305K+G477K

W 140Y+E21 2D+G305K+G477K

W140Y+G305K+R439N+G477K and

W 140Y+G305K+W469T+G477K

25

31. The variant according to any of the above claims, comprising alterations in positions corresponding to the following positions in SEQ ID NO: 2:

W140Y+Y160S

W140Y+E194D

30 W140Y+N260P

W140Y+G304K

W140Y+G304R

W140Y+W439T

W140Y+W469T

35 W140Y+G476K

W140Y+G477R  
Y160S+E194D  
Y160S+E212D  
Y160S+N260P  
5 Y160S+G304K  
Y160S+G304R  
Y160S+W439T  
Y160S+W469T  
Y160S+G476K  
10 Y160S+G477R  
N260P+G304K  
N260P+G305R  
N260P+W439K  
N260P+W469R  
15 N260P+G476K  
N260P+G477R  
W284G+G304K  
W284G+G305R  
W284G+W439R  
20 W284G+W469T  
W284G+G476K  
W284G+G477R  
L279T+W284G+H324N+G304K  
L279T+W284G+H324N+G305R  
25 L279T+W284G+H324N+W439R  
L279T+W284G+H324N+W469T  
L279T+W284G+H324N+G476K  
L279T+W284G+H324N+G477R  
G304K+W439K  
30 G304K+W469R  
G304K+G476K  
G304K+G477R  
G305K+W439K  
G305K+W469R  
35 G305K+G476K

- G305K+G477R
- W439R+W469R
- W439R+G476K
- W439R+G477R
- 5 W469T+G476K
- W469T+G477R
- W140Y+G304R+G475K
- W 140Y+N260P+G304R+G475K
- W 140Y+E21 2D+G304R+G475K
- 10 W140Y+G304R+W438R+G475K
- W 140Y+G304R+W468T+G475K
- W140Y+G305K+G475K
- W 140Y+N260P+G305K+G476K
- W 140Y+E21 2D+G305K+G476K
- 15 W140Y+G305K+W439R+G476K
- W 140Y+G305K+W469T+G476K
- W140Y+G304R+G476K
- W 140Y+N260P+G304R+G477K
- W 140Y+E21 2D+G304R+G477K
- 20 W140Y+G304R+W439R+G477K
- W 140Y+G304R+W469T+G477K
- W140Y+G305K+G477K
- W 140Y+W284K+G305K+G477K
- W 140Y+N260P+G305K+G477K
- 25 W140Y+E212D+G305K+G477K
- W140Y+G305K+W439R+G477K and
- W 140Y+G305K+W469T+G477K

32. The variant according to any of the above claims, wherein the alterations consist of the  
 30 alterations in positions corresponding to the following positions in SEQ ID NO: 2:

- W140Y+Y160S
- W140Y+E194D
- W140Y+N260P
- W140Y+G304K
- 35 W140Y+G304R

W140Y+W439T  
W140Y+W469T  
W140Y+G476K  
W140Y+G477R  
5 Y160S+E194D  
Y160S+E212D  
Y160S+N260P  
Y160S+G304K  
Y160S+G304R  
10 Y160S+W439T  
Y160S+W469T  
Y160S+G476K  
Y160S+G477R  
N260P+G304K  
15 N260P+G305R  
N260P+W439K  
N260P+W469R  
N260P+G476K  
N260P+G477R  
20 W284G+G304K  
W284G+G305R  
W284G+W439R  
W284G+W469T  
W284G+G476K  
25 W284G+G477R  
L279T+W284G+H324N+G304K  
L279T+W284G+H324N+G305R  
L279T+W284G+H324N+W439R  
L279T+W284G+H324N+W469T  
30 L279T+W284G+H324N+G476K  
L279T+W284G+H324N+G477R  
G304K+W439K  
G304K+W469R  
G304K+G476K  
35 G304K+G477R

- G305K+W439K
- G305K+W469R
- G305K+G476K
- G305K+G477R
- 5 W439R+W469R
- W439R+G476K
- W439R+G477R
- W469T+G476K
- W469T+G477R
- 10 W140Y+G304R+G475K
- W 140Y+N260P+G304R+G475K
- W 140Y+E21 2D+G304R+G475K
- W 140Y+G304R+W438R+G475K
- W 140Y+G304R+W468T+G475K
- 15 W140Y+G305K+G475K
- W 140Y+N260P+G305K+G476K
- W 140Y+E21 2D+G305K+G476K
- W 140Y+G305K+W439R+G476K
- W 140Y+G305K+W469T+G476K
- 20 W140Y+G304R+G476K
- W 140Y+N260P+G304R+G477K
- W 140Y+E21 2D+G304R+G477K
- W 140Y+G304R+W439R+G477K
- W 140Y+G304R+W469T+G477K
- 25 W140Y+G305K+G477K
- W 140Y+W284K+G305K+G477K
- W 140Y+N260P+G305K+G477K
- W 140Y+E21 2D+G305K+G477K
- W140Y+G305K+W439R+G477K and
- 30 W140Y+G305K+W469T+G477K

33. The variant of any of claims 1-32, wherein the number of alterations is 2-20, e.g., 2-10 and 2-5, such as 2, 3, 4, 5, 6, 7, 8, 9 or 10 alterations.

34. The variant of any of claims 1-32 wherein the variant consists of 450 to 490, e.g., 460 to 485, 480 to 484, amino acids, such as 483 amino acids.

35. The variant of any of the above claims, which has at least 86%, at least 87%, at least 88%,  
5 at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%  
identity, at least 96%, at least 97%, at least 98%, or at least 99%, but less than 100%, sequence  
identity to the amino acid sequence of SEQ ID NO: 1.

36. The variant of any of the above claims, which has at least 86%, at least 87%, at least 88%,  
10 at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%  
identity, at least 96%, at least 97%, at least 98%, or at least 99%, but less than 100%, sequence  
identity to the amino acid sequence of SEQ ID NO: 2.

37. The variant of any of the above claims, which has at least 85%, at least 86%, at least 87%,  
15 at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at  
least 95% identity, at least 96%, at least 97%, at least 98%, or at least 99%, but less than 100%,  
sequence identity, to the amino acid sequence of the parent alpha-amylase.

38. The variant of any of the above claims, which is a variant of a parent alpha-amylase  
20 selected from the group consisting of:

a. a polypeptide having at least 85% sequence identity to the mature  
polypeptide of SEQ ID NO: 1;

b. a polypeptide having at least 85% sequence identity to the mature  
polypeptide of SEQ ID NO: 2;

25 c. a fragment of the mature polypeptide of SEQ ID NO: 1, which has alpha-  
amylase activity;

d. a fragment of the mature polypeptide of SEQ ID NO: 2, which has alpha-  
amylase activity;

30 e. a polypeptide having immunological cross reactivity with an antibody raised  
against the mature polypeptide of SEQ ID NO: 1;

f. a polypeptide having immunological cross reactivity with an antibody raised  
against the mature polypeptide of SEQ ID NO: 2.

39. The variant of claim 38, wherein the parent has at least 86%, at least 87%, at least 88%, at  
35 least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%

identity, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 1 or 2.

40. The variant of any of the above claims, wherein the parent alpha-amylase comprises or  
5 consists of the mature polypeptide of SEQ ID NO: 1 or 2.

41. The variant of any of claims 1-40, which has an improved property relative to the parent,  
wherein the improved property is selected from the group consisting of catalytic efficiency, catalytic  
10 rate, chemical stability, oxidation stability, pH activity, pH stability, specific activity, stability under  
storage conditions, substrate binding, substrate cleavage, substrate specificity, substrate stability,  
surface properties, thermal activity, thermo stability, and preferably improved washing performance  
at low temperature.

42. The variant of any of the above claims which is an isolated variant.  
15

43. A detergent composition comprising a variant alpha-amylase of any of the claims 1-42.

44. Use of a variant alpha-amylase according to any of the claims 1-42 in a cleaning process  
such as laundry or hard surface cleaning including automated dish wash.  
20

45. An isolated polynucleotide encoding the variant of any of claims 1-42.

46. A nucleic acid construct comprising the polynucleotide of claim 45.

25 47. An expression vector comprising the polynucleotide of claim 45.

48. A host cell comprising the polynucleotide of claim 45.

49. A method of producing an alpha-amylase variant, comprising:  
30 a. cultivating the host cell of claim 48 under conditions suitable for expression of the  
variant; and  
b. recovering the variant.

50. A method for obtaining an alpha-amylase variant, comprising introducing into a parent  
35 alpha-amylase having at least 85% sequence identity to SEQ ID NO: 1 or 2, an alteration at two or

more positions corresponding to positions W140; W159; W167, Q169, W189, E194, N260, F262, F289, W284, G304, G305, W347, R439, W469, D476 and G477 of the mature polypeptide of SEQ ID NO: 1, wherein each alteration is independently a substitution, deletion or insertion and the variant has alpha-amylase activity; and recovering the variant.

5

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP2013/077678

## Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of:
  - a. (means)
    - on paper
    - in electronic form
  - b. (time)
    - in the international application as filed
    - together with the international application in electronic form
    - subsequently to this Authority for the purpose of search
2.  In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP2013/077678

## Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
  
2.  As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
  
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos. :  
  
10, 20, 21 (completely) ; 1-9, 27-50 (partially)
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos. :

### Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No  
PCT/EP2013/077678

A. CLASSIFICATION OF SUBJECT MATTER  
**INV. C12N9/28**  
 ADD.  
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED  
 Minimum documentation searched (classification system followed by classification symbols)  
**C12N**

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
**EPO-Internal , BIOSIS, COMPENDEX, EMBASE, FSTA, WPI Data**

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 2 540 824 A1 (PROCTER & GAMBLE [US] ) 2 January 2013 (2013-01-02) the whole document, in parti cul ar [0008-0010] , claims and sequences -----	1-10, 27-50
X	WO 01/66712 A2 (NOVOZYMES AS [DK] ; ANDERSEN CARSTEN [DK] ; BØRCHERT TORBEN VEDEL [DK] ; ) 13 September 2001 (2001-09-13) the whole document, in parti cul ar p. 24 and claims -----	1-10, 27-50
X	WO 96/23873 A1 (NOVO NØRDISK A/S) 8 August 1996 (1996-08-08) cited in the applicati on the whole document, in parti cul ar p.23/24 and Fig. 1 ----- -/- .	1-10, 27-50

Further documents are listed in the continuation of Box C.

See patent family annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search <b>3 April 2014</b>	Date of mailing of the international search report <b>11/04/2014</b>
--	---

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer <b>Bassi as, Ioanni s</b>
--	---

## INTERNATIONAL SEARCH REPORT

International application No  
PCT/EP2013/077678

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 093 562 A (BISGAARD-FRANTZEN HENRI K [DK] ET AL) 25 July 2000 (2000-07-25) the whole document, in particular column 11, 2nd paragraph -----	1-9 ,20, 21,27-50
X	EP 2 045 317 A1 (LANXESS DEUTSCHLAND GMBH [DE]) 8 April 2009 (2009-04-08) the whole document, in particular [0013] and claim 8 -----	1-9 ,20, 21,27-50
X	wo 2006/002643 A2 (NOVOZYMES AS [DK] ; ANDERSEN CARSTEN [DK] ; ØESTDAL HENRIK [DK] ; SKAGERL) 12 January 2006 (2006-01-12) the whole document, in particular p.13 and claims 1 and 2 -----	1-9 ,20, 21,27-50
X	US 2012/045822 A1 (CONCAR EDWARD M [US] ET AL) 23 February 2012 (2012-02-23) the whole document, in particular [0225] -----	1-9 ,20, 21,27-50
X	EP 1 975 229 A2 (NOVOZYMES AS [DK] ) 1 October 2008 (2008-10-01) the whole document, in particular [0129] -----	1-9 ,20, 21,27-50
X	wo 2011/080352 A1 (NOVOZYMES AS [DK] ; ANDERSEN CARSTEN [DK] ; POULSEN THOMAS AGERSTEN [DK] ) 7 July 2011 (2011-07-07) the whole document, in particular Table 1 -----	1-9 ,20, 27-50
X	wo 97/41213 A1 (NOVO NORDISK AS [DK] ; SVENDSEN ALLAN [DK] ; BORCHERT TORBEN VEDEL [DK] ; ) 6 November 1997 (1997-11-06) the whole document, in particular paragraph bridging p.11/12 and claim 1 -----	1-9 ,21 , 27-50
A	wo 00/60058 A2 (NOVO NORDISK AS [DK] NOVOZYMES AS [DK] ) 12 October 2000 (2000-10-12) cited in the application -----	1-10,20, 21,27-50
A	NI ELSEN<A> J E ET AL: "Protein engineering of bacterial alpha-amylases" , BIOCHIMICA ET BIOPHYSICA ACTA. PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, ELSEVIER, AMSTERDAM; NL, vol . 1543 , no. 2 , 29 December 2000 (2000-12-29) , pages 253-274, XP004279109 , ISSN : 0167-4838, DOI : 10. 1016/50167-4838(00)00240-5 ----- -/--	1-10,20, 21,27-50

## INTERNATIONAL SEARCH REPORT

International application No  
PCT/EP2013/077678

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>NATHALIE DECLERCK ET AL: "Engineering the thermostability of Bacillus licheniformis alpha-amylase", BIOLOGIA, SAP-SLOVAK ACADEMIC PRESS, BRATISLAVA, SK , vol . 57, no. suppl . 11 1 January 2002 (2002-01-01) , pages 203-211 , XP002685107 , ISSN: 0006-3088 Retrieved from the Internet: URL: <a href="http://biologia.savba.sk/Suppl_11/Declerck.pdf">http://biologia.savba.sk/Suppl_11/Declerck.pdf</a> -----</p>	1-10,20, 21,27-50

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2013/077678

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
EP 2540824	AI	02-01-2013	CN 103703126 A	02-04-2014
			EP 2540824 AI	02-01-2013
			EP 2540825 A2	02-01-2013
			US 2013000055 AI	03-01-2013
			WO 2013003659 AI	03-01-2013
-----				
WO 0166712	A2	13-09-2001	AR 028515 AI	14-05-2003
			AR 078073 A2	12-10-2011
			AU 4047301 A	17-09-2001
			CN 1436232 A	13-08-2003
			CN 101532000 A	16-09-2009
			CN 101532001 A	16-09-2009
			EP 1263942 A2	11-12-2002
			EP 2221365 AI	25-08-2010
			EP 2298875 A2	23-03-2011
			EP 2302048 AI	30-03-2011
			JP 2004505606 A	26-02-2004
			US 2003129718 AI	10-07-2003
			US 2009082246 AI	26-03-2009
			US 2011275136 AI	10-11-2011
			US 2014073553 AI	13-03-2014
			WO 0166712 A2	13-09-2001
-----				
WO 9623873	AI	08-08-1996	AR 000862 AI	06-08-1997
			AR 024280 A2	25-09-2002
			AR 053946 A2	23-05-2007
			AT 335077 T	15-08-2006
			AT 360026 T	15-05-2007
			AU 4483396 A	21-08-1996
			BR 9607735 A	14-07-1998
			CA 2211405 AI	08-08-1996
			CA 2821537 AI	08-08-1996
			CN 1172500 A	04-02-1998
			CN 1624124 A	08-06-2005
			DE 05002888 T1	08-02-2007
			DE 69636408 T2	26-07-2007
			DE 69637036 T2	30-04-2008
			DE 96900894 T1	31-03-2005
			DK 0815208 T3	27-11-2006
			DK 1538155 T3	02-07-2007
			EP 0815208 AI	07-01-1998
			EP 1538155 A2	08-06-2005
			EP 1752525 AI	14-02-2007
			EP 2455465 A2	23-05-2012
			EP 2455468 A2	23-05-2012
			EP 2465930 A2	20-06-2012
			ES 2226609 T1	01-04-2005
			ES 2269020 T1	01-04-2007
			JP 4116074 B2	09-07-2008
			JP H11503003 A	23-03-1999
			JP 2008178412 A	07-08-2008
			PT 1538155 E	05-06-2007
			WO 9623873 AI	08-08-1996
-----				
US 6093562	A	25-07-2000	US 6093562 A	25-07-2000
			US 6297038 B1	02-10-2001
			US 2002098996 AI	25-07-2002
			US 2003064908 AI	03-04-2003

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2013/077678

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		US 2004253676 AI	16-12-2004
		US 2005059131 AI	17-03-2005
		US 2005250664 AI	10-11-2005
		US 2009280527 AI	12-11-2009
		US 2010099597 AI	22-04-2010
		US 2010099598 AI	22-04-2010
		US 2011177990 AI	21-07-2011
-----			
EP 2045317	AI	08-04-2009	
		DE 102007047433 AI	09-04-2009
		EP 2045317 AI	08-04-2009
		US 2009093391 AI	09-04-2009
-----			
WO 2006002643	A2	12-01-2006	
		AU 2005259686 AI	12-01-2006
		BR PI0512776 A	08-04-2008
		CA 2571864 AI	12-01-2006
		CN 103275951 A	04-09-2013
		EP 1781790 A2	09-05-2007
		JP 4955546 B2	20-06-2012
		JP 2008504811 A	21-02-2008
		JP 2009165486 A	30-07-2009
		US 2008193999 AI	14-08-2008
		US 2011136205 AI	09-06-2011
		WO 2006002643 A2	12-01-2006
-----			
US 2012045822	AI	23-02-2012	
		CA 2757343 AI	07-10-2010
		CA 2757347 AI	07-10-2010
		CN 102378813 A	14-03-2012
		CN 102388132 A	21-03-2012
		EP 2414514 A2	08-02-2012
		EP 2414515 A2	08-02-2012
		JP 2012522514 A	27-09-2012
		JP 2012522875 A	27-09-2012
		RU 2011143721 A	10-05-2013
		RU 2011144134 A	10-05-2013
		US 2012045817 AI	23-02-2012
		US 2012045822 AI	23-02-2012
		WO 2010115021 A2	07-10-2010
		WO 2010115028 A2	07-10-2010
-----			
EP 1975229	A2	01-10-2008	
		EP 1975229 A2	01-10-2008
		US 2004091994 AI	13-05-2004
-----			
WO 2011080352	AI	07-07-2011	
		AU 2011203460 AI	05-07-2012
		CA 2785924 AI	07-07-2011
		CA 2786006 AI	07-07-2011
		CN 102884183 A	16-01-2013
		CN 102918148 A	06-02-2013
		CN 102918149 A	06-02-2013
		CN 102918150 A	06-02-2013
		CN 103068975 A	24-04-2013
		EP 2521771 AI	14-11-2012
		EP 2521772 AI	14-11-2012
		EP 2521773 AI	14-11-2012
		EP 2521774 A2	14-11-2012
		EP 2521775 AI	14-11-2012
		JP 2013516166 A	13-05-2013
		RU 2012133453 A	20-02-2014
		US 2012258497 AI	11-10-2012

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No <b>PCT/EP2013/077678</b>
--

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		US 2012264171 AI	18-10 -2012
		US 2012264176 AI	18-10 -2012
		US 2012270267 AI	25-10 -2012
		US 2012282658 AI	08-11 -2012
		US 2013203126 AI	08-08 -2013
		US 2014075601 AI	13-03 -2014
		W0 2011080352 AI	07-07 -2011
		W0 2011080353 AI	07-07 -2011
		W0 2011080354 AI	07-07 -2011
		W0 2011082425 A2	07-07 -2011
		W0 2011082429 AI	07-07 -2011
-----			
W0 9741213	AI	06-11-1997	
		AU 2692897 A	19-11 -1997
		BR 9708887 A	03-08 -1999
		CN 1217020 A	19-05 -1999
		DK 0904360 T3	14-10 -2013
		EP 0904360 AI	31-03 -1999
		ES 2432519 T3	04-12 -2013
		JP 4290763 B2	08-07 -2009
		JP 4580012 B2	10-11 -2010
		JP 2000508914 A	18-07 -2000
		JP 2009072204 A	09-04 -2009
		US 6143708 A	07-11 -2000
		US 6436888 B1	20-08 -2002
		US 2003171236 AI	11-09 -2003
		US 2004048351 AI	11-03 -2004
		US 2005118695 AI	02-06 -2005
		US 2008083406 AI	10-04 -2008
		US 2011207201 AI	25-08 -2011
		US 2012282672 AI	08-11 -2012
		US 2014024083 AI	23-01 -2014
		W0 9741213 AI	06-11 -1997
-----			
W0 0060058	A2	12-10-2000	
		AR 023230 AI	04-09 -2002
		AT 422538 T	15-02 -2009
		AU 3419200 A	23-10 -2000
		CN 1351657 A	29-05 -2002
		EP 1169434 A2	09-01 -2002
		ES 2322426 T3	22-06 -2009
		JP 4750284 B2	17-08 -2011
		JP 2002540784 A	03-12 -2002
		W0 0060058 A2	12-10 -2000
-----			

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: IO(completely) ; 1-9, 27-50(partially)

An alpha-amylase variant comprising an alteration at two or more (several) positions wherein one of the positions corresponds to position W140 of the mature polypeptide of SEQ ID NO: 1 or 2, wherein each alteration is independently a substitution, deletion or insertion, and wherein the variant has at least 85%, such as at least 90%, but less than 100% sequence identity with the mature polypeptide of SEQ ID NO: 1 or 2 and wherein the variant has alpha-amylase activity, detergent compositions comprising said variant alpha-amylase, isolated polynucleotides encoding said variant, expression vectors and host cells comprising said polynucleotides and methods for producing or obtaining said alpha-amylase variants.

---

2. claims: II (completely) ; 1-9, 27-50(partially)

An alpha-amylase variant comprising an alteration at two or more (several) positions wherein one of the positions corresponds to position W159 of the mature polypeptide of SEQ ID NO: 1 or 2, wherein each alteration is independently a substitution, deletion or insertion, and wherein the variant has at least 85%, such as at least 90%, but less than 100% sequence identity with the mature polypeptide of SEQ ID NO: 1 or 2 and wherein the variant has alpha-amylase activity, detergent compositions comprising said variant alpha-amylase, isolated polynucleotides encoding said variant, expression vectors and host cells comprising said polynucleotides and methods for producing or obtaining said alpha-amylase variants.

---

3. claims: 12 (completely) ; 1-9, 27-50(partially)

An alpha-amylase variant comprising an alteration at two or more (several) positions wherein one of the positions corresponds to position W167 of the mature polypeptide of SEQ ID NO: 1 or 2, wherein each alteration is independently a substitution, deletion or insertion, and wherein the variant has at least 85%, such as at least 90%, but less than 100% sequence identity with the mature polypeptide of SEQ ID NO: 1 or 2 and wherein the variant has alpha-amylase activity, detergent compositions comprising said variant alpha-amylase, isolated polynucleotides encoding said variant, expression vectors and host cells comprising said polynucleotides and methods for producing or obtaining said alpha-amylase variants.

---

4. claims: 13 (completely) ; 1-9, 27-50(partially)

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

An alpha-amylase variant comprising an alteration at two or more (several) positions wherein one of the positions corresponds to position Q169 of the mature polypeptide of SEQ ID NO: 1 or 2, wherein each alteration is independently a substitution, deletion or insertion, and wherein the variant has at least 85%, such as at least 90%, but less than 100% sequence identity with the mature polypeptide of SEQ ID NO: 1 or 2 and wherein the variant has alpha-amylase activity, detergent compositions comprising said variant alpha-amylase, isolated polynucleotides encoding said variant, expression vectors and host cells comprising said polynucleotides and methods for producing or obtaining said alpha-amylase variants.

---

## 5. claims: Incompletely ; 1-9, 27-50(partially)

An alpha-amylase variant comprising an alteration at two or more (several) positions wherein one of the positions corresponds to position W189 of the mature polypeptide of SEQ ID NO: 1 or 2, wherein each alteration is independently a substitution, deletion or insertion, and wherein the variant has at least 85%, such as at least 90%, but less than 100% sequence identity with the mature polypeptide of SEQ ID NO: 1 or 2 and wherein the variant has alpha-amylase activity, detergent compositions comprising said variant alpha-amylase, isolated polynucleotides encoding said variant, expression vectors and host cells comprising said polynucleotides and methods for producing or obtaining said alpha-amylase variants.

---

## 6. claims: 15 (completely) ; 1-9, 27-50(partially)

An alpha-amylase variant comprising an alteration at two or more (several) positions wherein one of the positions corresponds to position E194 of the mature polypeptide of SEQ ID NO: 1 or 2, wherein each alteration is independently a substitution, deletion or insertion, and wherein the variant has at least 85%, such as at least 90%, but less than 100% sequence identity with the mature polypeptide of SEQ ID NO: 1 or 2 and wherein the variant has alpha-amylase activity, detergent compositions comprising said variant alpha-amylase, isolated polynucleotides encoding said variant, expression vectors and host cells comprising said polynucleotides and methods for producing or obtaining said alpha-amylase variants.

---

## 7. claims: 16(completely) ; 1-9, 27-50(partially)

An alpha-amylase variant comprising an alteration at two or more (several) positions wherein one of the positions corresponds to position N260 of the mature polypeptide of

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

SEQ ID NO: 1 or 2, wherein each alteration is independently a substitution, deletion or insertion, and wherein the variant has at least 85%, such as at least 90%, but less than 100% sequence identity with the mature polypeptide of SEQ ID NO: 1 or 2 and wherein the variant has alpha-amylase activity, detergent compositions comprising said variant alpha-amylase, isolated polynucleotides encoding said variant, expression vectors and host cells comprising said polynucleotides and methods for producing or obtaining said alpha-amylase variants.

---

## 8. claims: 17 (completely) ; 1-9, 27-50 (partially)

An alpha-amylase variant comprising an alteration at two or more (several) positions wherein one of the positions corresponds to position F262 of the mature polypeptide of SEQ ID NO: 1 or 2, wherein each alteration is independently a substitution, deletion or insertion, and wherein the variant has at least 85%, such as at least 90%, but less than 100% sequence identity with the mature polypeptide of SEQ ID NO: 1 or 2 and wherein the variant has alpha-amylase activity, detergent compositions comprising said variant alpha-amylase, isolated polynucleotides encoding said variant, expression vectors and host cells comprising said polynucleotides and methods for producing or obtaining said alpha-amylase variants.

---

## 9. claims: 18 (completely) ; 1-9, 27-50 (partially)

An alpha-amylase variant comprising an alteration at two or more (several) positions wherein one of the positions corresponds to position W284 of the mature polypeptide of SEQ ID NO: 1 or 2, wherein each alteration is independently a substitution, deletion or insertion, and wherein the variant has at least 85%, such as at least 90%, but less than 100% sequence identity with the mature polypeptide of SEQ ID NO: 1 or 2 and wherein the variant has alpha-amylase activity, detergent compositions comprising said variant alpha-amylase, isolated polynucleotides encoding said variant, expression vectors and host cells comprising said polynucleotides and methods for producing or obtaining said alpha-amylase variants.

---

## 10. claims: 19 (completely) ; 1-9, 27-50 (partially)

An alpha-amylase variant comprising an alteration at two or more (several) positions wherein one of the positions corresponds to position F289 of the mature polypeptide of SEQ ID NO: 1 or 2, wherein each alteration is independently a substitution, deletion or insertion, and wherein the variant has at least 85%, such as at least 90%, but less than 100% sequence identity with the mature polypeptide of

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

SEQ ID NO: 1 or 2 and wherein the variant has alpha-amylase activity, detergent compositions comprising said variant alpha-amylase, isolated polynucleotides encoding said variant, expression vectors and host cells comprising said polynucleotides and methods for producing or obtaining said alpha-amylase variants.

---

11. claims: 20(completely) ; 1-9, 27-50(partially)

An alpha-amylase variant comprising an alteration at two or more (several) positions wherein one of the positions corresponds to position G304 of the mature polypeptide of SEQ ID NO: 1, or S304 of the mature polypeptide of SEQ ID NO: 2, wherein each alteration is independently a substitution, deletion or insertion, and wherein the variant has at least 85%, such as at least 90%, but less than 100% sequence identity with the mature polypeptide of SEQ ID NO: 1 or 2 and wherein the variant has alpha-amylase activity, detergent compositions comprising said variant alpha-amylase, isolated polynucleotides encoding said variant, expression vectors and host cells comprising said polynucleotides and methods for producing or obtaining said alpha-amylase variants.

---

12. claims: 21(completely) ; 1-9, 27-50(partially)

An alpha-amylase variant comprising an alteration at two or more (several) positions wherein one of the positions corresponds to position G305 of the mature polypeptide of SEQ ID NO: 1 or 2, wherein each alteration is independently a substitution, deletion or insertion, and wherein the variant has at least 85%, such as at least 90%, but less than 100% sequence identity with the mature polypeptide of SEQ ID NO: 1 or 2 and wherein the variant has alpha-amylase activity, detergent compositions comprising said variant alpha-amylase, isolated polynucleotides encoding said variant, expression vectors and host cells comprising said polynucleotides and methods for producing or obtaining said alpha-amylase variants.

---

13. claims: 22(completely) ; 1-9, 27-50(partially)

An alpha-amylase variant comprising an alteration at two or more (several) positions wherein one of the positions corresponds to position W347 of the mature polypeptide of SEQ ID NO: 1 or 2, wherein each alteration is independently a substitution, deletion or insertion, and wherein the variant has at least 85%, such as at least 90%, but less than 100% sequence identity with the mature polypeptide of SEQ ID NO: 1 or 2 and wherein the variant has alpha-amylase activity, detergent compositions comprising said variant alpha-amylase, isolated polynucleotides encoding said

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

variant, expression vectors and host cells comprising said polynucleotides and methods for producing or obtaining said alpha-amylase variants .

---

## 14. claims : 23 (completely) ; 1-9 , 27-50 (partially)

An alpha-amylase variant comprising an alteration at two or more (several) positions wherein one of the positions corresponds to position R439 of the mature polypeptide of SEQ ID NO: 1, or W439 of the mature polypeptide of SEQ ID NO: 2, wherein each alteration is independently a substitution, deletion or insertion, and wherein the variant has at least 85%, such as at least 90%, but less than 100% sequence identity with the mature polypeptide of SEQ ID NO: 1 or 2 and wherein the variant has alpha-amylase activity, detergent compositions comprising said variant alpha-amylase, isolated polynucleotides encoding said variant, expression vectors and host cells comprising said polynucleotides and methods for producing or obtaining said alpha-amylase variants .

---

## 15. claims : 24 (completely) ; 1-9 , 27-50 (partially)

An alpha-amylase variant comprising an alteration at two or more (several) positions wherein one of the positions corresponds to position W469 of the mature polypeptide of SEQ ID NO: 1 or 2, wherein each alteration is independently a substitution, deletion or insertion, and wherein the variant has at least 85%, such as at least 90%, but less than 100% sequence identity with the mature polypeptide of SEQ ID NO: 1 or 2 and wherein the variant has alpha-amylase activity, detergent compositions comprising said variant alpha-amylase, isolated polynucleotides encoding said variant, expression vectors and host cells comprising said polynucleotides and methods for producing or obtaining said alpha-amylase variants .

---

## 16. claims : 25 (completely) ; 1-9 , 27-50 (partially)

An alpha-amylase variant comprising an alteration at two or more (several) positions wherein one of the positions corresponds to position D476 of the mature polypeptide of SEQ ID NO: 1, or G476 of the mature polypeptide of SEQ ID NO: 2, wherein each alteration is independently a substitution, deletion or insertion, and wherein the variant has at least 85%, such as at least 90%, but less than 100% sequence identity with the mature polypeptide of SEQ ID NO: 1 or 2 and wherein the variant has alpha-amylase activity, detergent compositions comprising said variant alpha-amylase, isolated polynucleotides encoding said variant, expression vectors and host cells comprising said polynucleotides and methods for producing or obtaining said

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

alpha-amylase variants .

---

17. claims: 26(completely) ; 1-9, 27-50(partially)

An alpha-amylase variant comprising an alteration at two or more (several) positions wherein one of the positions corresponds to position G477 of the mature polypeptide of SEQ ID NO: 1 or 2, wherein each alteration is independently a substitution, deletion or insertion, and wherein the variant has at least 85%, such as at least 90%, but less than 100% sequence identity with the mature polypeptide of SEQ ID NO: 1 or 2 and wherein the variant has alpha-amylase activity, detergent compositions comprising said variant alpha-amylase, isolated polynucleotides encoding said variant, expression vectors and host cells comprising said polynucleotides and methods for producing or obtaining said alpha-amylase variants .

---